window.__IS_SSR__=true
window.__INITIAL_STATE__={
"attachmentsReducer": {
"audio_0": {
"type": "attachments",
"id": "audio_0",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background0.jpg"
}
}
},
"audio_1": {
"type": "attachments",
"id": "audio_1",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background1.jpg"
}
}
},
"audio_2": {
"type": "attachments",
"id": "audio_2",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background2.jpg"
}
}
},
"audio_3": {
"type": "attachments",
"id": "audio_3",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background3.jpg"
}
}
},
"audio_4": {
"type": "attachments",
"id": "audio_4",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background4.jpg"
}
}
},
"placeholder": {
"type": "attachments",
"id": "placeholder",
"imgSizes": {
"thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"medium": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"medium_large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-768x512.jpg",
"width": 768,
"height": 512,
"mimeType": "image/jpeg"
},
"large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"1536x1536": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-lrg": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-med": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"fd-sm": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"post-thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"twentyfourteen-full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1038x576.jpg",
"width": 1038,
"height": 576,
"mimeType": "image/jpeg"
},
"xxsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"xsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"small": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"xlarge": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1920x1280.jpg",
"width": 1920,
"height": 1280,
"mimeType": "image/jpeg"
},
"guest-author-32": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 32,
"height": 32,
"mimeType": "image/jpeg"
},
"guest-author-50": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 50,
"height": 50,
"mimeType": "image/jpeg"
},
"guest-author-64": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 64,
"height": 64,
"mimeType": "image/jpeg"
},
"guest-author-96": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 96,
"height": 96,
"mimeType": "image/jpeg"
},
"guest-author-128": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 128,
"height": 128,
"mimeType": "image/jpeg"
},
"detail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 160,
"height": 160,
"mimeType": "image/jpeg"
},
"kqedFullSize": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1.jpg",
"width": 2000,
"height": 1333
}
}
},
"futureofyou_159223": {
"type": "attachments",
"id": "futureofyou_159223",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "159223",
"found": true
},
"parent": 157867,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-400x267.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 267
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-960x640.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 640
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood.jpg",
"width": 4201,
"height": 2799
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-1180x786.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 786
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-800x533.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 533
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-1920x1279.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1279
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-1180x786.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 786
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-150x150.jpg",
"width": 150,
"mimeType": "image/jpeg",
"height": 150
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-768x512.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 512
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/blood-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1462579337,
"modified": 1462579359,
"caption": null,
"description": null,
"title": "blood test lab",
"credit": "iStock",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_156559": {
"type": "attachments",
"id": "futureofyou_156559",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "156559",
"found": true
},
"parent": 156558,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-400x225.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 225
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-960x540.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 540
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-e1469754321977.jpg",
"width": 1920,
"height": 1080
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1180x664.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 664
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-800x450.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 450
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1920x1080.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1080
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1180x664.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 664
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-150x150.jpg",
"width": 150,
"mimeType": "image/jpeg",
"height": 150
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-768x432.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 432
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1462214538,
"modified": 1469754349,
"caption": null,
"description": "Elizabeth Holmes speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.",
"title": "Elizabeth Holmes, founder and CEO of Theranos, speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.",
"credit": null,
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_152361": {
"type": "attachments",
"id": "futureofyou_152361",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "152361",
"found": true
},
"parent": 152359,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-400x346.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 346
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-960x829.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 829
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-e1461624309161.jpg",
"width": 1920,
"height": 1658
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1180x1019.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1019
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-695x600.jpg",
"width": 695,
"mimeType": "image/jpeg",
"height": 600
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1920x1658.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1658
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1180x1019.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1019
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-768x663.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 663
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1461624188,
"modified": 1461625314,
"caption": null,
"description": null,
"title": "theranoshome",
"credit": "Photo by Steve Jurvetson/Flickr",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_148281": {
"type": "attachments",
"id": "futureofyou_148281",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "148281",
"found": true
},
"parent": 148241,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-400x199.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 199
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1.jpg",
"width": 632,
"height": 315
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1461002135,
"modified": 1464120443,
"caption": "Elizabeth Holmes discusses Theranos' problems on the 'Today' show in April.",
"description": null,
"title": "Holmes",
"credit": "Today show",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_58611": {
"type": "attachments",
"id": "futureofyou_58611",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "58611",
"found": true
},
"parent": 0,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-400x146.png",
"width": 400,
"mimeType": "image/png",
"height": 146
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915.png",
"width": 598,
"height": 218
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-96x96.png",
"width": 96,
"mimeType": "image/png",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-64x64.png",
"width": 64,
"mimeType": "image/png",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-75x75.png",
"width": 75,
"mimeType": "image/png",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-32x32.png",
"width": 32,
"mimeType": "image/png",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2015/10/theranos-e1445976010915-128x128.png",
"width": 128,
"mimeType": "image/png",
"height": 128
}
},
"publishDate": 1445975846,
"modified": 1454610976,
"caption": "Theranos and its finger-prick blood-testing technology has come under siege from a Wall Street Journal investigation.",
"description": "Silicon Valley-based Theranos says it can diagnose a variety of diseases with a finger stick that takes just a few drops of blood — as opposed to a blood draw.",
"title": "theranos",
"credit": "Theranos",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_145322": {
"type": "attachments",
"id": "futureofyou_145322",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "145322",
"found": true
},
"parent": 145291,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-400x266.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 266
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-960x639.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 639
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-e1460580069776.jpg",
"width": 1920,
"height": 1278
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1180x785.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 785
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-800x532.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 532
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1920x1278.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1278
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1180x785.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 785
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-768x511.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 511
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1460580012,
"modified": 1523548902,
"caption": "Theranos founder Elizabeth Holmes in 2015.",
"description": "Theranos founder Eliabeth Holmes at the Fortune Global Forum, November 2015.",
"title": "Holmes",
"credit": "Stuart Isett/Fortune Global Forum",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_103649": {
"type": "attachments",
"id": "futureofyou_103649",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "103649",
"found": true
},
"parent": 103581,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-400x266.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 266
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-960x638.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 638
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-e1453851409558.jpg",
"width": 1920,
"height": 1275
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1180x784.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 784
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-800x531.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 531
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1920x1275.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1275
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-1180x784.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 784
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-768x510.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 510
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/01/Theranos-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1453851359,
"modified": 1453851403,
"caption": "Theranos founder and CEO Elizabeth Holmes at the Fortune Global Forum, November 2015.",
"description": null,
"title": "Theranos",
"credit": " Stuart Isett/Fortune Global Forum",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_129625": {
"type": "attachments",
"id": "futureofyou_129625",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "129625",
"found": true
},
"parent": 129430,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-400x267.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 267
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-960x640.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 640
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary.jpg",
"width": 1920,
"height": 1280
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-1180x787.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 787
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-800x533.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 533
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-1920x1280.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1280
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-1180x787.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 787
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-768x512.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 512
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/03/Hillary-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1458169120,
"modified": 1458169229,
"caption": null,
"description": "Hillary Clinton: running for president. Theranos: Running in place.",
"title": "Hillary",
"credit": "Andrew Burton/Getty Images",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
}
},
"audioPlayerReducer": {
"postId": "stream_live",
"isPaused": true,
"isPlaying": false,
"pfsActive": false,
"pledgeModalIsOpen": true,
"playerDrawerIsOpen": false,
"liveAudioPlayStartedAt": 0,
"liveAudioPlayContext": ""
},
"authorsReducer": {
"byline_futureofyou_156558": {
"type": "authors",
"id": "byline_futureofyou_156558",
"meta": {
"override": true
},
"slug": "byline_futureofyou_156558",
"name": "Laura Sydell\u003cbr />NPR All Tech Considered",
"isLoading": false
},
"byline_futureofyou_152359": {
"type": "authors",
"id": "byline_futureofyou_152359",
"meta": {
"override": true
},
"slug": "byline_futureofyou_152359",
"name": "Norman A. Paradis, Dartmouth College\u003cbr />The Conversation",
"isLoading": false
},
"jbrooks": {
"type": "authors",
"id": "80",
"meta": {
"index": "authors_1716337520",
"id": "80",
"found": true
},
"name": "Jon Brooks",
"firstName": "Jon",
"lastName": "Brooks",
"slug": "jbrooks",
"email": "jbrooks@kqed.org",
"display_author_email": true,
"staff_mastheads": [
"science"
],
"title": "Digital Editor",
"bio": "Jon Brooks is a former Digital Editor for KQED Science. He is the former editor of KQED’s daily news blog, News Fix. In 2014, he won a California Journalism Award for his coverage of ride services like Uber and Lyft and the taxi industry. A veteran blogger, he previously worked for Yahoo! in various news writing and editing roles. Jon is also a playwright whose work has been produced in San Francisco, New York, Italy, and around the U.S. He has written about film for his own blog and studied film at Boston University.",
"avatar": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twitter": "jbrooksfoy",
"facebook": null,
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "arts",
"roles": [
"Contributor",
"editor"
]
},
{
"site": "news",
"roles": [
"author"
]
},
{
"site": "futureofyou",
"roles": [
"administrator"
]
},
{
"site": "mindshift",
"roles": [
"editor"
]
},
{
"site": "stateofhealth",
"roles": [
"editor"
]
},
{
"site": "science",
"roles": [
"administrator"
]
},
{
"site": "quest",
"roles": [
"editor"
]
}
],
"headData": {
"title": "Jon Brooks | KQED",
"description": "Digital Editor",
"ogImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g"
},
"isLoading": false,
"link": "/author/jbrooks"
},
"andrea-kissack": {
"type": "authors",
"id": "212",
"meta": {
"index": "authors_1716337520",
"id": "212",
"found": true
},
"name": "Andrea Kissack",
"firstName": "Andrea",
"lastName": "Kissack",
"slug": "andrea-kissack",
"email": "akissack@kqed.org",
"display_author_email": false,
"staff_mastheads": [],
"title": "KQED Contributor",
"bio": "Andrea has nearly three decades of experience working as a reporter, anchor, producer and editor for public radio, large market television news and CBS radio. In her current role as KQED’s Sr. Science Editor, Andrea helps lead a talented team covering science, technology, health and the environment for broadcast and digital platforms. Most recently she helped KQED launch a new, multimedia initiative covering the intersection of technology, health and medical science. She has earned a number of accolades for her work including awards from the Radio and Television News Directors Association, the National Academy of Television Arts and Sciences and the Associated Press. Her work can be seen, and heard, on a number of networks, Including NPR, PBS, CBS and the BBC.",
"avatar": "https://secure.gravatar.com/avatar/3eae7a251f0aee43b3c0137a636cb386?s=600&d=blank&r=g",
"twitter": "andreakissack",
"facebook": null,
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "news",
"roles": [
"subscriber"
]
},
{
"site": "stateofhealth",
"roles": [
"subscriber"
]
},
{
"site": "science",
"roles": []
},
{
"site": "quest",
"roles": [
"add_users",
"create_users",
"edit_files",
"edit_users",
"level_10",
"level_8",
"level_9",
"promote_users",
"view_cimy_extra_fields",
"subscriber"
]
}
],
"headData": {
"title": "Andrea Kissack | KQED",
"description": "KQED Contributor",
"ogImgSrc": "https://secure.gravatar.com/avatar/3eae7a251f0aee43b3c0137a636cb386?s=600&d=blank&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/3eae7a251f0aee43b3c0137a636cb386?s=600&d=blank&r=g"
},
"isLoading": false,
"link": "/author/andrea-kissack"
}
},
"pagesReducer": {
"futureofyou_tag_theranos": {
"type": "terms",
"id": "futureofyou_617",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "617",
"score": 9.108458
},
"featImg": null,
"name": "theranos",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "theranos Archives | KQED Arts",
"ogDescription": null
},
"ttid": 617,
"slug": "theranos",
"isLoading": false,
"title": "theranos",
"pageMeta": {
"site": "futureofyou",
"WpPageTemplate": "page-topic-editorial",
"currentPage": 3
},
"blocks": [
{
"blockName": "kqed/post-list",
"attrs": {
"layout": "cardArticle2",
"query": "posts/futureofyou?tag=theranos",
"seeMore": false,
"paginated": true,
"page": 3
}
},
{
"blockName": "kqed/ad"
}
]
}
},
"pfsSessionReducer": {},
"postsReducer": {
"stream_live": {
"type": "live",
"id": "stream_live",
"audioUrl": "https://hls.kqed.org/hls/kqed_app/playlist.m3u8",
"title": "Live Stream",
"excerpt": "Live Stream information currently unavailable.",
"link": "/radio",
"featImg": "",
"label": {
"name": "KQED Live",
"link": "/"
}
},
"stream_kqedNewscast": {
"type": "posts",
"id": "stream_kqedNewscast",
"audioUrl": "https://www.kqed.org/.stream/anon/radio/RDnews/newscast.mp3?_=1",
"title": "KQED Newscast",
"featImg": "",
"label": {
"name": "88.5 FM",
"link": "/"
}
},
"futureofyou_157867": {
"type": "posts",
"id": "futureofyou_157867",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "157867",
"score": null,
"sort": [
1462815014000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1462815014,
"format": "standard",
"disqusTitle": "Should You Be Allowed to Order Your Own Blood Tests?",
"title": "Should You Be Allowed to Order Your Own Blood Tests?",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>One aspect of the multidimensional mess that is the \u003ca href=\"http://ww2.kqed.org/futureofyou/tag/theranos/\" target=\"_blank\">Theranos story\u003c/a> is the company's leveraging of the Do-It-Yourself ethos to promote its product. Theranos provides consumers with a \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">menu of over 200\u003c/a> low-cost diagnostic blood tests for any array of ailments and diseases.\u003c/p>\n\u003caside class=\"pullquote alignright\">It's legal to order blood tests without consulting a doctor in some two dozen states. But should you?\u003c/aside>\n\u003cp>Here's the company's founder, Elizabeth Holmes, at TEDMED in 2014, lacing her stem-winder of a \u003ca href=\"https://www.youtube.com/watch?v=dBvzKp0AERE\" target=\"_blank\">presentation\u003c/a> with the ideals of patient self-empowerment.\u003c/p>\n\u003cp>“My own life’s work in building Theranos is to redefine the paradigm of diagnosis away from one in which people have to present with a symptom in order to get access to information about their bodies,\" she said, \"to one in which every person, no matter how much money they have or where they live, has access to actionable health information at the time it matters.”\u003c/p>\n\u003cp>She also pitched the crowd an absurdity:\u003c/p>\n\u003cp>\"(T)oday, I can go buy a deadly, exotic animal, a venomous viper, a military truck or armored vehicle. I can buy a tank ... but I can't order a blood-based pregnancy test, or an allergy test. Because \u003cem>that\u003c/em> could be dangerous.\"\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>https://www.youtube.com/watch?v=dBvzKp0AERE\u003c/p>\n\u003cp>Theranos is currently waiting for the Centers for Medicare & Medicaid Services to render a final decision on whether it will lose its license to operate its labs. But for now the company still does tests at its wellness centers in dozens of Walgreens and other locations in Arizona, plus one in California.\u003c/p>\n\u003caside class=\"pullquote alignright\">“I can go buy a deadly, exotic animal, a venomous viper, a military truck or armored vehicle ... but I can’t order a blood-based pregnancy test.\u003ccite>Theranos founder Elizabeth Holmes in 2014\u003c/cite>\u003c/aside>\n\u003cp>Theranos isn't the only company offering blood tests to the worried well. \u003ca href=\"http://www.wellnessfx.com/\" target=\"_blank\">WellnessFX\u003c/a>, for instance, has a partnership with Quest Diagnostics, and consumers in all but seven states can use the company's website to order their own tests online.\u003c/p>\n\u003cp>Like Theranos, WellnessFX has similarly baked in the ideals of patient access and independence.\u003c/p>\n\u003cp>\"A lot of the data that can be used to help understand what is best for the patient, historically that's always been the clipboard that's been turned around facing the physician... and never really been shown to the patient,\" said WellnessFX cofounder Brent Vaughan in a 2013 \u003ca href=\"https://www.youtube.com/watch?v=_sSq0KZZl5Q\" target=\"_blank\">promotional video\u003c/a>. \"Because there's always been this belief that patients can't understand or they don't want to understand this information.\"\u003c/p>\n\u003cp>\u003cstrong>A Growing Trend\u003c/strong>\u003c/p>\n\u003cp>Last year, health diagnostics behemoth LabCorp dipped a toe in the DIY waters by allowing Arizona consumers to order their own tests. Labcorp CEO David King said in an email the company's market research shows a \"significant percentage\" of consumers are interested in initiating tests on their own. The company plans to expand the service into other states later this year.\u003c/p>\n\u003cp>\"As consumers bear more of the cost of health care out of pocket, they should be, and are becoming increasingly engaged in managing their healthcare,\" King said. \"We absolutely support them in doing so.\"\u003c/p>\n\u003cp>Last April, Arizona enacted a law -- \u003ca href=\"http://www.azcentral.com/story/news/arizona/politics/2015/02/27/high-tech-pushes-consumer-friendly-lab-testing/24150229/\" target=\"_blank\">pushed by Theranos\u003c/a> -- that allowed consumers to order their own tests. The bill passed in the House 60 to 0 and the Senate 26 to 2. Democrat Steve Farley was one of the no votes. He isn't surprised at Theranos' unraveling.\u003c/p>\n\u003cp>\"Really what we were being asked to do in that bill was to allow our constituents in Arizona to become beta testers, and use their own bodies as the tool of that beta testing,\" he said. (Theranos declined to comment.)\u003c/p>\n\u003cp>The debate over cutting doctors out of the diagnostic loop has been going on \u003ca href=\"http://www.nytimes.com/2002/03/12/health/blood-test-labs-bypass-doctors-spurring-debate.html?pagewanted=all\" target=\"_blank\">a long time\u003c/a>. Some academics have been vocal about their reservations. Dr. Norman Paradis, a professor of medicine at Dartmouth who has consulted for diagnostic startups, said the model of offering a wide assortment of tests -- as Theranos does -- is a recipe for disaster.\u003c/p>\n\u003cp>“If you simply run medical tests in large numbers of people who don’t have the signs and symptoms of a certain disease, then many of the results you get will be false positives,” he said.\u003c/p>\n\u003cp>And those patients could then wind up going further down the rabbit hole of more invasive, potentially harmful tests and treatment.\u003c/p>\n\u003cp>Paradis said getting medical students and even residents to appropriately order tests is difficult enough. “So if it’s difficult for them, it’s even harder for the layperson. “\u003c/p>\n\u003cp>Dr. H. Gilbert Welch, the author of several books on the topic of overdiagnosis, thinks getting your own blood tests is part of the larger negative trend of testing people who aren’t really sick.\u003c/p>\n\u003cp>\"I’m afraid there's a growing sense the path to health is through testing,\" he said. \"But you don’t test yourself to health. Health is much more about how you move, what you eat and finding joy and purpose in life.”\u003c/p>\n\u003cp>WellnessFX has taken concerns about false positives into account, said Dr. Murdoc Khalegi, its medical director. He said the company works with physicians to make sure the tests it offers are not susceptible to inaccurate results.\u003c/p>\n\u003cp>\"We work very hard to [offer tests] that are something a consumer can understand, like having elevated cholesterol or blood sugar,\" Khalegi said. \"We encourage all of our results to be shared with physicians. But to restrict people from even having that information, which is the way it currently exists in some settings, would be unfortunate. People should be aware if they have certain health risks.\"\u003c/p>\n\u003cp>The Center for Democracy & Technology's Michelle De Mooy, who has worked on privacy and transparency issues in health care, dismisses the argument that patients can't make knowledgeable decisions about when to get tested. She said the issue of false positives is \"pretty reasonably addressed\" with warnings.\u003c/p>\n\u003cp>Both she\u003cstrong> a\u003c/strong>nd Khalegi point to the high cost of health care as one reason to enable easier access to diagnostic tests. High deductibles and lack of access to transportation or child care are reasons people might choose to get tests in the most efficient, least time-consuming way possible.\u003c/p>\n\u003cp>\"The economic disparity question is one that the health care establishment tends to gloss over,\" she said.\u003c/p>\n\u003cp>\u003cstrong>A Vegan Gets Tested\u003c/strong>\u003c/p>\n\u003cp>Despite being asymptomatic, last year, Amy, who lives in Santa Cruz, California, went online to order her own test for anemia. (She didn't want her last name used for reasons of privacy.) The U.S. Preventive Services Task Force has no opinion on testing for iron-deficiency anemia among those who are asymptomatic. But Amy's fellow vegans had convinced her to get tested because cutting out meat and dairy can \u003ca href=\"http://www.everydayhealth.com/anemia/anemia-risk-for-vegans-and-vegetarians.aspx\">increase the risk\u003c/a> of iron deficiency.\u003c/p>\n\u003cp>Because of a high deductible and bad experiences with insurance companies, Amy didn't want to go through her insurer.\u003c/p>\n\u003cp>Her iron level came back low. But rather than take action on her own, she went to a doctor, to whom she mentioned having donated blood a week before the test. Amy hadn't known this would deplete her iron. And because her other numbers were fine, her doctor told her not to worry.\u003c/p>\n\u003cp>\"As a layperson I wouldn’t understand that,\" Amy said.\u003c/p>\n\u003cp>The whole experience -- the blood draw notwithstanding -- was painless.\u003c/p>\n\u003cp>\"I liked being able to answer my own questions and to go to the site and pick which things I was curious about. I like being able to do it independently, since I don’t have a regular general practitioner I go to.\"\u003c/p>\n\u003cp>In some ways Amy fits the profile that both advocates and opponents of self-testing point to: She had no symptoms of anemia and got a test that wound up being unnecessary. But she also had a psychological need to know and a financial need to pursue that cheaply.\u003c/p>\n\u003cp>Dr. Murdoc of WellnessFX said that while he defers to official guidelines, as a vegan, Amy probably did the right thing.\u003c/p>\n\u003cp>\"It's a very cheap blood test,\" he said.\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\u003cem>Note: This post was corrected to reflect updated recommendations from the U.S. Preventive Services Task Force on testing for iron-deficiency anemia. Originally, the story said the task force recommended testing in asymptomatic women and small children. But in September 2015 the USPSTF concluded \"that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia\" in both pregnant women and children ages 6 to 24 months.\u003c/em>\u003c/p>\n\n",
"disqusIdentifier": "157867 http://ww2.kqed.org/futureofyou/?p=157867",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/05/09/should-you-be-allowed-to-order-your-own-blood-tests/",
"stats": {
"hasVideo": true,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1534,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 38
},
"modified": 1476850798,
"excerpt": "Startups have allowed consumers to take diagnostic matters into their own hands. Some doctors think that's a bad idea. ",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Startups have allowed consumers to take diagnostic matters into their own hands. Some doctors think that's a bad idea. ",
"title": "Should You Be Allowed to Order Your Own Blood Tests? | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Should You Be Allowed to Order Your Own Blood Tests?",
"datePublished": "2016-05-09T10:30:14-07:00",
"dateModified": "2016-10-18T21:19:58-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "should-you-be-allowed-to-order-your-own-blood-tests",
"status": "publish",
"path": "/futureofyou/157867/should-you-be-allowed-to-order-your-own-blood-tests",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>One aspect of the multidimensional mess that is the \u003ca href=\"http://ww2.kqed.org/futureofyou/tag/theranos/\" target=\"_blank\">Theranos story\u003c/a> is the company's leveraging of the Do-It-Yourself ethos to promote its product. Theranos provides consumers with a \u003ca href=\"https://www.theranos.com/test-menu\" target=\"_blank\">menu of over 200\u003c/a> low-cost diagnostic blood tests for any array of ailments and diseases.\u003c/p>\n\u003caside class=\"pullquote alignright\">It's legal to order blood tests without consulting a doctor in some two dozen states. But should you?\u003c/aside>\n\u003cp>Here's the company's founder, Elizabeth Holmes, at TEDMED in 2014, lacing her stem-winder of a \u003ca href=\"https://www.youtube.com/watch?v=dBvzKp0AERE\" target=\"_blank\">presentation\u003c/a> with the ideals of patient self-empowerment.\u003c/p>\n\u003cp>“My own life’s work in building Theranos is to redefine the paradigm of diagnosis away from one in which people have to present with a symptom in order to get access to information about their bodies,\" she said, \"to one in which every person, no matter how much money they have or where they live, has access to actionable health information at the time it matters.”\u003c/p>\n\u003cp>She also pitched the crowd an absurdity:\u003c/p>\n\u003cp>\"(T)oday, I can go buy a deadly, exotic animal, a venomous viper, a military truck or armored vehicle. I can buy a tank ... but I can't order a blood-based pregnancy test, or an allergy test. Because \u003cem>that\u003c/em> could be dangerous.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\u003c/p>\u003cp>\u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutube'>\n \u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutubeInside'>\n \u003ciframe\n loading='lazy'\n class='utils-parseShortcode-shortcodes-__youtubeShortcode__youtubePlayer'\n type='text/html'\n src='//www.youtube.com/embed/dBvzKp0AERE'\n title='//www.youtube.com/embed/dBvzKp0AERE'\n allowfullscreen='true'\n style='border:0;'>\u003c/iframe>\n \u003c/span>\n \u003c/span>\u003c/p>\u003cp>\u003cp>Theranos is currently waiting for the Centers for Medicare & Medicaid Services to render a final decision on whether it will lose its license to operate its labs. But for now the company still does tests at its wellness centers in dozens of Walgreens and other locations in Arizona, plus one in California.\u003c/p>\n\u003caside class=\"pullquote alignright\">“I can go buy a deadly, exotic animal, a venomous viper, a military truck or armored vehicle ... but I can’t order a blood-based pregnancy test.\u003ccite>Theranos founder Elizabeth Holmes in 2014\u003c/cite>\u003c/aside>\n\u003cp>Theranos isn't the only company offering blood tests to the worried well. \u003ca href=\"http://www.wellnessfx.com/\" target=\"_blank\">WellnessFX\u003c/a>, for instance, has a partnership with Quest Diagnostics, and consumers in all but seven states can use the company's website to order their own tests online.\u003c/p>\n\u003cp>Like Theranos, WellnessFX has similarly baked in the ideals of patient access and independence.\u003c/p>\n\u003cp>\"A lot of the data that can be used to help understand what is best for the patient, historically that's always been the clipboard that's been turned around facing the physician... and never really been shown to the patient,\" said WellnessFX cofounder Brent Vaughan in a 2013 \u003ca href=\"https://www.youtube.com/watch?v=_sSq0KZZl5Q\" target=\"_blank\">promotional video\u003c/a>. \"Because there's always been this belief that patients can't understand or they don't want to understand this information.\"\u003c/p>\n\u003cp>\u003cstrong>A Growing Trend\u003c/strong>\u003c/p>\n\u003cp>Last year, health diagnostics behemoth LabCorp dipped a toe in the DIY waters by allowing Arizona consumers to order their own tests. Labcorp CEO David King said in an email the company's market research shows a \"significant percentage\" of consumers are interested in initiating tests on their own. The company plans to expand the service into other states later this year.\u003c/p>\n\u003cp>\"As consumers bear more of the cost of health care out of pocket, they should be, and are becoming increasingly engaged in managing their healthcare,\" King said. \"We absolutely support them in doing so.\"\u003c/p>\n\u003cp>Last April, Arizona enacted a law -- \u003ca href=\"http://www.azcentral.com/story/news/arizona/politics/2015/02/27/high-tech-pushes-consumer-friendly-lab-testing/24150229/\" target=\"_blank\">pushed by Theranos\u003c/a> -- that allowed consumers to order their own tests. The bill passed in the House 60 to 0 and the Senate 26 to 2. Democrat Steve Farley was one of the no votes. He isn't surprised at Theranos' unraveling.\u003c/p>\n\u003cp>\"Really what we were being asked to do in that bill was to allow our constituents in Arizona to become beta testers, and use their own bodies as the tool of that beta testing,\" he said. (Theranos declined to comment.)\u003c/p>\n\u003cp>The debate over cutting doctors out of the diagnostic loop has been going on \u003ca href=\"http://www.nytimes.com/2002/03/12/health/blood-test-labs-bypass-doctors-spurring-debate.html?pagewanted=all\" target=\"_blank\">a long time\u003c/a>. Some academics have been vocal about their reservations. Dr. Norman Paradis, a professor of medicine at Dartmouth who has consulted for diagnostic startups, said the model of offering a wide assortment of tests -- as Theranos does -- is a recipe for disaster.\u003c/p>\n\u003cp>“If you simply run medical tests in large numbers of people who don’t have the signs and symptoms of a certain disease, then many of the results you get will be false positives,” he said.\u003c/p>\n\u003cp>And those patients could then wind up going further down the rabbit hole of more invasive, potentially harmful tests and treatment.\u003c/p>\n\u003cp>Paradis said getting medical students and even residents to appropriately order tests is difficult enough. “So if it’s difficult for them, it’s even harder for the layperson. “\u003c/p>\n\u003cp>Dr. H. Gilbert Welch, the author of several books on the topic of overdiagnosis, thinks getting your own blood tests is part of the larger negative trend of testing people who aren’t really sick.\u003c/p>\n\u003cp>\"I’m afraid there's a growing sense the path to health is through testing,\" he said. \"But you don’t test yourself to health. Health is much more about how you move, what you eat and finding joy and purpose in life.”\u003c/p>\n\u003cp>WellnessFX has taken concerns about false positives into account, said Dr. Murdoc Khalegi, its medical director. He said the company works with physicians to make sure the tests it offers are not susceptible to inaccurate results.\u003c/p>\n\u003cp>\"We work very hard to [offer tests] that are something a consumer can understand, like having elevated cholesterol or blood sugar,\" Khalegi said. \"We encourage all of our results to be shared with physicians. But to restrict people from even having that information, which is the way it currently exists in some settings, would be unfortunate. People should be aware if they have certain health risks.\"\u003c/p>\n\u003cp>The Center for Democracy & Technology's Michelle De Mooy, who has worked on privacy and transparency issues in health care, dismisses the argument that patients can't make knowledgeable decisions about when to get tested. She said the issue of false positives is \"pretty reasonably addressed\" with warnings.\u003c/p>\n\u003cp>Both she\u003cstrong> a\u003c/strong>nd Khalegi point to the high cost of health care as one reason to enable easier access to diagnostic tests. High deductibles and lack of access to transportation or child care are reasons people might choose to get tests in the most efficient, least time-consuming way possible.\u003c/p>\n\u003cp>\"The economic disparity question is one that the health care establishment tends to gloss over,\" she said.\u003c/p>\n\u003cp>\u003cstrong>A Vegan Gets Tested\u003c/strong>\u003c/p>\n\u003cp>Despite being asymptomatic, last year, Amy, who lives in Santa Cruz, California, went online to order her own test for anemia. (She didn't want her last name used for reasons of privacy.) The U.S. Preventive Services Task Force has no opinion on testing for iron-deficiency anemia among those who are asymptomatic. But Amy's fellow vegans had convinced her to get tested because cutting out meat and dairy can \u003ca href=\"http://www.everydayhealth.com/anemia/anemia-risk-for-vegans-and-vegetarians.aspx\">increase the risk\u003c/a> of iron deficiency.\u003c/p>\n\u003cp>Because of a high deductible and bad experiences with insurance companies, Amy didn't want to go through her insurer.\u003c/p>\n\u003cp>Her iron level came back low. But rather than take action on her own, she went to a doctor, to whom she mentioned having donated blood a week before the test. Amy hadn't known this would deplete her iron. And because her other numbers were fine, her doctor told her not to worry.\u003c/p>\n\u003cp>\"As a layperson I wouldn’t understand that,\" Amy said.\u003c/p>\n\u003cp>The whole experience -- the blood draw notwithstanding -- was painless.\u003c/p>\n\u003cp>\"I liked being able to answer my own questions and to go to the site and pick which things I was curious about. I like being able to do it independently, since I don’t have a regular general practitioner I go to.\"\u003c/p>\n\u003cp>In some ways Amy fits the profile that both advocates and opponents of self-testing point to: She had no symptoms of anemia and got a test that wound up being unnecessary. But she also had a psychological need to know and a financial need to pursue that cheaply.\u003c/p>\n\u003cp>Dr. Murdoc of WellnessFX said that while he defers to official guidelines, as a vegan, Amy probably did the right thing.\u003c/p>\n\u003cp>\"It's a very cheap blood test,\" he said.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003cem>Note: This post was corrected to reflect updated recommendations from the U.S. Preventive Services Task Force on testing for iron-deficiency anemia. Originally, the story said the task force recommended testing in asymptomatic women and small children. But in September 2015 the USPSTF concluded \"that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia\" in both pregnant women and children ages 6 to 24 months.\u003c/em>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/157867/should-you-be-allowed-to-order-your-own-blood-tests",
"authors": [
"80"
],
"categories": [
"futureofyou_1060"
],
"tags": [
"futureofyou_164",
"futureofyou_814",
"futureofyou_909",
"futureofyou_617",
"futureofyou_908"
],
"featImg": "futureofyou_159223",
"label": "futureofyou"
},
"futureofyou_156558": {
"type": "posts",
"id": "futureofyou_156558",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "156558",
"score": null,
"sort": [
1462215379000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1462215379,
"format": "standard",
"disqusTitle": "Theranos Debacle Shows Differences Between Silicon Valley and Biomed",
"title": "Theranos Debacle Shows Differences Between Silicon Valley and Biomed",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Elizabeth Holmes fit into the Silicon Valley success mold. A young Stanford dropout who left school to pursue her entrepreneurial vision, she founded Theranos and said she would disrupt the world of medicine with easy and inexpensive blood tests.\u003c/p>\n\u003caside class=\"pullquote alignright\">In Silicon Valley, secrecy and raising big money before achieving results are par for the course. Not so in the world of biomed.\u003c/aside>\n\u003cp>But now her company is \u003ca href=\"http://www.npr.org/2016/04/19/474868428/innovative-blood-testing-company-theranos-under-criminal-investigation\">under federal investigation\u003c/a> and extra scrutiny \u003ca href=\"http://www.latimes.com/business/la-fi-theranos-investigations-20160419-story.html\">by federal regulators\u003c/a>. And questions are being raised about whether applying hardware and software business culture to biotechnology is dangerous.\u003c/p>\n\u003cp>Holmes was an alluring figure; young and intense in the kind of way Apple founder Steve Jobs was. Like Jobs, she wore \u003ca href=\"http://www.glamour.com/story/theranos-founder-elizabeth-holmes-career-advice\">only black turtlenecks\u003c/a> because she didn't have time to think about her wardrobe.\u003c/p>\n\u003cp>And of course, there was \u003ca href=\"http://www.tedmed.com/talks/show?id=309114\">the TED talk\u003c/a> in which Holmes painted a picture of a world in which too many people avoided blood tests because of the cost, inconvenience and discomfort of giving so much blood. Sometimes they learned too late about a serious health condition. But, her company — \u003ca href=\"https://www.theranos.com/\">Theranos\u003c/a> — had the solution.\u003c/p>\n\u003cp>\"We've made it possible to run comprehensive laboratory tests from a tiny sample or a few drops of blood that could be taken from a finger,\" she told the audience.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Holmes had a beautiful vision, backed by hundreds of millions of dollars in investment, and \u003ca href=\"https://www.theranos.com/leadership\">a board of big names\u003c/a> like Henry Kissinger and George P. Schulz. The media had a love fest. \u003cem>Time\u003c/em> magazine called Holmes \u003ca href=\"http://time.com/3822734/elizabeth-holmes-2015-time-100/\">one of the 100 most influential people\u003c/a> in the world. She was profiled in \u003ca href=\"http://fortune.com/2014/06/12/theranos-blood-holmes/\">Fortune\u003c/a> and \u003ca href=\"http://www.newyorker.com/magazine/2014/12/15/blood-simpler\">The New Yorker\u003c/a>. Even medical professionals like \u003ca href=\"http://www.businessinsider.com/scientist-skeptical-thranos-blood-test-elizabeth-holmes-2015-6\">Dr. John Ioannidis\u003c/a>, a professor at Stanford University Medical School were intrigued.\u003c/p>\n\u003caside class=\"pullquote alignright\">“This is equivalent to me, being a biomedical researcher, trying to become an architect and build a skyscraper. Would you give me a few billion dollars please?”\u003ccite> Dr. John Ioannidis, Stanford Medical School professor\u003c/cite>\u003c/aside>\n\u003cp>\"My first reaction was, it sounds really brilliant,\" Ioannides says. \"I would like to collaborate with these people and maybe even use their technology in my own studies.\" Studies — that's what medicine and science is built upon.\u003c/p>\n\u003cp>\"So the first thing that I did as a researcher, as a scientist is check the scientific literature,\" says Ioannidis. \"How much do we know about what they do? And I couldn't find even a single paper.\"\u003c/p>\n\u003cp>Then there was the advisory board: big names in politics, not science. And Holmes had no background in medicine. \"This is equivalent to me, being a biomedical researcher, trying to become an architect and build a skyscraper. Would you give me a few billion dollars please?\"\u003c/p>\n\u003cp>Of course, no one would give him a few billion dollars.\u003c/p>\n\u003cp>But in the tech world, maybe they would. Jo-Ellen Pozner, a professor at the University of California, Berkeley Haas School of Business, says some of the greatest companies were built on hype and a big idea.\u003c/p>\n\u003cp>\"Often the product comes after the money, and so the first job is to get the investors to give you the money and that requires that you really sell them on this big idea before it's actually in hand,\" Pozner says.\u003c/p>\n\u003cp>Pozner points to \u003ca href=\"http://www.npr.org/sections/theprotojournalist/2014/01/08/260457752/can-jeff-bezos-save-planet-earth\">Jeff Bezos\u003c/a> and his company Amazon, which started as an online bookseller. \"He called the company Amazon because he wanted it to be the biggest retailer in the world, so he named it after the biggest river in the world,\" she says. \"That projects a certain kind of optimism about where we're going and what we have in mind and what we're able to accomplish.\"\u003c/p>\n\u003cp>Despite many years when Amazon made no profit, Bezos drew investors and in turn he expanded and got more customers.\u003c/p>\n\u003cp>Secrecy is also part of the tech world playbook — no studies needed. Google keeps its search algorithms secret — as a way to keep them out of the hands of competitors.\u003c/p>\n\u003cp>\"So there are so many things going on in our firm and we're not telling you about them and that's part of the allure and the mystique of the organization,\" says Pozner. \"That keeps people excited about what's coming next.\"\u003c/p>\n\u003cp>This is totally contrary to how the medical and biotech fields work — studies are published in journals and reviewed by peers and products require government approval. This may gum up the works of Silicon Valley's fast-paced innovation economy, but it's for a good reason, says Stanford's Ioannidis.\u003c/p>\n\u003cp>\"It's not such a horrible thing if your mobile phone battery dies an hour earlier than it's supposed to,\" he says. \"But if a patient gets given the wrong results and then going down the path of making wrong decisions, that's serious. People can lose their lives.\"\u003c/p>\n\u003cp>As for Theranos and Elizabeth Holmes — the company is \u003ca href=\"http://www.bloomberg.com/news/articles/2016-04-18/theranos-is-under-investigation-by-sec-u-s-attorney-s-office\">facing scrutiny\u003c/a> from the Securities and Exchange Commission and the U.S. Attorney's Office for the Northern District of California. Some Theranos supporters believe in the end Holmes will turn out to be right.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Meanwhile, venture capital dollars going into biotech rose nearly 20 percent between 2014 and 2015. Perhaps this round of funding will come with less hype and more scrutiny.\u003c/p>\n\u003cdiv class=\"fullattribution\">Copyright 2016 NPR. To see more, visit http://www.npr.org/.\u003cimg src=\"http://www.google-analytics.com/__utm.gif?utmac=UA-5828686-4&utmdt=Biotech%27s+Theranos+Offers+A+Cautionary+Tale+For+Silicon+Valley&utme=8(APIKey)9(MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004)\">\u003c/div>\n\n",
"disqusIdentifier": "156558 http://ww2.kqed.org/futureofyou/?p=156558",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/05/02/theranos-debacle-shows-differences-between-silicon-valley-and-biomed/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 890,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 22
},
"modified": 1462229859,
"excerpt": "The blood-testing startup led by Elizabeth Holmes soared on hype and celebrity boosters.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The blood-testing startup led by Elizabeth Holmes soared on hype and celebrity boosters.",
"title": "Theranos Debacle Shows Differences Between Silicon Valley and Biomed | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Debacle Shows Differences Between Silicon Valley and Biomed",
"datePublished": "2016-05-02T11:56:19-07:00",
"dateModified": "2016-05-02T15:57:39-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-debacle-shows-differences-between-silicon-valley-and-biomed",
"status": "publish",
"nprApiLink": "http://api.npr.org/query?id=475972922&apiKey=MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004",
"nprByline": "Laura Sydell\u003cbr />NPR All Tech Considered",
"nprStoryDate": "Mon, 02 May 2016 12:16:55 -0400",
"nprLastModifiedDate": "Mon, 02 May 2016 12:16:55 -0400",
"nprHtmlLink": "http://www.npr.org/sections/alltechconsidered/2016/05/02/475972922/biotechs-theranos-offers-a-cautionary-tale-for-silicon-valley?ft=nprml&f=475972922",
"nprImageAgency": "AP",
"nprImageCredit": "Jeff Chiu",
"nprStoryId": "475972922",
"nprRetrievedStory": "1",
"nprPubDate": "Mon, 02 May 2016 12:16:00 -0400",
"path": "/futureofyou/156558/theranos-debacle-shows-differences-between-silicon-valley-and-biomed",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Elizabeth Holmes fit into the Silicon Valley success mold. A young Stanford dropout who left school to pursue her entrepreneurial vision, she founded Theranos and said she would disrupt the world of medicine with easy and inexpensive blood tests.\u003c/p>\n\u003caside class=\"pullquote alignright\">In Silicon Valley, secrecy and raising big money before achieving results are par for the course. Not so in the world of biomed.\u003c/aside>\n\u003cp>But now her company is \u003ca href=\"http://www.npr.org/2016/04/19/474868428/innovative-blood-testing-company-theranos-under-criminal-investigation\">under federal investigation\u003c/a> and extra scrutiny \u003ca href=\"http://www.latimes.com/business/la-fi-theranos-investigations-20160419-story.html\">by federal regulators\u003c/a>. And questions are being raised about whether applying hardware and software business culture to biotechnology is dangerous.\u003c/p>\n\u003cp>Holmes was an alluring figure; young and intense in the kind of way Apple founder Steve Jobs was. Like Jobs, she wore \u003ca href=\"http://www.glamour.com/story/theranos-founder-elizabeth-holmes-career-advice\">only black turtlenecks\u003c/a> because she didn't have time to think about her wardrobe.\u003c/p>\n\u003cp>And of course, there was \u003ca href=\"http://www.tedmed.com/talks/show?id=309114\">the TED talk\u003c/a> in which Holmes painted a picture of a world in which too many people avoided blood tests because of the cost, inconvenience and discomfort of giving so much blood. Sometimes they learned too late about a serious health condition. But, her company — \u003ca href=\"https://www.theranos.com/\">Theranos\u003c/a> — had the solution.\u003c/p>\n\u003cp>\"We've made it possible to run comprehensive laboratory tests from a tiny sample or a few drops of blood that could be taken from a finger,\" she told the audience.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Holmes had a beautiful vision, backed by hundreds of millions of dollars in investment, and \u003ca href=\"https://www.theranos.com/leadership\">a board of big names\u003c/a> like Henry Kissinger and George P. Schulz. The media had a love fest. \u003cem>Time\u003c/em> magazine called Holmes \u003ca href=\"http://time.com/3822734/elizabeth-holmes-2015-time-100/\">one of the 100 most influential people\u003c/a> in the world. She was profiled in \u003ca href=\"http://fortune.com/2014/06/12/theranos-blood-holmes/\">Fortune\u003c/a> and \u003ca href=\"http://www.newyorker.com/magazine/2014/12/15/blood-simpler\">The New Yorker\u003c/a>. Even medical professionals like \u003ca href=\"http://www.businessinsider.com/scientist-skeptical-thranos-blood-test-elizabeth-holmes-2015-6\">Dr. John Ioannidis\u003c/a>, a professor at Stanford University Medical School were intrigued.\u003c/p>\n\u003caside class=\"pullquote alignright\">“This is equivalent to me, being a biomedical researcher, trying to become an architect and build a skyscraper. Would you give me a few billion dollars please?”\u003ccite> Dr. John Ioannidis, Stanford Medical School professor\u003c/cite>\u003c/aside>\n\u003cp>\"My first reaction was, it sounds really brilliant,\" Ioannides says. \"I would like to collaborate with these people and maybe even use their technology in my own studies.\" Studies — that's what medicine and science is built upon.\u003c/p>\n\u003cp>\"So the first thing that I did as a researcher, as a scientist is check the scientific literature,\" says Ioannidis. \"How much do we know about what they do? And I couldn't find even a single paper.\"\u003c/p>\n\u003cp>Then there was the advisory board: big names in politics, not science. And Holmes had no background in medicine. \"This is equivalent to me, being a biomedical researcher, trying to become an architect and build a skyscraper. Would you give me a few billion dollars please?\"\u003c/p>\n\u003cp>Of course, no one would give him a few billion dollars.\u003c/p>\n\u003cp>But in the tech world, maybe they would. Jo-Ellen Pozner, a professor at the University of California, Berkeley Haas School of Business, says some of the greatest companies were built on hype and a big idea.\u003c/p>\n\u003cp>\"Often the product comes after the money, and so the first job is to get the investors to give you the money and that requires that you really sell them on this big idea before it's actually in hand,\" Pozner says.\u003c/p>\n\u003cp>Pozner points to \u003ca href=\"http://www.npr.org/sections/theprotojournalist/2014/01/08/260457752/can-jeff-bezos-save-planet-earth\">Jeff Bezos\u003c/a> and his company Amazon, which started as an online bookseller. \"He called the company Amazon because he wanted it to be the biggest retailer in the world, so he named it after the biggest river in the world,\" she says. \"That projects a certain kind of optimism about where we're going and what we have in mind and what we're able to accomplish.\"\u003c/p>\n\u003cp>Despite many years when Amazon made no profit, Bezos drew investors and in turn he expanded and got more customers.\u003c/p>\n\u003cp>Secrecy is also part of the tech world playbook — no studies needed. Google keeps its search algorithms secret — as a way to keep them out of the hands of competitors.\u003c/p>\n\u003cp>\"So there are so many things going on in our firm and we're not telling you about them and that's part of the allure and the mystique of the organization,\" says Pozner. \"That keeps people excited about what's coming next.\"\u003c/p>\n\u003cp>This is totally contrary to how the medical and biotech fields work — studies are published in journals and reviewed by peers and products require government approval. This may gum up the works of Silicon Valley's fast-paced innovation economy, but it's for a good reason, says Stanford's Ioannidis.\u003c/p>\n\u003cp>\"It's not such a horrible thing if your mobile phone battery dies an hour earlier than it's supposed to,\" he says. \"But if a patient gets given the wrong results and then going down the path of making wrong decisions, that's serious. People can lose their lives.\"\u003c/p>\n\u003cp>As for Theranos and Elizabeth Holmes — the company is \u003ca href=\"http://www.bloomberg.com/news/articles/2016-04-18/theranos-is-under-investigation-by-sec-u-s-attorney-s-office\">facing scrutiny\u003c/a> from the Securities and Exchange Commission and the U.S. Attorney's Office for the Northern District of California. Some Theranos supporters believe in the end Holmes will turn out to be right.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Meanwhile, venture capital dollars going into biotech rose nearly 20 percent between 2014 and 2015. Perhaps this round of funding will come with less hype and more scrutiny.\u003c/p>\n\u003cdiv class=\"fullattribution\">Copyright 2016 NPR. To see more, visit http://www.npr.org/.\u003cimg src=\"http://www.google-analytics.com/__utm.gif?utmac=UA-5828686-4&utmdt=Biotech%27s+Theranos+Offers+A+Cautionary+Tale+For+Silicon+Valley&utme=8(APIKey)9(MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004)\">\u003c/div>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/156558/theranos-debacle-shows-differences-between-silicon-valley-and-biomed",
"authors": [
"byline_futureofyou_156558"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_87",
"futureofyou_617"
],
"featImg": "futureofyou_156559",
"label": "futureofyou"
},
"futureofyou_152359": {
"type": "posts",
"id": "futureofyou_152359",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "152359",
"score": null,
"sort": [
1461627046000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1461627046,
"format": "standard",
"disqusTitle": "Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos",
"title": "Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>The last few months have witnessed the unraveling of the remarkable life sciences company Theranos, culminating in the latest news that federal regulators may \u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\">ban founder\u003c/a> Elizabeth Holmes from the blood-testing industry for at least two years. The company is also facing a \u003ca href=\"http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055\">federal criminal investigation\u003c/a> into whether it misled investors about its technology and company operations.\u003c/p>\n\u003cp>How has this widely acclaimed biomedical innovator fallen so far, so fast?\u003c/p>\n\u003caside class=\"pullquote alignright\">\"Theranos has had medical laboratory experts – including me – scratching their heads for some time.\"\u003c/aside>\n\u003cp>Theranos' revolutionary claim that won over investors was that it could accurately run \u003ca href=\"http://fortune.com/2014/06/12/theranos-blood-holmes/\">tests\u003c/a> using a small amount of blood taken from a poke in the patient’s finger, instead of a syringe full from a needle stuck in a vein. The idea was that dozens of tests, such as cholesterol and thyroid hormone levels, could be run on a single, tiny blood sample.\u003c/p>\n\u003cp>Theranos has had \u003ca href=\"http://www.degruyter.com/view/j/cclm.2015.53.issue-7/cclm-2015-0356/cclm-2015-0356.xml\">medical laboratory experts\u003c/a> – including me – scratching their heads for some time. Having worked quite a bit in development of innovative medical tests, I knew what the company was promising just didn’t make a lot of sense.\u003c/p>\n\u003cp>\u003cstrong>Theranos' Much-Hyped Blood Testing Technology\u003c/strong>\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Theranos \u003ca href=\"http://www.cleveland.com/healthfit/index.ssf/2015/03/cleveland_clinic_partners_with.html\">wowed investors\u003c/a>, journalists and even groups like the Cleveland Clinic and Walgreens with what you might call an “iMedicine” vision of blood testing. \u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-thumbnail wp-image-152329\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/The-Conversation-400x32.png\" alt=\"The Conversation\" width=\"400\" height=\"32\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-400x32.png 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-800x63.png 800w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-768x61.png 768w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-1180x93.png 1180w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-1920x152.png 1920w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-960x76.png 960w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation.png 2000w\" sizes=\"(max-width: 400px) 100vw, 400px\">Basically, the idea was this. A few drops of blood from a fingertip are collected into a “nanotainer” collection tube and analyzed on the company’s proprietary machine, named after famed inventor Thomas Edison. How exactly the Edison devices \u003ca href=\"http://www.techinsider.io/how-theranos-revolutionary-technology-works-2015-10\">work is unknown\u003c/a>. But the claim was that many – possibly dozens – of tests could be run on those few drops of blood.\u003c/p>\n\u003cp>From a clinical perspective, this was always concerning, as such a shotgun approach to medical testing is actually very bad medicine. It is well-known that running numerous tests without symptoms or signs of disease \u003ca href=\"http://well.blogs.nytimes.com/2015/04/13/quantifying-tests-instead-of-good-care\">invariably leads to false positive results\u003c/a>.\u003c/p>\n\u003cp>Questions about the company’s technology came to a head in October. The Wall Street Journal alleged that Theranos might actually be performing the majority of its tests using \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\">traditional machines\u003c/a>, the kind already in use in labs across the country, instead of its own much touted Edison devices. And then the FDA called the nanotainer an “\u003ca href=\"http://money.cnn.com/2015/10/27/technology/theranos-fda-reports/\">uncleared medical device\u003c/a>.” The company stopped using its signature collection tube, except in \u003ca href=\"http://www.bloomberg.com/news/articles/2015-10-16/theranos-limits-new-blood-technology-to-one-in-200-tests\">the single test\u003c/a> that had been cleared by the FDA.\u003c/p>\n\u003cp>And, by the way, a machine capable of measuring many molecules on a drop of blood might seem like a breakthrough, unless you are someone familiar enough with life sciences technology to know that such capability has been invented numerous times. For instance, in my laboratory, we have a small handheld analyzer called an \u003ca href=\"https://www.abbottpointofcare.com/products-services/istat-handheld\">I-STAT\u003c/a>. It can do 25 different tests on very small amounts of blood. It was developed more than 20 years ago and is commonplace today.\u003c/p>\n\u003cp>\u003cstrong>Blood From a Finger Isn’t Same as Blood From a Vein\u003c/strong>\u003c/p>\n\u003cp>Let’s leave the technical issues aside for a moment and focus on those drops of blood from a fingertip.\u003c/p>\n\u003cfigure id=\"attachment_148281\" class=\"wp-caption alignright\" style=\"max-width: 400px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/Holmes-1.jpg\">\u003cimg class=\"wp-image-148281 size-thumbnail\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/Holmes-1-400x199.jpg\" alt=\"Elizabeth Holmes discussing Theranos' problems last week on the 'Today' show.\" width=\"400\" height=\"199\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-400x199.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1.jpg 632w\" sizes=\"(max-width: 400px) 100vw, 400px\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">Elizabeth Holmes discussing Theranos' problems last week on the 'Today' show. \u003ccite>(Today show)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>The vast majority of FDA-approved medically important laboratory tests are based on blood taken from a vein, not from the finger. In fact, the package inserts for medical tests cleared by the FDA say something like “blood should be collected using standard venous blood collection techniques.”\u003c/p>\n\u003cp>To understand why that matters, let’s start with some simple physiology. The human body can be considered a series of compartments; the concentration of any given molecule in blood or tissue fluid may vary from one compartment to the next.\u003c/p>\n\u003cp>A small molecule, such as glucose, can move easily between these compartments, and any bodily fluid can generally be used to test its concentration. This is why testing blood sugar with a finger prick works.\u003c/p>\n\u003cp>But large, medically important molecules like proteins and lipids are not always found in uniform concentrations throughout the body. The \u003ca href=\"http://ajcp.oxfordjournals.org/content/144/6/885.abstract\">composition of blood from finger pricks\u003c/a> from the same person can vary, a problem that doesn’t happen in blood taken from a vein.\u003c/p>\n\u003cp>When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein.\u003c/p>\n\u003cp>The point is that blood taken from a finger would be considered another bodily fluid by the FDA, and any tests using finger prick blood would need to cleared by the FDA. According to news reports, at one time Theranos was seeking FDA clearances for as many as \u003ca href=\"http://fortune.com/2015/07/16/fda-clears-theranos-to-do-test-outside-lab/\">120 tests\u003c/a>. Even if its technology actually works, hundreds of FDA clearances would have required hundreds of clinical trials, a process that would have taken years to complete.\u003c/p>\n\u003cp>Theranos has gotten only one test cleared by the FDA. That test – for Herpes infection – is for the detection of antibodies, not a measurement of their concentration. Tests for the presence or absence of a molecule are much simpler than those that quantify its concentration.\u003c/p>\n\u003cp>In March, researchers at the Mount Sinai School of Medicine published a \u003ca href=\"http://www.jci.org/articles/view/86318\">secret shopper study\u003c/a> comparing Theranos to Quest and LabCorp, two major medical testing companies. Overall, more of the results from Theranos were outside the normal range, indicating a need for further medical testing. This is a worrisome result because the secret shoppers were healthy adults. But it’s also difficult to interpret because we don’t know if Theranos used its Edison machines or ran diluted samples on conventional analyzers.\u003c/p>\n\u003cp>\u003cstrong>Millions Invested Without Any Proof\u003c/strong>\u003c/p>\n\u003cp>Why didn’t investors and journalists dig more deeply, such as by demanding a head-to-head comparison of Theranos' Edison machine to standard chemistry analyzers?\u003c/p>\n\u003cp>Part of the problem seems to have been the secrecy surrounding these types of startups. Theranos \u003ca href=\"http://www.newyorker.com/magazine/2014/12/15/blood-simpler\">always asserted\u003c/a> that it had to operate in “stealth mode” to protect its lead in breakthrough technology, which means that there was literally no peer-reviewed information out there about its technology.\u003c/p>\n\u003cp>But the leading explanation seems to be that they were \u003ca href=\"http://www.unz.com/isteve/the-elizabeth-holmes-reality-distortion-field/\">enthralled by the company’s charismatic young founder\u003c/a>. Laudatory magazine cover articles about Holmes have been so numerous that \u003ca href=\"http://recode.net/2015/10/26/theranos-ceo-elizabeth-holmess-five-best-cover-story-appearances-ranked/\">the phenomenon\u003c/a> has itself been a topic of discussion.\u003c/p>\n\u003cp>Theranos' \u003ca href=\"http://www.wsj.com/articles/at-theranos-many-strategies-and-snags-1451259629\">board of directors\u003c/a> also lacked anyone with expertise in laboratory testing or medical diagnostics. This should have been \u003ca href=\"http://www.businessinsider.com/theranos-board-of-directors-2015-10\">a warning sign\u003c/a>.\u003c/p>\n\u003cp>\u003cstrong>Show Me the Data\u003c/strong>\u003c/p>\n\u003cp>Just a few weeks before regulators proposed banning Holmes and Theranos President Sunny Balwani from the blood-testing industry, the \u003ca href=\"http://fortune.com/2016/04/07/theranos-adds-startlingly-well-qualified-medical-board/\">company tried to remedy this\u003c/a> by bulking up its medical advisor board with well-qualified experts in chemistry, pathology and clinical chemistry.\u003c/p>\n\u003cp>It’s hard to imagine these experts would have signed on amid all the bad publicity and allegations without demanding proof that the technology works, but who knows?\u003c/p>\n\u003cp>It still remains possible that Theranos has discovered a breakthrough technology that can do hundreds of lab tests on a drop of fluid from a patient’s finger. But even if this increasingly unlikely prospect is a reality, Holmes' erstwhile acolytes need to remember the lessons learned from the pantheon of past pied pipers and summed up by statistician W. Edwards Deming:\u003c/p>\n\u003cblockquote>\u003cp>In God we trust; all others must bring data.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cimg src=\"https://counter.theconversation.edu.au/content/57787/count.gif\" alt=\"The Conversation\" width=\"1\" height=\"1\">\u003cem>\u003ca href=\"http://theconversation.com/profiles/norman-a-paradis-166604\">Norman A. Paradis\u003c/a>, Professor of Medicine, \u003ca href=\"http://theconversation.com/institutions/dartmouth-college\">Dartmouth College\u003c/a>\u003c/em>\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\u003cem>This article was originally published on \u003ca href=\"http://theconversation.com\">The Conversation\u003c/a>. Read the \u003ca href=\"https://theconversation.com/the-rise-and-fall-of-theranos-so-many-lessons-in-a-drop-of-blood-57787\">original article\u003c/a>.\u003c/em>\u003c/p>\n\n",
"disqusIdentifier": "152359 http://ww2.kqed.org/futureofyou/?p=152359",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1267,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 34
},
"modified": 1461626546,
"excerpt": "\"I knew what the company was promising just didn’t make a lot of sense.\"",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": ""I knew what the company was promising just didn’t make a lot of sense."",
"title": "Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos",
"datePublished": "2016-04-25T16:30:46-07:00",
"dateModified": "2016-04-25T16:22:26-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "analysis-why-medical-lab-experts-were-always-skeptical-of-theranos",
"status": "publish",
"nprByline": "Norman A. Paradis, Dartmouth College\u003cbr />The Conversation",
"path": "/futureofyou/152359/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The last few months have witnessed the unraveling of the remarkable life sciences company Theranos, culminating in the latest news that federal regulators may \u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\">ban founder\u003c/a> Elizabeth Holmes from the blood-testing industry for at least two years. The company is also facing a \u003ca href=\"http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055\">federal criminal investigation\u003c/a> into whether it misled investors about its technology and company operations.\u003c/p>\n\u003cp>How has this widely acclaimed biomedical innovator fallen so far, so fast?\u003c/p>\n\u003caside class=\"pullquote alignright\">\"Theranos has had medical laboratory experts – including me – scratching their heads for some time.\"\u003c/aside>\n\u003cp>Theranos' revolutionary claim that won over investors was that it could accurately run \u003ca href=\"http://fortune.com/2014/06/12/theranos-blood-holmes/\">tests\u003c/a> using a small amount of blood taken from a poke in the patient’s finger, instead of a syringe full from a needle stuck in a vein. The idea was that dozens of tests, such as cholesterol and thyroid hormone levels, could be run on a single, tiny blood sample.\u003c/p>\n\u003cp>Theranos has had \u003ca href=\"http://www.degruyter.com/view/j/cclm.2015.53.issue-7/cclm-2015-0356/cclm-2015-0356.xml\">medical laboratory experts\u003c/a> – including me – scratching their heads for some time. Having worked quite a bit in development of innovative medical tests, I knew what the company was promising just didn’t make a lot of sense.\u003c/p>\n\u003cp>\u003cstrong>Theranos' Much-Hyped Blood Testing Technology\u003c/strong>\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Theranos \u003ca href=\"http://www.cleveland.com/healthfit/index.ssf/2015/03/cleveland_clinic_partners_with.html\">wowed investors\u003c/a>, journalists and even groups like the Cleveland Clinic and Walgreens with what you might call an “iMedicine” vision of blood testing. \u003c/p>\n\u003cp>\u003cimg class=\"alignleft size-thumbnail wp-image-152329\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/The-Conversation-400x32.png\" alt=\"The Conversation\" width=\"400\" height=\"32\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-400x32.png 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-800x63.png 800w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-768x61.png 768w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-1180x93.png 1180w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-1920x152.png 1920w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation-960x76.png 960w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/The-Conversation.png 2000w\" sizes=\"(max-width: 400px) 100vw, 400px\">Basically, the idea was this. A few drops of blood from a fingertip are collected into a “nanotainer” collection tube and analyzed on the company’s proprietary machine, named after famed inventor Thomas Edison. How exactly the Edison devices \u003ca href=\"http://www.techinsider.io/how-theranos-revolutionary-technology-works-2015-10\">work is unknown\u003c/a>. But the claim was that many – possibly dozens – of tests could be run on those few drops of blood.\u003c/p>\n\u003cp>From a clinical perspective, this was always concerning, as such a shotgun approach to medical testing is actually very bad medicine. It is well-known that running numerous tests without symptoms or signs of disease \u003ca href=\"http://well.blogs.nytimes.com/2015/04/13/quantifying-tests-instead-of-good-care\">invariably leads to false positive results\u003c/a>.\u003c/p>\n\u003cp>Questions about the company’s technology came to a head in October. The Wall Street Journal alleged that Theranos might actually be performing the majority of its tests using \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\">traditional machines\u003c/a>, the kind already in use in labs across the country, instead of its own much touted Edison devices. And then the FDA called the nanotainer an “\u003ca href=\"http://money.cnn.com/2015/10/27/technology/theranos-fda-reports/\">uncleared medical device\u003c/a>.” The company stopped using its signature collection tube, except in \u003ca href=\"http://www.bloomberg.com/news/articles/2015-10-16/theranos-limits-new-blood-technology-to-one-in-200-tests\">the single test\u003c/a> that had been cleared by the FDA.\u003c/p>\n\u003cp>And, by the way, a machine capable of measuring many molecules on a drop of blood might seem like a breakthrough, unless you are someone familiar enough with life sciences technology to know that such capability has been invented numerous times. For instance, in my laboratory, we have a small handheld analyzer called an \u003ca href=\"https://www.abbottpointofcare.com/products-services/istat-handheld\">I-STAT\u003c/a>. It can do 25 different tests on very small amounts of blood. It was developed more than 20 years ago and is commonplace today.\u003c/p>\n\u003cp>\u003cstrong>Blood From a Finger Isn’t Same as Blood From a Vein\u003c/strong>\u003c/p>\n\u003cp>Let’s leave the technical issues aside for a moment and focus on those drops of blood from a fingertip.\u003c/p>\n\u003cfigure id=\"attachment_148281\" class=\"wp-caption alignright\" style=\"max-width: 400px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/Holmes-1.jpg\">\u003cimg class=\"wp-image-148281 size-thumbnail\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/04/Holmes-1-400x199.jpg\" alt=\"Elizabeth Holmes discussing Theranos' problems last week on the 'Today' show.\" width=\"400\" height=\"199\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-400x199.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1.jpg 632w\" sizes=\"(max-width: 400px) 100vw, 400px\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">Elizabeth Holmes discussing Theranos' problems last week on the 'Today' show. \u003ccite>(Today show)\u003c/cite>\u003c/figcaption>\u003c/figure>\n\u003cp>The vast majority of FDA-approved medically important laboratory tests are based on blood taken from a vein, not from the finger. In fact, the package inserts for medical tests cleared by the FDA say something like “blood should be collected using standard venous blood collection techniques.”\u003c/p>\n\u003cp>To understand why that matters, let’s start with some simple physiology. The human body can be considered a series of compartments; the concentration of any given molecule in blood or tissue fluid may vary from one compartment to the next.\u003c/p>\n\u003cp>A small molecule, such as glucose, can move easily between these compartments, and any bodily fluid can generally be used to test its concentration. This is why testing blood sugar with a finger prick works.\u003c/p>\n\u003cp>But large, medically important molecules like proteins and lipids are not always found in uniform concentrations throughout the body. The \u003ca href=\"http://ajcp.oxfordjournals.org/content/144/6/885.abstract\">composition of blood from finger pricks\u003c/a> from the same person can vary, a problem that doesn’t happen in blood taken from a vein.\u003c/p>\n\u003cp>When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein.\u003c/p>\n\u003cp>The point is that blood taken from a finger would be considered another bodily fluid by the FDA, and any tests using finger prick blood would need to cleared by the FDA. According to news reports, at one time Theranos was seeking FDA clearances for as many as \u003ca href=\"http://fortune.com/2015/07/16/fda-clears-theranos-to-do-test-outside-lab/\">120 tests\u003c/a>. Even if its technology actually works, hundreds of FDA clearances would have required hundreds of clinical trials, a process that would have taken years to complete.\u003c/p>\n\u003cp>Theranos has gotten only one test cleared by the FDA. That test – for Herpes infection – is for the detection of antibodies, not a measurement of their concentration. Tests for the presence or absence of a molecule are much simpler than those that quantify its concentration.\u003c/p>\n\u003cp>In March, researchers at the Mount Sinai School of Medicine published a \u003ca href=\"http://www.jci.org/articles/view/86318\">secret shopper study\u003c/a> comparing Theranos to Quest and LabCorp, two major medical testing companies. Overall, more of the results from Theranos were outside the normal range, indicating a need for further medical testing. This is a worrisome result because the secret shoppers were healthy adults. But it’s also difficult to interpret because we don’t know if Theranos used its Edison machines or ran diluted samples on conventional analyzers.\u003c/p>\n\u003cp>\u003cstrong>Millions Invested Without Any Proof\u003c/strong>\u003c/p>\n\u003cp>Why didn’t investors and journalists dig more deeply, such as by demanding a head-to-head comparison of Theranos' Edison machine to standard chemistry analyzers?\u003c/p>\n\u003cp>Part of the problem seems to have been the secrecy surrounding these types of startups. Theranos \u003ca href=\"http://www.newyorker.com/magazine/2014/12/15/blood-simpler\">always asserted\u003c/a> that it had to operate in “stealth mode” to protect its lead in breakthrough technology, which means that there was literally no peer-reviewed information out there about its technology.\u003c/p>\n\u003cp>But the leading explanation seems to be that they were \u003ca href=\"http://www.unz.com/isteve/the-elizabeth-holmes-reality-distortion-field/\">enthralled by the company’s charismatic young founder\u003c/a>. Laudatory magazine cover articles about Holmes have been so numerous that \u003ca href=\"http://recode.net/2015/10/26/theranos-ceo-elizabeth-holmess-five-best-cover-story-appearances-ranked/\">the phenomenon\u003c/a> has itself been a topic of discussion.\u003c/p>\n\u003cp>Theranos' \u003ca href=\"http://www.wsj.com/articles/at-theranos-many-strategies-and-snags-1451259629\">board of directors\u003c/a> also lacked anyone with expertise in laboratory testing or medical diagnostics. This should have been \u003ca href=\"http://www.businessinsider.com/theranos-board-of-directors-2015-10\">a warning sign\u003c/a>.\u003c/p>\n\u003cp>\u003cstrong>Show Me the Data\u003c/strong>\u003c/p>\n\u003cp>Just a few weeks before regulators proposed banning Holmes and Theranos President Sunny Balwani from the blood-testing industry, the \u003ca href=\"http://fortune.com/2016/04/07/theranos-adds-startlingly-well-qualified-medical-board/\">company tried to remedy this\u003c/a> by bulking up its medical advisor board with well-qualified experts in chemistry, pathology and clinical chemistry.\u003c/p>\n\u003cp>It’s hard to imagine these experts would have signed on amid all the bad publicity and allegations without demanding proof that the technology works, but who knows?\u003c/p>\n\u003cp>It still remains possible that Theranos has discovered a breakthrough technology that can do hundreds of lab tests on a drop of fluid from a patient’s finger. But even if this increasingly unlikely prospect is a reality, Holmes' erstwhile acolytes need to remember the lessons learned from the pantheon of past pied pipers and summed up by statistician W. Edwards Deming:\u003c/p>\n\u003cblockquote>\u003cp>In God we trust; all others must bring data.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cimg src=\"https://counter.theconversation.edu.au/content/57787/count.gif\" alt=\"The Conversation\" width=\"1\" height=\"1\">\u003cem>\u003ca href=\"http://theconversation.com/profiles/norman-a-paradis-166604\">Norman A. Paradis\u003c/a>, Professor of Medicine, \u003ca href=\"http://theconversation.com/institutions/dartmouth-college\">Dartmouth College\u003c/a>\u003c/em>\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003cem>This article was originally published on \u003ca href=\"http://theconversation.com\">The Conversation\u003c/a>. Read the \u003ca href=\"https://theconversation.com/the-rise-and-fall-of-theranos-so-many-lessons-in-a-drop-of-blood-57787\">original article\u003c/a>.\u003c/em>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/152359/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos",
"authors": [
"byline_futureofyou_152359"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_152361",
"label": "futureofyou"
},
"futureofyou_148241": {
"type": "posts",
"id": "futureofyou_148241",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "148241",
"score": null,
"sort": [
1461025837000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1461025837,
"format": "aside",
"disqusTitle": "Theranos Under Criminal Investigation",
"title": "Theranos Under Criminal Investigation",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>\u003cstrong>Update 5:40 p.m.\u003c/strong> Both \u003ca href=\"http://www.bloomberg.com/news/articles/2016-04-18/theranos-is-under-investigation-by-sec-u-s-attorney-s-office\" target=\"_blank\">Bloomberg\u003c/a> and \u003ca href=\"http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055\" target=\"_blank\">The Wall Street Journal\u003c/a> are reporting federal prosecutors and the Securities and Exchange Commission are investigating Theranos. Bloomberg identified the U.S. Attorney’s Office for the Northern District of California as launching a probe, and said Theranos had confirmed both investigations.\u003c/p>\n\u003cp>The Journal, citing anonymous sources, said that Walgreens and the New York State Dept. of Health have received subpoenas seeking information on Theranos' description of its technology.\u003c/p>\n\u003cp>Meanwhile, the SEC is looking into potentially deceptive statements Theranos may have made to investors, the paper said.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>\u003c!-- iframe plugin v.4.3 wordpress.org/plugins/iframe/ -->\u003cbr>\n\u003ciframe src=\"http://www.today.com/offsite/theranos-ceo-elizabeth-holmes-i-m-devastated-about-blood-test-issues-668286019825\" width=\"640\" height=\"350\" frameborder=\"0\" scrolling=\"no\" class=\"iframe-class\">\u003c/iframe>\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>NBC's Today show this morning broadcast an interview with Theranos CEO and founder Elizabeth Holmes, the first time Holmes has spoken in public about the federal government's scathing inspection report on the company's California blood lab. That assessment found problems at the lab that it said were potentially life-threatening to patients.\u003c/p>\n\u003cp>Holmes took responsibility for the lab's failures and told interviewer Maria Shriver she felt \"devastated that we did not catch and fix these issues faster.\"\u003c/p>\n\u003cp>When asked if she thought that Theranos would survive, Holmes said, \"Absolutely.\"\u003c/p>\n\u003cp>She told Shriver the experience had made her \"a better person\" and \"a better leader.\"\u003c/p>\n\u003cp>Theranos, which has attempted to revolutionize the blood-testing industry, is currently in a holding period while the Centers for Medicaid & Medicare Services review the company's arguments as to why it shouldn't be subject to severe sanctions. CMS is threatening penalties after it found Theranos' attempt to correct the lab's deficiencies insufficient.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>The agency has proposed revoking the company's license to operate the lab, as well as banning Holmes from owning a testing facility for at least two years.\u003c/p>\n\n",
"disqusIdentifier": "148241 http://ww2.kqed.org/futureofyou/?p=148241",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 305,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 13
},
"modified": 1461162144,
"excerpt": "More problems for the beleaguered blood-testing company.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "More problems for the beleaguered blood-testing company.",
"title": "Theranos Under Criminal Investigation | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Under Criminal Investigation",
"datePublished": "2016-04-18T17:30:37-07:00",
"dateModified": "2016-04-20T07:22:24-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "elizabeth-holmes-says-theranos-will-absolutely-survive-video",
"status": "publish",
"path": "/futureofyou/148241/elizabeth-holmes-says-theranos-will-absolutely-survive-video",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cstrong>Update 5:40 p.m.\u003c/strong> Both \u003ca href=\"http://www.bloomberg.com/news/articles/2016-04-18/theranos-is-under-investigation-by-sec-u-s-attorney-s-office\" target=\"_blank\">Bloomberg\u003c/a> and \u003ca href=\"http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055\" target=\"_blank\">The Wall Street Journal\u003c/a> are reporting federal prosecutors and the Securities and Exchange Commission are investigating Theranos. Bloomberg identified the U.S. Attorney’s Office for the Northern District of California as launching a probe, and said Theranos had confirmed both investigations.\u003c/p>\n\u003cp>The Journal, citing anonymous sources, said that Walgreens and the New York State Dept. of Health have received subpoenas seeking information on Theranos' description of its technology.\u003c/p>\n\u003cp>Meanwhile, the SEC is looking into potentially deceptive statements Theranos may have made to investors, the paper said.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>\u003c!-- iframe plugin v.4.3 wordpress.org/plugins/iframe/ -->\u003cbr>\n\u003ciframe src=\"http://www.today.com/offsite/theranos-ceo-elizabeth-holmes-i-m-devastated-about-blood-test-issues-668286019825\" width=\"640\" height=\"350\" frameborder=\"0\" scrolling=\"no\" class=\"iframe-class\">\u003c/iframe>\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>NBC's Today show this morning broadcast an interview with Theranos CEO and founder Elizabeth Holmes, the first time Holmes has spoken in public about the federal government's scathing inspection report on the company's California blood lab. That assessment found problems at the lab that it said were potentially life-threatening to patients.\u003c/p>\n\u003cp>Holmes took responsibility for the lab's failures and told interviewer Maria Shriver she felt \"devastated that we did not catch and fix these issues faster.\"\u003c/p>\n\u003cp>When asked if she thought that Theranos would survive, Holmes said, \"Absolutely.\"\u003c/p>\n\u003cp>She told Shriver the experience had made her \"a better person\" and \"a better leader.\"\u003c/p>\n\u003cp>Theranos, which has attempted to revolutionize the blood-testing industry, is currently in a holding period while the Centers for Medicaid & Medicare Services review the company's arguments as to why it shouldn't be subject to severe sanctions. CMS is threatening penalties after it found Theranos' attempt to correct the lab's deficiencies insufficient.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>The agency has proposed revoking the company's license to operate the lab, as well as banning Holmes from owning a testing facility for at least two years.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/148241/elizabeth-holmes-says-theranos-will-absolutely-survive-video",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_148281",
"label": "futureofyou"
},
"futureofyou_148427": {
"type": "posts",
"id": "futureofyou_148427",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "148427",
"score": null,
"sort": [
1461018603000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1461018603,
"format": "standard",
"disqusTitle": "Elizabeth Holmes to Present Theranos Data at Scientific Conference",
"title": "Elizabeth Holmes to Present Theranos Data at Scientific Conference",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>\u003cem>Update 5:30 p.m.\u003c/em> Meanwhile, the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">company is under criminal investigation\u003c/a>.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003cbr>\nIn what is sure to be a hot ticket this summer, Elizabeth Holmes is going to present data on Theranos' technology at a meeting of scientists well-equipped to judge its validity.\u003c/p>\n\u003cp>The American Association for Clinical Chemistry said today that Holmes will speak at a plenary session of its annual meeting in Philadelphia on Aug. 1.\u003c/p>\n\u003cp>Theranos spokeswoman Brooke Buchanan confirmed the presentation, saying, \"We're really excited about the opportunity to share our technology with the world.”\u003c/p>\n\u003cp>Molly Pollen, the AACC's director of communications and PR, said the organization had been talking to Theranos for \"a few weeks\" with confirmation coming today.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>The AACC will review Holmes' slides before they are presented, Pollen said, but it won't investigate the validity of their content.\u003c/p>\n\u003cp>Holmes will answer questions from the audience -- made up of laboratory medicine experts and academics -- at the end of her presentation. Pollen said those in attendance will include people who work on \u003ca href=\"https://www.google.com/search?q=microfluidics\" target=\"_blank\">microfluidics\u003c/a> and will be able to \"speak to what [Theranos'] technology does and how valid it is.\"\u003c/p>\n\u003cp>Theranos has never presented data or published research in a scientific journal that would demonstrate the effectiveness of its proprietary blood-analysis technology, which the company calls \"Edison.\"\u003c/p>\n\u003cp>Theranos, a private company, came to prominence and achieved a \u003ca href=\"http://www.wsj.com/articles/theranos-authorizes-new-shares-that-could-raise-valuation-1446083616\" target=\"_blank\">valuation as high as $10 billion\u003c/a> by claiming it could perform a variety of tests using only the small amount of blood obtained from a single finger prick, collected in small capsules called \"nanotainers.\"\u003c/p>\n\u003cp>But the FDA has only approved that technology for one test, for herpes, and more recently an investigation by The Wall Street Journal and a scathing government report on Theranos' California lab have cast serious doubt over whether the company's claims have any merit. The Centers for Medicare & Medicaid Services, which issued the report, is now considering whether to levy harsh penalties on both Theranos and Holmes.\u003c/p>\n\u003cp>In February, The Financial Times \u003ca href=\"http://www.ft.com/intl/cms/s/0/09b69eb8-de5f-11e5-b072-006d8d362ba3.html#axzz46DvRDg1w\" target=\"_blank\">reported\u003c/a> that pharmacy chain Walgreens was looking for a way out of its partnership with the startup.\u003c/p>\n\u003cp>Just today, on NBC's \"Today\" show, Holmes \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">broke her silence\u003c/a> on the government's contention that problems at its lab have put patients in serious jeopardy, saying she was \"devastated that we did not catch and fix these issues faster.\"\u003c/p>\n\u003cp>When asked if the company would survive its current travails, she said, \"Absolutely.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>AACC press release:\u003c/em>\u003c/p>\n\u003cblockquote>\u003cp>AACC is pleased to announce that Theranos founder and CEO Elizabeth Holmes will give a plenary presentation at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia. For the first time, Holmes will present data at a scientific conference that describes Theranos' technologies, including small sample volume testing and finger-stick collection.\u003c/p>\n\u003cp>After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the United States. The company asserted that its proprietary technologies could perform tests on a capsule-sized blood sample collected from patients via finger-stick. Using these tiny samples, the company promised to improve access and provide results more quickly than traditional lab companies, while charging less.\u003c/p>\n\u003cp>Holmes will present on Theranos' technologies on August 1 at the 68th AACC Annual Scientific Meeting, the largest and most recognized international forum for presenting vital science and groundbreaking advances in laboratory medicine. Attendees of the meeting are experts in the field, with the knowledge and experience needed to assess Theranos' data. After her presentation, Holmes will answer questions from these experts to further clarify the science, accuracy, and reliability of Theranos' technologies, as well as its impact on patient care and safety.\u003c/p>\n\u003cp>\"There is no better place to present Theranos' technology than at the AACC Annual Scientific Meeting, where leaders in laboratory medicine can evaluate Ms. Holmes' data and research,\" said AACC CEO Janet B. Kreizman. \"AACC members have been asking for this information, and we are thrilled that Ms. Holmes is presenting the science behind the technology for the first time at AACC, the premier scientific forum for laboratory medicine.\"\u003c/p>\u003c/blockquote>\n\n",
"disqusIdentifier": "148427 http://ww2.kqed.org/futureofyou/?p=148427",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-to-present-theranos-data-at-scientific-conference/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 707,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 20
},
"modified": 1461027313,
"excerpt": "Holmes will present at a plenary session of the American Association for Clinical Chemistry on Aug. 1 in Philadelphia.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Holmes will present at a plenary session of the American Association for Clinical Chemistry on Aug. 1 in Philadelphia.",
"title": "Elizabeth Holmes to Present Theranos Data at Scientific Conference | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Elizabeth Holmes to Present Theranos Data at Scientific Conference",
"datePublished": "2016-04-18T15:30:03-07:00",
"dateModified": "2016-04-18T17:55:13-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "elizabeth-holmes-to-present-theranos-data-at-scientific-conference",
"status": "publish",
"path": "/futureofyou/148427/elizabeth-holmes-to-present-theranos-data-at-scientific-conference",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cem>Update 5:30 p.m.\u003c/em> Meanwhile, the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">company is under criminal investigation\u003c/a>.\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003cbr>\nIn what is sure to be a hot ticket this summer, Elizabeth Holmes is going to present data on Theranos' technology at a meeting of scientists well-equipped to judge its validity.\u003c/p>\n\u003cp>The American Association for Clinical Chemistry said today that Holmes will speak at a plenary session of its annual meeting in Philadelphia on Aug. 1.\u003c/p>\n\u003cp>Theranos spokeswoman Brooke Buchanan confirmed the presentation, saying, \"We're really excited about the opportunity to share our technology with the world.”\u003c/p>\n\u003cp>Molly Pollen, the AACC's director of communications and PR, said the organization had been talking to Theranos for \"a few weeks\" with confirmation coming today.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>The AACC will review Holmes' slides before they are presented, Pollen said, but it won't investigate the validity of their content.\u003c/p>\n\u003cp>Holmes will answer questions from the audience -- made up of laboratory medicine experts and academics -- at the end of her presentation. Pollen said those in attendance will include people who work on \u003ca href=\"https://www.google.com/search?q=microfluidics\" target=\"_blank\">microfluidics\u003c/a> and will be able to \"speak to what [Theranos'] technology does and how valid it is.\"\u003c/p>\n\u003cp>Theranos has never presented data or published research in a scientific journal that would demonstrate the effectiveness of its proprietary blood-analysis technology, which the company calls \"Edison.\"\u003c/p>\n\u003cp>Theranos, a private company, came to prominence and achieved a \u003ca href=\"http://www.wsj.com/articles/theranos-authorizes-new-shares-that-could-raise-valuation-1446083616\" target=\"_blank\">valuation as high as $10 billion\u003c/a> by claiming it could perform a variety of tests using only the small amount of blood obtained from a single finger prick, collected in small capsules called \"nanotainers.\"\u003c/p>\n\u003cp>But the FDA has only approved that technology for one test, for herpes, and more recently an investigation by The Wall Street Journal and a scathing government report on Theranos' California lab have cast serious doubt over whether the company's claims have any merit. The Centers for Medicare & Medicaid Services, which issued the report, is now considering whether to levy harsh penalties on both Theranos and Holmes.\u003c/p>\n\u003cp>In February, The Financial Times \u003ca href=\"http://www.ft.com/intl/cms/s/0/09b69eb8-de5f-11e5-b072-006d8d362ba3.html#axzz46DvRDg1w\" target=\"_blank\">reported\u003c/a> that pharmacy chain Walgreens was looking for a way out of its partnership with the startup.\u003c/p>\n\u003cp>Just today, on NBC's \"Today\" show, Holmes \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">broke her silence\u003c/a> on the government's contention that problems at its lab have put patients in serious jeopardy, saying she was \"devastated that we did not catch and fix these issues faster.\"\u003c/p>\n\u003cp>When asked if the company would survive its current travails, she said, \"Absolutely.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>AACC press release:\u003c/em>\u003c/p>\n\u003cblockquote>\u003cp>AACC is pleased to announce that Theranos founder and CEO Elizabeth Holmes will give a plenary presentation at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia. For the first time, Holmes will present data at a scientific conference that describes Theranos' technologies, including small sample volume testing and finger-stick collection.\u003c/p>\n\u003cp>After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the United States. The company asserted that its proprietary technologies could perform tests on a capsule-sized blood sample collected from patients via finger-stick. Using these tiny samples, the company promised to improve access and provide results more quickly than traditional lab companies, while charging less.\u003c/p>\n\u003cp>Holmes will present on Theranos' technologies on August 1 at the 68th AACC Annual Scientific Meeting, the largest and most recognized international forum for presenting vital science and groundbreaking advances in laboratory medicine. Attendees of the meeting are experts in the field, with the knowledge and experience needed to assess Theranos' data. After her presentation, Holmes will answer questions from these experts to further clarify the science, accuracy, and reliability of Theranos' technologies, as well as its impact on patient care and safety.\u003c/p>\n\u003cp>\"There is no better place to present Theranos' technology than at the AACC Annual Scientific Meeting, where leaders in laboratory medicine can evaluate Ms. Holmes' data and research,\" said AACC CEO Janet B. Kreizman. \"AACC members have been asking for this information, and we are thrilled that Ms. Holmes is presenting the science behind the technology for the first time at AACC, the premier scientific forum for laboratory medicine.\"\u003c/p>\u003c/blockquote>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/148427/elizabeth-holmes-to-present-theranos-data-at-scientific-conference",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_865",
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_58611",
"label": "futureofyou"
},
"futureofyou_145291": {
"type": "posts",
"id": "futureofyou_145291",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "145291",
"score": null,
"sort": [
1460577703000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1460577703,
"format": "standard",
"disqusTitle": "Feds Seek Severe Sanctions Against Theranos and Holmes",
"title": "Feds Seek Severe Sanctions Against Theranos and Holmes",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Theranos' beleaguered founder, Elizabeth Holmes, may be banned from heading or working in her own labs, and her company's license to operate its laboratory in Newark, California may be revoked.\u003c/p>\n\u003caside class=\"pullquote alignright\">'(We) have determined that the laboratory's submission does not constitute a credible allegation of compliance and acceptable evidence of correction ...'\u003ccite>Centers for Medicare & Medicaid Services' letter to Theranos\u003c/cite>\u003c/aside>\n\u003cp>Despite Theranos' assurances to the contrary, federal regulators say the company has not fixed deficiencies at the lab, some of which the government classified as life-threatening, identified in a November inspection.\u003c/p>\n\u003cp>The \u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\" target=\"_blank\">news broke\u003c/a> in the Wall Street Journal, which has broken just about all of the news on Theranos' decline since last fall.\u003c/p>\n\u003cp>'(W)e have determined that the laboratory's submission does not constitute a credible allegation of compliance and acceptable evidence of correction ...\" the agency wrote to Theranos in a letter dated March 18, portions of which were posted online by the Journal.\u003c/p>\n\u003cp>As a result, CMS is threatening to ban founder Elizabeth Holmes and president Sunny Balwani from lab operations for at least two years, the Journal says. CMS is also threatening to revoke the Newark lab's federal license, which means the lab will no longer be allowed to perform any testing.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>[contextly_sidebar id=\"ye0MLE65kwmdouPEpQDTZBtCKHywriNp\"]The letter to Theranos has not yet been made public, but you can \u003ca href=\"https://drive.google.com/viewerng/viewer?url=http://online.wsj.com/public/resources/documents/cms20160412.pdf\" target=\"_blank\">read excerpts from it here\u003c/a> or below. Those portions do not mention Holmes.\u003c/p>\n\u003cp>Here are the basics from the Journal's reporting and the excerpts from the CMS letter it has posted. (\u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\" target=\"_blank\">Read The Wall Street Journal article here\u003c/a>, or below, for further detail.)\u003c/p>\n\u003cul>\n\u003cli>CMS has concluded Theranos failed to adequately fix 43 of 45 deficiencies that the agency found in its November inspection of the Newark lab. CMS said earlier this year that certain problems with the lab's \"hematology\" required immediate correction because \"serious injury or harm, or death\" would likely result, otherwise. CMS later released the specifics of the problems it found, including incorrect results on a test called \"prothrombin time,\" which measures how long it takes for blood to clot. These inaccuracies could have led doctors dangerously astray in changing the dosage for patients taking Coumadin.\u003c/li>\n\u003cli>Theranos had until March 28 to make its case to CMS as to why the agency's recommended sanctions shouldn't be carried out. Company spokesperson Brooke Buchanan says Theranos has done just that and is waiting to hear back from CMS. A spokesperson for CMS said she couldn't comment.\u003c/li>\n\u003cli>The threatened sanctions, aside from the ones mentioned above, include potentially fining Theranos $10,000 per day until the lab is in compliance with all regulations. The company would also no longer be eligible to receive Medicare or Medicaid payments for lab services.\u003c/li>\n\u003cli>CMS also wanted Theranos to submit a list of doctors and patients who have been tested at the Newark lab from January 14 to the present. Theranos said in early March that it had already contacted \"any affected patients\" who had been subject to inaccurate tests. Theranos' Buchanan said today that CMS was \"asking for even more detail\" regarding patients, and that has now been submitted.\u003c/li>\n\u003cli>If CMS responds negatively to the response Theranos sent in March, the company can avail itself of two levels of appeal before the sanctions take effect, during which time it could keep its license and keep Holmes and Balwani active while a decision is reached.\u003c/li>\n\u003cli>CMS said Theranos cannot avoid penalties by closing the lab or ceasing to perform tests.\u003c/li>\n\u003c/ul>\n\u003cp>http://online.wsj.com/public/resources/documents/cms20160412.pdf\u003c/p>\n\u003cp>http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>This post has been corrected. Originally, it stated that Theranos currently has 10 days to respond to CMS, when in fact the company has already responded.\u003c/em>\u003c/p>\n\n",
"disqusIdentifier": "145291 http://ww2.kqed.org/futureofyou/?p=145291",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/13/wsj-feds-may-ban-elizabeth-holmes-from-theranos/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 646,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 10
},
"modified": 1460659641,
"excerpt": "The federal government finds the company did not correct 43 out of 45 problems found at its Newark, California blood-testing lab. ",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The federal government finds the company did not correct 43 out of 45 problems found at its Newark, California blood-testing lab. ",
"title": "Feds Seek Severe Sanctions Against Theranos and Holmes | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Feds Seek Severe Sanctions Against Theranos and Holmes",
"datePublished": "2016-04-13T13:01:43-07:00",
"dateModified": "2016-04-14T11:47:21-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "wsj-feds-may-ban-elizabeth-holmes-from-theranos",
"status": "publish",
"path": "/futureofyou/145291/wsj-feds-may-ban-elizabeth-holmes-from-theranos",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Theranos' beleaguered founder, Elizabeth Holmes, may be banned from heading or working in her own labs, and her company's license to operate its laboratory in Newark, California may be revoked.\u003c/p>\n\u003caside class=\"pullquote alignright\">'(We) have determined that the laboratory's submission does not constitute a credible allegation of compliance and acceptable evidence of correction ...'\u003ccite>Centers for Medicare & Medicaid Services' letter to Theranos\u003c/cite>\u003c/aside>\n\u003cp>Despite Theranos' assurances to the contrary, federal regulators say the company has not fixed deficiencies at the lab, some of which the government classified as life-threatening, identified in a November inspection.\u003c/p>\n\u003cp>The \u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\" target=\"_blank\">news broke\u003c/a> in the Wall Street Journal, which has broken just about all of the news on Theranos' decline since last fall.\u003c/p>\n\u003cp>'(W)e have determined that the laboratory's submission does not constitute a credible allegation of compliance and acceptable evidence of correction ...\" the agency wrote to Theranos in a letter dated March 18, portions of which were posted online by the Journal.\u003c/p>\n\u003cp>As a result, CMS is threatening to ban founder Elizabeth Holmes and president Sunny Balwani from lab operations for at least two years, the Journal says. CMS is also threatening to revoke the Newark lab's federal license, which means the lab will no longer be allowed to perform any testing.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>The letter to Theranos has not yet been made public, but you can \u003ca href=\"https://drive.google.com/viewerng/viewer?url=http://online.wsj.com/public/resources/documents/cms20160412.pdf\" target=\"_blank\">read excerpts from it here\u003c/a> or below. Those portions do not mention Holmes.\u003c/p>\n\u003cp>Here are the basics from the Journal's reporting and the excerpts from the CMS letter it has posted. (\u003ca href=\"http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\" target=\"_blank\">Read The Wall Street Journal article here\u003c/a>, or below, for further detail.)\u003c/p>\n\u003cul>\n\u003cli>CMS has concluded Theranos failed to adequately fix 43 of 45 deficiencies that the agency found in its November inspection of the Newark lab. CMS said earlier this year that certain problems with the lab's \"hematology\" required immediate correction because \"serious injury or harm, or death\" would likely result, otherwise. CMS later released the specifics of the problems it found, including incorrect results on a test called \"prothrombin time,\" which measures how long it takes for blood to clot. These inaccuracies could have led doctors dangerously astray in changing the dosage for patients taking Coumadin.\u003c/li>\n\u003cli>Theranos had until March 28 to make its case to CMS as to why the agency's recommended sanctions shouldn't be carried out. Company spokesperson Brooke Buchanan says Theranos has done just that and is waiting to hear back from CMS. A spokesperson for CMS said she couldn't comment.\u003c/li>\n\u003cli>The threatened sanctions, aside from the ones mentioned above, include potentially fining Theranos $10,000 per day until the lab is in compliance with all regulations. The company would also no longer be eligible to receive Medicare or Medicaid payments for lab services.\u003c/li>\n\u003cli>CMS also wanted Theranos to submit a list of doctors and patients who have been tested at the Newark lab from January 14 to the present. Theranos said in early March that it had already contacted \"any affected patients\" who had been subject to inaccurate tests. Theranos' Buchanan said today that CMS was \"asking for even more detail\" regarding patients, and that has now been submitted.\u003c/li>\n\u003cli>If CMS responds negatively to the response Theranos sent in March, the company can avail itself of two levels of appeal before the sanctions take effect, during which time it could keep its license and keep Holmes and Balwani active while a decision is reached.\u003c/li>\n\u003cli>CMS said Theranos cannot avoid penalties by closing the lab or ceasing to perform tests.\u003c/li>\n\u003c/ul>\n\u003cp>http://online.wsj.com/public/resources/documents/cms20160412.pdf\u003c/p>\n\u003cp>http://www.wsj.com/articles/regulators-propose-banning-theranos-founder-elizabeth-holmes-for-at-least-two-years-1460570869\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\u003cem>This post has been corrected. Originally, it stated that Theranos currently has 10 days to respond to CMS, when in fact the company has already responded.\u003c/em>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/145291/wsj-feds-may-ban-elizabeth-holmes-from-theranos",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_145322",
"label": "futureofyou"
},
"futureofyou_141585": {
"type": "posts",
"id": "futureofyou_141585",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "141585",
"score": null,
"sort": [
1460073275000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1460073275,
"format": "standard",
"disqusTitle": "Theranos Turns to New Medical Advisers to Help Validate Technology",
"title": "Theranos Turns to New Medical Advisers to Help Validate Technology",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Saying Theranos needs to do some damage control is like suggesting Donald Trump may want to take a moment to collect his thoughts before opening his mouth to speak.\u003c/p>\n\u003cp>After damning investigations into the high-flying company's blood-testing technology by both \u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\">The Wall Street Journal\u003c/a> and the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/01/report-shows-theranos-blood-tests-fail-even-the-companys-standards/\" target=\"_blank\">federal government\u003c/a>, Theranos, once valued at $9 billion, is now struggling to regain legitimacy.\u003c/p>\n\u003cp>On Thursday, the company \u003ca href=\"https://www.theranos.com/news/posts/theranos-announces-leading-medical-and-laboratory-experts-join-scientific-and-medical-advisory-board\" target=\"_blank\">announced\u003c/a> what appears to be an attempt at rehabilitating its reputation, stating that \"nationally respected laboratory and medical experts\" have joined its Scientific and Medical Advisory Board. (You can see who the board members are and the company's description of them below.)\u003c/p>\n\u003cp>Company spokeswoman Brooke Buchanan says all of the board members have taken part in at least one of three scientific review panels looking at the company's technology.\u003c/p>\n\u003cp>Buchanan said the board members are being paid \"the industry average of an expert in the medical field.\"\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>The board's co-chair, Dr. David Helfet, director of the Orthopedic Trauma Service, Hospital for Special Surgery and New York-Presbyterian Hospital, was quoted in Thursday's press release as saying the company \"literally took the lid off of the box\" when it came to providing board members access to its operations . (He meant \"figuratively,\" we'll have to assume.)\u003c/p>\n\u003cp>\"Experts were shown Theranos’ technology, met with Theranos scientists, and had access to any data,\" Helfet said.\u003c/p>\n\u003cp>So what did these panels conclude? I asked Brooke Buchanan. She said the board will meet again in two weeks to \"decide and strategize delivery of our data and publication.\" (See the Friday update below for a Forbes report on what two board members have to say about Theranos.)\u003c/p>\n\u003cp>The new board members join an \u003ca href=\"http://www.nytimes.com/2015/10/29/business/theranos-facing-criticism-says-it-has-changed-board-structure.html\" target=\"_blank\">initial group \u003c/a>announced by Theranos last October, formed after \u003ca href=\"http://www.businessinsider.com/theranos-board-of-directors-2015-10\" target=\"_blank\">criticism\u003c/a> that its board of directors, which included Henry Kissinger and George P. Schultz, had just one practicing medical professional.\u003c/p>\n\u003cp>If Theranos does present evidence of its technology's efficacy, it'll be a big deal. To date, the company has \u003ca href=\"http://www.forbes.com/sites/brucelee/2016/03/31/theranos-could-have-avoided-recent-problems-by-engaging-the-scientific-community/#3293c17a2559\" target=\"_blank\">published no scientific research\u003c/a> to validate its methods, though it said it \u003ca href=\"http://gizmodo.com/theranos-ceo-agrees-to-publish-data-proving-reliability-1738934618\" target=\"_blank\">intended to do so\u003c/a> as early as last October. In the absence of publicly available evidence that it can do what it says it can do, the company has left itself wide open to criticism, especially of the kind based on facts.\u003c/p>\n\u003cp>Those include the deficiencies revealed in a federal inspection of Theranos' Newark laboratory -- the nearly 30 percent failure rate of its proprietary finger-prick blood tests to meet \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/01/report-shows-theranos-blood-tests-fail-even-the-companys-standards/\" target=\"_blank\">quality control standards\u003c/a> among them. Other tests failed as much as 87 percent of the time, the inspection report said.\u003c/p>\n\u003cp>Despite those eye-popping numbers, Dr. Helfet, the medical board's co-chair, is bullish on the company's prospects, or at least its scientific credibility.\u003c/p>\n\u003cp>\"It is clear that Theranos has done what people thought was impossible,” he said in the press release. \"... Theranos’ technology is a groundbreaking feat of science and engineering, making it possible to accurately analyze micro amounts of blood for the same tests routinely done today with traditional venipuncture.”\u003c/p>\n\u003cp>Dr. Helfet has not returned calls seeking further comment.\u003c/p>\n\u003cp>\u003cstrong>Update Friday, April 8\u003c/strong>: Forbes' Matthew Herper \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/04/08/outside-experts-hired-by-theranos-see-promise-but-still-seek-proof/#3424f9683d92\" target=\"_blank\">spoke with three members of the advisory board\u003c/a>: Helfit, Jack Ladenson, a pathologist at the Washington University School of Medicine in St. Louis, and Steven Spitalnik, vice chairman of laboratory medicine at Columbia University Medical Center. He also talked to Elizabeth Holmes. From his post:\u003c/p>\n\u003cblockquote>\n\u003cul>\n\u003cli>\u003cstrong>Both Ladenson and Spitalnik describe what they saw as “promising” and “intriguing.”\u003c/strong> But they declined to answer questions about whether or not these devices are ready to be used clinically, or whether they were ready when they were in use a year ago.“I don’t feel like I have enough information to answer that question,” Spitalnik told me. “Eight hours sitting around a table looking at data and asking questions and having a conversation is enough to whet my appetite, but not to go beyond that.”\u003c/li>\n\u003c/ul>\n\u003c/blockquote>\n\u003cp>Said Ladenson: \"“I wouldn’t have joined this thing if I thought this was a loser.”\u003c/p>\n\u003cp>\u003cem>Theranos medical and advisory board members and their company descriptions:\u003c/em>\u003c/p>\n\u003cblockquote>\u003cp>Susan A. Evans, PhD, FACB\u003cbr>\nDr. Evans has over 30 years of experience in diagnostics and health technology companies. She served as President, Secretary, and member of the Board of Directors for the American Association for Clinical Chemistry (AACC), for which she received an award in 2008 for outstanding contributions through service to the profession. Dr. Evans also served as a member of the Board of Directors and President of the National Academy of Clinical Biochemistry (NACB), now the Academy of the AACC.\u003c/p>\n\u003cp>William H. Foege, MD\u003cbr>\nDr. Foege is an epidemiologist and former Director of the U.S. Center for Disease Control and Prevention (CDC). He is recognized as the health innovator behind the successful campaign to eradicate smallpox in the 1970s, Dr. Foege received the Presidential Medal of Freedom in 2012, the nation’s highest civilian honor. He was a senior medical advisor for the Bill and Melinda Gates Foundation from 1999 until his retirement in 2011. Dr. Foege is a member of the Theranos Board of Counselors and has served on Theranos’ Medical Board.\u003c/p>\n\u003cp>Ann M. Gronowski, PhD, DABCC\u003cbr>\nDr. Gronowski is a professor in the Department of Pathology and Immunology and the Department of Obstetrics and Gynecology at the Washington University School of Medicine in St. Louis. She is board certified in Clinical Chemistry and is Co-Medical Director of the clinical chemistry, serology, and immunology laboratories at Barnes-Jewish Hospital. She is a past President of the American Association of Clinical Chemistry (AACC) and a past President of the American Board of Clinical Chemistry (ABCC). Dr. Gronowski is author of over seventy peer-reviewed articles and a number of textbooks including Tietz’s Applied Laboratory Medicine and Handbook of Clinical Laboratory Testing During Pregnancy.\u003c/p>\n\u003cp>David Helfet, MD, Co-Chairman\u003cbr>\nDr. Helfet is the Director of the Orthopedic Trauma Service, Hospital for Special Surgery and New York-Presbyterian Hospital, and Professor of Orthopedic Surgery, Weill Cornell Medicine. Dr. Helfet is the Past President of the Orthopaedic Trauma Association and has been extensively involved nationally and internationally on boards and courses dealing with trauma. Dr. Helfet is annually ranked as one of New York Magazine’s “Best Doctors in New York” and Castle-Connolly’s “America’s Top Doctors.” Dr. Helfet has published extensively on orthopedic trauma topics including numerous articles and book chapters.\u003c/p>\n\u003cp>Larry J. Kricka, D. Phil, FRCPath\u003cbr>\nDr. Kricka is a professor of Pathology and Laboratory Medicine at the University of Pennsylvania and was director of the General Chemistry Laboratory and the Endocrinology Laboratory at the Hospital of the University of Pennsylvania. He is a Fellow of the Royal College of Pathologists, and a member of the Editorial Board of Clinical Chemistry, and Analytical Biochemistry, and past editor-in-chief of Luminescence. He was President of the American Association for Clinical Chemistry (AACC) in 2001 and was a member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Executive Board. Dr. Kricka holds over 30 U.S. patents; and is the author/co-author of over 500 articles, abstracts, book chapters, and papers; and 22 books.\u003c/p>\n\u003cp>Jack Ladenson, PhD, DABCC\u003cbr>\nDr. Ladenson is the Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry at Washington University School of Medicine. He has been active in a number of professional organizations and has served as President of the American Association for Clinical Chemistry (AACC) and the Academy of Clinical Laboratory Physicians and Scientists (ACLPS). He is also a past chair of the Editorial Board of the journal Clinical Chemistry. He has received numerous awards from professional organizations, Washington University, and its Medical Alumni Association. He also directs clinical pathology programs for Pathologists Overseas Inc.\u003c/p>\n\u003cp>Andy O. Miller, MD\u003cbr>\nDr. Miller is an Assistant Attending Physician in Infectious Diseases at the Hospital for Special Surgery and New York-Presbyterian Hospital, and an Assistant Professor of Clinical Medicine at Weill Cornell Medicine. His areas of clinical expertise and research activity are orthopedic and rheumatologic infectious disease. He has been selected for inclusion on the Super Doctors® 2015 list. He is board certified in Infectious Diseases and Internal Medicine by the American Board of Internal Medicine.\u003c/p>\n\u003cp>Steven Spitalnik, MD\u003cbr>\nDr. Spitalnik is a Professor of Pathology and Cell Biology and the Vice-Chairman of Laboratory Medicine at Columbia University Medical Center (CUMC). As the Medical Director of the Clinical laboratories on the CUMC campus of the New York-Presbyterian Hospital, he coordinates the clinical service, educational, and scholarly activities of the Division. In addition, he is the Co-Director of the Laboratory of Transfusion Biology, which pursues NIH-funded research aimed at improving transfusion practice. He is a long-standing member of the Academy of Clinical Laboratory Physicians & Scientists, serving as its President in 2002-03 and, in 2005, receiving its Gerald T. Evans Award for outstanding leadership and service to the Academy. In addition to being board certified in both Anatomic and Clinical Pathology, Dr. Spitalnik is a member of the Editorial Boards of Transfusion, Transfusion Medicine Reviews, and Current Opinion in Hematology, and is the lead author of Clinical Pathology Board Review.\u003c/p>\u003c/blockquote>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp> \u003c/p>\n\n",
"disqusIdentifier": "141585 http://ww2.kqed.org/futureofyou/?p=141585",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/07/theranos-says-new-medical-advisors-will-help-publish-data/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1609,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 27
},
"modified": 1460133173,
"excerpt": "The beleaguered company announced it was expanding its medical advisory board, and that members had been given full access to its operations.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The beleaguered company announced it was expanding its medical advisory board, and that members had been given full access to its operations.",
"title": "Theranos Turns to New Medical Advisers to Help Validate Technology | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Turns to New Medical Advisers to Help Validate Technology",
"datePublished": "2016-04-07T16:54:35-07:00",
"dateModified": "2016-04-08T09:32:53-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-says-new-medical-advisors-will-help-publish-data",
"status": "publish",
"path": "/futureofyou/141585/theranos-says-new-medical-advisors-will-help-publish-data",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Saying Theranos needs to do some damage control is like suggesting Donald Trump may want to take a moment to collect his thoughts before opening his mouth to speak.\u003c/p>\n\u003cp>After damning investigations into the high-flying company's blood-testing technology by both \u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\">The Wall Street Journal\u003c/a> and the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/01/report-shows-theranos-blood-tests-fail-even-the-companys-standards/\" target=\"_blank\">federal government\u003c/a>, Theranos, once valued at $9 billion, is now struggling to regain legitimacy.\u003c/p>\n\u003cp>On Thursday, the company \u003ca href=\"https://www.theranos.com/news/posts/theranos-announces-leading-medical-and-laboratory-experts-join-scientific-and-medical-advisory-board\" target=\"_blank\">announced\u003c/a> what appears to be an attempt at rehabilitating its reputation, stating that \"nationally respected laboratory and medical experts\" have joined its Scientific and Medical Advisory Board. (You can see who the board members are and the company's description of them below.)\u003c/p>\n\u003cp>Company spokeswoman Brooke Buchanan says all of the board members have taken part in at least one of three scientific review panels looking at the company's technology.\u003c/p>\n\u003cp>Buchanan said the board members are being paid \"the industry average of an expert in the medical field.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>The board's co-chair, Dr. David Helfet, director of the Orthopedic Trauma Service, Hospital for Special Surgery and New York-Presbyterian Hospital, was quoted in Thursday's press release as saying the company \"literally took the lid off of the box\" when it came to providing board members access to its operations . (He meant \"figuratively,\" we'll have to assume.)\u003c/p>\n\u003cp>\"Experts were shown Theranos’ technology, met with Theranos scientists, and had access to any data,\" Helfet said.\u003c/p>\n\u003cp>So what did these panels conclude? I asked Brooke Buchanan. She said the board will meet again in two weeks to \"decide and strategize delivery of our data and publication.\" (See the Friday update below for a Forbes report on what two board members have to say about Theranos.)\u003c/p>\n\u003cp>The new board members join an \u003ca href=\"http://www.nytimes.com/2015/10/29/business/theranos-facing-criticism-says-it-has-changed-board-structure.html\" target=\"_blank\">initial group \u003c/a>announced by Theranos last October, formed after \u003ca href=\"http://www.businessinsider.com/theranos-board-of-directors-2015-10\" target=\"_blank\">criticism\u003c/a> that its board of directors, which included Henry Kissinger and George P. Schultz, had just one practicing medical professional.\u003c/p>\n\u003cp>If Theranos does present evidence of its technology's efficacy, it'll be a big deal. To date, the company has \u003ca href=\"http://www.forbes.com/sites/brucelee/2016/03/31/theranos-could-have-avoided-recent-problems-by-engaging-the-scientific-community/#3293c17a2559\" target=\"_blank\">published no scientific research\u003c/a> to validate its methods, though it said it \u003ca href=\"http://gizmodo.com/theranos-ceo-agrees-to-publish-data-proving-reliability-1738934618\" target=\"_blank\">intended to do so\u003c/a> as early as last October. In the absence of publicly available evidence that it can do what it says it can do, the company has left itself wide open to criticism, especially of the kind based on facts.\u003c/p>\n\u003cp>Those include the deficiencies revealed in a federal inspection of Theranos' Newark laboratory -- the nearly 30 percent failure rate of its proprietary finger-prick blood tests to meet \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/01/report-shows-theranos-blood-tests-fail-even-the-companys-standards/\" target=\"_blank\">quality control standards\u003c/a> among them. Other tests failed as much as 87 percent of the time, the inspection report said.\u003c/p>\n\u003cp>Despite those eye-popping numbers, Dr. Helfet, the medical board's co-chair, is bullish on the company's prospects, or at least its scientific credibility.\u003c/p>\n\u003cp>\"It is clear that Theranos has done what people thought was impossible,” he said in the press release. \"... Theranos’ technology is a groundbreaking feat of science and engineering, making it possible to accurately analyze micro amounts of blood for the same tests routinely done today with traditional venipuncture.”\u003c/p>\n\u003cp>Dr. Helfet has not returned calls seeking further comment.\u003c/p>\n\u003cp>\u003cstrong>Update Friday, April 8\u003c/strong>: Forbes' Matthew Herper \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/04/08/outside-experts-hired-by-theranos-see-promise-but-still-seek-proof/#3424f9683d92\" target=\"_blank\">spoke with three members of the advisory board\u003c/a>: Helfit, Jack Ladenson, a pathologist at the Washington University School of Medicine in St. Louis, and Steven Spitalnik, vice chairman of laboratory medicine at Columbia University Medical Center. He also talked to Elizabeth Holmes. From his post:\u003c/p>\n\u003cblockquote>\n\u003cul>\n\u003cli>\u003cstrong>Both Ladenson and Spitalnik describe what they saw as “promising” and “intriguing.”\u003c/strong> But they declined to answer questions about whether or not these devices are ready to be used clinically, or whether they were ready when they were in use a year ago.“I don’t feel like I have enough information to answer that question,” Spitalnik told me. “Eight hours sitting around a table looking at data and asking questions and having a conversation is enough to whet my appetite, but not to go beyond that.”\u003c/li>\n\u003c/ul>\n\u003c/blockquote>\n\u003cp>Said Ladenson: \"“I wouldn’t have joined this thing if I thought this was a loser.”\u003c/p>\n\u003cp>\u003cem>Theranos medical and advisory board members and their company descriptions:\u003c/em>\u003c/p>\n\u003cblockquote>\u003cp>Susan A. Evans, PhD, FACB\u003cbr>\nDr. Evans has over 30 years of experience in diagnostics and health technology companies. She served as President, Secretary, and member of the Board of Directors for the American Association for Clinical Chemistry (AACC), for which she received an award in 2008 for outstanding contributions through service to the profession. Dr. Evans also served as a member of the Board of Directors and President of the National Academy of Clinical Biochemistry (NACB), now the Academy of the AACC.\u003c/p>\n\u003cp>William H. Foege, MD\u003cbr>\nDr. Foege is an epidemiologist and former Director of the U.S. Center for Disease Control and Prevention (CDC). He is recognized as the health innovator behind the successful campaign to eradicate smallpox in the 1970s, Dr. Foege received the Presidential Medal of Freedom in 2012, the nation’s highest civilian honor. He was a senior medical advisor for the Bill and Melinda Gates Foundation from 1999 until his retirement in 2011. Dr. Foege is a member of the Theranos Board of Counselors and has served on Theranos’ Medical Board.\u003c/p>\n\u003cp>Ann M. Gronowski, PhD, DABCC\u003cbr>\nDr. Gronowski is a professor in the Department of Pathology and Immunology and the Department of Obstetrics and Gynecology at the Washington University School of Medicine in St. Louis. She is board certified in Clinical Chemistry and is Co-Medical Director of the clinical chemistry, serology, and immunology laboratories at Barnes-Jewish Hospital. She is a past President of the American Association of Clinical Chemistry (AACC) and a past President of the American Board of Clinical Chemistry (ABCC). Dr. Gronowski is author of over seventy peer-reviewed articles and a number of textbooks including Tietz’s Applied Laboratory Medicine and Handbook of Clinical Laboratory Testing During Pregnancy.\u003c/p>\n\u003cp>David Helfet, MD, Co-Chairman\u003cbr>\nDr. Helfet is the Director of the Orthopedic Trauma Service, Hospital for Special Surgery and New York-Presbyterian Hospital, and Professor of Orthopedic Surgery, Weill Cornell Medicine. Dr. Helfet is the Past President of the Orthopaedic Trauma Association and has been extensively involved nationally and internationally on boards and courses dealing with trauma. Dr. Helfet is annually ranked as one of New York Magazine’s “Best Doctors in New York” and Castle-Connolly’s “America’s Top Doctors.” Dr. Helfet has published extensively on orthopedic trauma topics including numerous articles and book chapters.\u003c/p>\n\u003cp>Larry J. Kricka, D. Phil, FRCPath\u003cbr>\nDr. Kricka is a professor of Pathology and Laboratory Medicine at the University of Pennsylvania and was director of the General Chemistry Laboratory and the Endocrinology Laboratory at the Hospital of the University of Pennsylvania. He is a Fellow of the Royal College of Pathologists, and a member of the Editorial Board of Clinical Chemistry, and Analytical Biochemistry, and past editor-in-chief of Luminescence. He was President of the American Association for Clinical Chemistry (AACC) in 2001 and was a member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Executive Board. Dr. Kricka holds over 30 U.S. patents; and is the author/co-author of over 500 articles, abstracts, book chapters, and papers; and 22 books.\u003c/p>\n\u003cp>Jack Ladenson, PhD, DABCC\u003cbr>\nDr. Ladenson is the Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry at Washington University School of Medicine. He has been active in a number of professional organizations and has served as President of the American Association for Clinical Chemistry (AACC) and the Academy of Clinical Laboratory Physicians and Scientists (ACLPS). He is also a past chair of the Editorial Board of the journal Clinical Chemistry. He has received numerous awards from professional organizations, Washington University, and its Medical Alumni Association. He also directs clinical pathology programs for Pathologists Overseas Inc.\u003c/p>\n\u003cp>Andy O. Miller, MD\u003cbr>\nDr. Miller is an Assistant Attending Physician in Infectious Diseases at the Hospital for Special Surgery and New York-Presbyterian Hospital, and an Assistant Professor of Clinical Medicine at Weill Cornell Medicine. His areas of clinical expertise and research activity are orthopedic and rheumatologic infectious disease. He has been selected for inclusion on the Super Doctors® 2015 list. He is board certified in Infectious Diseases and Internal Medicine by the American Board of Internal Medicine.\u003c/p>\n\u003cp>Steven Spitalnik, MD\u003cbr>\nDr. Spitalnik is a Professor of Pathology and Cell Biology and the Vice-Chairman of Laboratory Medicine at Columbia University Medical Center (CUMC). As the Medical Director of the Clinical laboratories on the CUMC campus of the New York-Presbyterian Hospital, he coordinates the clinical service, educational, and scholarly activities of the Division. In addition, he is the Co-Director of the Laboratory of Transfusion Biology, which pursues NIH-funded research aimed at improving transfusion practice. He is a long-standing member of the Academy of Clinical Laboratory Physicians & Scientists, serving as its President in 2002-03 and, in 2005, receiving its Gerald T. Evans Award for outstanding leadership and service to the Academy. In addition to being board certified in both Anatomic and Clinical Pathology, Dr. Spitalnik is a member of the Editorial Boards of Transfusion, Transfusion Medicine Reviews, and Current Opinion in Hematology, and is the lead author of Clinical Pathology Board Review.\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp> \u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/141585/theranos-says-new-medical-advisors-will-help-publish-data",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_617"
],
"featImg": "futureofyou_103649",
"label": "futureofyou"
},
"futureofyou_138294": {
"type": "posts",
"id": "futureofyou_138294",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "138294",
"score": null,
"sort": [
1459546212000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1459546212,
"format": "standard",
"disqusTitle": "Report Shows Theranos Blood Tests Fail Even the Company's Standards",
"title": "Report Shows Theranos Blood Tests Fail Even the Company's Standards",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>This has been another bad week for the Palo Alto-based consumer blood testing company, \u003ca href=\"https://www.theranos.com/\" target=\"_blank\">Theranos\u003c/a>. Since last year, the start-up has been \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/10/15/critics-demand-theranos-lift-veil-of-secrecy-on-blood-test/\" target=\"_blank\">dogged by regulatory troubles\u003c/a>.\u003c/p>\n\u003cp>A newly released federal inspection report, by the Centers for Medicare and Medicaid Services (CMS), has found that the company's testing devices often fail the firm’s own accuracy requirements.\u003c/p>\n\u003cp>The 121 page redacted report about Theranos’s Newark laboratory, revealed that the company’s much touted finger-prick blood tests failed quality control checks nearly 30 percent of the time.\u003c/p>\n\u003caside class=\"pullquote alignright\">Theranos may now be facing sanctions that could range from fines to a retraction of the company’s approval to test human samples.\u003c/aside>\n\u003cp>\u003ca href=\"http://topics.wsj.com/person/C/john-carreyrou/1282\" target=\"_blank\">John Carreyrou\u003c/a> is an investigative reporter for \u003ca href=\"http://www.wsj.com/\" target=\"_blank\">The Wall Street Journal\u003c/a> who has been covering Theranos and first reported the story today. He told KQED’s \u003ca href=\"https://twitter.com/danielleventon?lang=en\" target=\"_blank\">Danielle Venton\u003c/a> that the company's pattern has been to criticize any information made public by others.\u003c/p>\n\u003cp>“This data is important because it comes directly from the company. The company can't say, 'well this person or that person has an agenda and they are out to get us'. This is their own data,\" says Carreyrou.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>“This is [government inspectors] going in and looking at data and records from Theranos itself and then reporting that the records show an incredibly high rate of failure during quality checks, incredibly wide variations,\" explains Carreyrou.\u003c/p>\n\u003cp>In reviewing the report, Carreyrou described a hormone test that failed 87 percent of quality control tests during one month and a test to help detect prostate cancer failed more than 20 percent of the time.\u003c/p>\n\u003cp>The current report follows \u003ca href=\"http://www.jci.org/articles/view/86318\">an independent study,\u003c/a> released earlier in the week, also showing inconsistent lab results.\u003c/p>\n\u003cp>Theranos, which has claimed its technology would revolutionize the blood testing industry, is now facing potential penalties. Carreyrou said that his understanding is that federal regulators plan to impose sanctions that could range from fines to a retraction of the company’s approval to test human samples.\u003c/p>\n\u003cp>When reached for comment about the government report, Theranos spokesperson, Brooke Buchanan, said, \"Quality and patient safety is our top priority. Theranos submitted a Plan of Correction to CMS and related evidence that addressed how the company has actively ensured that our lab operates at the highest standard. We’ve made mistakes in the past in the Newark, CA lab, but when the company was made aware of the deficiencies we have dedicated every resource to remedy those failures.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>In KQED's own interviews with Theranos and government regulators, we have not been able to clarify how many patients have been affected, or what they may have been told about the blood testing irregularities.\u003c/p>\n\n",
"disqusIdentifier": "138294 http://ww2.kqed.org/futureofyou/?p=138294",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/04/01/report-shows-theranos-blood-tests-fail-even-the-companys-standards/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 460,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 13
},
"modified": 1459552835,
"excerpt": "A new report finds the troubled blood testing company's results are often wrong.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "A new report finds the troubled blood testing company's results are often wrong.",
"title": "Report Shows Theranos Blood Tests Fail Even the Company's Standards | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Report Shows Theranos Blood Tests Fail Even the Company's Standards",
"datePublished": "2016-04-01T14:30:12-07:00",
"dateModified": "2016-04-01T16:20:35-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "report-shows-theranos-blood-tests-fail-even-the-companys-standards",
"status": "publish",
"path": "/futureofyou/138294/report-shows-theranos-blood-tests-fail-even-the-companys-standards",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>This has been another bad week for the Palo Alto-based consumer blood testing company, \u003ca href=\"https://www.theranos.com/\" target=\"_blank\">Theranos\u003c/a>. Since last year, the start-up has been \u003ca href=\"http://ww2.kqed.org/futureofyou/2015/10/15/critics-demand-theranos-lift-veil-of-secrecy-on-blood-test/\" target=\"_blank\">dogged by regulatory troubles\u003c/a>.\u003c/p>\n\u003cp>A newly released federal inspection report, by the Centers for Medicare and Medicaid Services (CMS), has found that the company's testing devices often fail the firm’s own accuracy requirements.\u003c/p>\n\u003cp>The 121 page redacted report about Theranos’s Newark laboratory, revealed that the company’s much touted finger-prick blood tests failed quality control checks nearly 30 percent of the time.\u003c/p>\n\u003caside class=\"pullquote alignright\">Theranos may now be facing sanctions that could range from fines to a retraction of the company’s approval to test human samples.\u003c/aside>\n\u003cp>\u003ca href=\"http://topics.wsj.com/person/C/john-carreyrou/1282\" target=\"_blank\">John Carreyrou\u003c/a> is an investigative reporter for \u003ca href=\"http://www.wsj.com/\" target=\"_blank\">The Wall Street Journal\u003c/a> who has been covering Theranos and first reported the story today. He told KQED’s \u003ca href=\"https://twitter.com/danielleventon?lang=en\" target=\"_blank\">Danielle Venton\u003c/a> that the company's pattern has been to criticize any information made public by others.\u003c/p>\n\u003cp>“This data is important because it comes directly from the company. The company can't say, 'well this person or that person has an agenda and they are out to get us'. This is their own data,\" says Carreyrou.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>“This is [government inspectors] going in and looking at data and records from Theranos itself and then reporting that the records show an incredibly high rate of failure during quality checks, incredibly wide variations,\" explains Carreyrou.\u003c/p>\n\u003cp>In reviewing the report, Carreyrou described a hormone test that failed 87 percent of quality control tests during one month and a test to help detect prostate cancer failed more than 20 percent of the time.\u003c/p>\n\u003cp>The current report follows \u003ca href=\"http://www.jci.org/articles/view/86318\">an independent study,\u003c/a> released earlier in the week, also showing inconsistent lab results.\u003c/p>\n\u003cp>Theranos, which has claimed its technology would revolutionize the blood testing industry, is now facing potential penalties. Carreyrou said that his understanding is that federal regulators plan to impose sanctions that could range from fines to a retraction of the company’s approval to test human samples.\u003c/p>\n\u003cp>When reached for comment about the government report, Theranos spokesperson, Brooke Buchanan, said, \"Quality and patient safety is our top priority. Theranos submitted a Plan of Correction to CMS and related evidence that addressed how the company has actively ensured that our lab operates at the highest standard. We’ve made mistakes in the past in the Newark, CA lab, but when the company was made aware of the deficiencies we have dedicated every resource to remedy those failures.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>In KQED's own interviews with Theranos and government regulators, we have not been able to clarify how many patients have been affected, or what they may have been told about the blood testing irregularities.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/138294/report-shows-theranos-blood-tests-fail-even-the-companys-standards",
"authors": [
"212"
],
"categories": [
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_164",
"futureofyou_617"
],
"featImg": "futureofyou_103649",
"label": "futureofyou"
},
"futureofyou_129430": {
"type": "posts",
"id": "futureofyou_129430",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "129430",
"score": null,
"sort": [
1458500419000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1458500419,
"format": "standard",
"disqusTitle": "Report: Hillary Clinton Fundraiser Will Not Be Held at Theranos After All",
"title": "Report: Hillary Clinton Fundraiser Will Not Be Held at Theranos After All",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>\u003cstrong>Update Sunday, March 20\u003c/strong>: It probably didn't take Nostradamus to predict this, but that Clinton fundraiser Monday that was reportedly going to be held by beleaguered Theranos founder Elizabeth Holmes at company headquarters ... is no longer going to be held by beleaguered Theranos founder Elizabeth Holmes at company headquarters. At least according to this \u003ca href=\"http://www.cnbc.com/2016/03/18/hillary-fundraiser-will-not-be-held-at-theranos-hq.html\" target=\"_blank\">CNBC report\u003c/a> . ...\u003c/p>\n\u003cblockquote>\u003cp>(A)n official invitation to the event, obtained by CNBC, shows that the Clinton fundraiser will not be held at the company's offices, but instead at the private home of Susie Hwang and Matt Glickman in Palo Alto. Holmes is listed first on a list of 11 female Silicon Valley figures hosting the event. According to the invitation, hosts contribute or raise $2,700 for Hillary for America presidential campaign, and attend a reception with the former first daughter.\u003c/p>\u003c/blockquote>\n\u003cp>A Clinton campaign official told the network that the event \"is not connected to a specific company or policy, but a chance to talk directly to women in tech. We frequently send initial invitations while host committees are still being formed and locations finalized. This was never a health care event and the location wasn't set. It will not be at Theranos.\"\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>\"This is what happens when you work to change things,\" Theranos founder Elizabeth Holmes said last October, \"First they think you're crazy, then they fight you, then you change the world,\"\u003c/p>\n\u003cp>Whether Theranos has progressed from \"you're crazy\" to \"they fight you\" may be a moot point -- they definitely haven't changed the world. Holmes was misquoting -- or disrupting, if you prefer -- a stirring \u003ca href=\"http://www.brainyquote.com/quotes/quotes/m/mahatmagan103630.html\" target=\"_blank\">adage\u003c/a> attributed to Mahatma Gandhi (which apparently, \u003ca href=\"http://www.csmonitor.com/USA/Politics/2011/0603/Political-misquotes-The-10-most-famous-things-never-actually-said/First-they-ignore-you.-Then-they-laugh-at-you.-Then-they-attack-you.-Then-you-win.-Mohandas-Gandhi\" target=\"_blank\">he never said\u003c/a>), while she talked \u003ca href=\"http://www.cnbc.com/2015/10/15/theranos-ceo-fires-back-at-wsj-i-was-shocked.html\" target=\"_blank\">with CNBC's Jim Cramer.\u003c/a> The Wall Street Journal had just published the \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">first\u003c/a> in a string of negative articles questioning the accuracy of Theranos' proprietary blood-test technology. That investigation has transformed Theranos from the golden child of Silicon Valley innovation into the poster child for Silicon Valley hype.\u003c/p>\n\u003caside class=\"pullquote alignright\">'It's pretty bizarre that she has decided to have a (reportedly) corrupt corporation host her next big fund-raiser.'\u003ccite>New York magazine\u003c/cite>\u003c/aside>\n\u003cp>Holmes has kept a low profile in the past several months, and when her name does crop up, it's not exactly to award her a Nobel Prize. Last week, reports surfaced she had \u003ca href=\"http://medcitynews.com/2016/03/scripps-future-of-genomic-medicine-conference-nowhere-to-sit-nowhere-to-charge-and-no-elizabeth-holmes/\" target=\"_blank\">withdrawn from a conference on genomic medicine\u003c/a> without explanation. And this week, there's a big to-do over \u003ca href=\"http://recode.net/2016/03/14/theranos-ceo-elizabeth-holmes-is-holding-a-hillary-fundraiser-with-chelsea-clinton/\" target=\"_blank\">news\u003c/a> that Holmes will host a fundraiser at the company's Palo Alto headquarters for Hillary Clinton, with an appearance by Chelsea Clinton as the key attraction. The first takes on this tidbit are now in, and they're not good. Here's New York magazine's headline:\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"\u003ca href=\"http://nymag.com/daily/intelligencer/2016/03/clinton-lets-theranos-throw-her-a-fund-raiser.html\" target=\"_blank\">Hillary Clinton Lets Scandal-Plagued Corporation Throw Her a Fund-raiser, for Some Stupid Reason\u003c/a>.\"\u003c/p>\n\u003cp>\"One of Clinton’s primary liabilities in her race against Bernie Sanders is the perception that she is overly friendly with corrupt corporate interests. So it's pretty bizarre that she has decided to have a (reportedly) corrupt corporation host her next big fund-raiser,\" wrote Eric Levitz.\u003c/p>\n\u003cp>\u003ca href=\"http://www.statnews.com/2016/03/14/theranos-clinton-fundraiser/\" target=\"_blank\">STAT \u003c/a>recounted the history of ties between Theranos and the Clintons and asked Robert Wachter, chief of medicine at UCSF Medical Center, for a reaction.\u003c/p>\n\u003cp>\"Today’s narrative about Theranos is that the company has focused more on its political relationships than on its core business, and that doing so created a hype that far exceeds the true value of the company’s products,\" he said. \"Given that, I’m not sure how this fundraiser does anything other than promote that narrative — one that Theranos needs to be aggressively trying to undo.”\u003c/p>\n\u003cp>Twitter, of course, is doing what it does best to this kind of low-hanging fruit: rubbing it in. Vox wonk Ezra Klein simply \u003ca href=\"https://twitter.com/ezraklein/status/709503000558084097\" target=\"_blank\">tweeted\u003c/a>: \"This seems like a bad idea.\" Others showed less mercy:\u003c/p>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">Wonder if Chelsea Clinton will do a quick fundraiser over at Zenefits once she's done at Theranos.\u003c/p>\n\u003cp>— Dan Primack (@danprimack) \u003ca href=\"https://twitter.com/danprimack/status/709747837903491072\">March 15, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">Elizabeth Holmes—the only person who's dropped more in the polls than Hillary—to host fundraiser for her. \u003ca href=\"https://t.co/tP1iXi2q6K\">https://t.co/tP1iXi2q6K\u003c/a>\u003c/p>\n\u003cp>— Nicholas Thompson (@nxthompson) \u003ca href=\"https://twitter.com/nxthompson/status/709515755130191872\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\u003cp>oh ffs seriously? Let me google that for you, Clinton advance team \u003ca href=\"https://t.co/OKUVhhngcp\">https://t.co/OKUVhhngcp\u003c/a> \u003ca href=\"https://t.co/MB6g5QwBmK\">https://t.co/MB6g5QwBmK\u003c/a>\u003c/p>\n\u003cp>— Emil Caillaux (@emilcDC) \u003ca href=\"https://twitter.com/emilcDC/status/709481319647027200\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">there’s an argument to be made that this entire election hinges on a bar bet over who least wants to be president \u003ca href=\"https://t.co/vWno4pdkoy\">https://t.co/vWno4pdkoy\u003c/a>\u003c/p>\n\u003cp>— Holly Anderson (@HollyAnderson) \u003ca href=\"https://twitter.com/HollyAnderson/status/709472353034448896\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>The Clinton campaign has yet to comment, though Clinton surrogate Jennifer Granholm did give a non-response response on \u003ca href=\"https://www.youtube.com/watch?v=E1cNc_uZouw\" target=\"_blank\">CNBC\u003c/a> when the issue was pressed. Whether any of this will have even a tiny impact on the presidential campaign remains to be seen. But the only thing worse than having The Wall Street Journal all up in your business just might be a round of 140-character assaults on your declining fortunes by -- well, \u003ca href=\"https://twitter.com/realdonaldtrump?lang=en\" target=\"_blank\">you know who\u003c/a>.\u003c/p>\n\n",
"disqusIdentifier": "129430 http://ww2.kqed.org/futureofyou/?p=129430",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/03/20/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 886,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 20
},
"modified": 1458502137,
"excerpt": "Monday's scheduled event is drawing more flack for the beleaguered blood-testing startup.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Monday's scheduled event is drawing more flack for the beleaguered blood-testing startup.",
"title": "Report: Hillary Clinton Fundraiser Will Not Be Held at Theranos After All | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Report: Hillary Clinton Fundraiser Will Not Be Held at Theranos After All",
"datePublished": "2016-03-20T12:00:19-07:00",
"dateModified": "2016-03-20T12:28:57-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows",
"status": "publish",
"customPermalink": "2016/03/16/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows/",
"path": "/futureofyou/129430/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cstrong>Update Sunday, March 20\u003c/strong>: It probably didn't take Nostradamus to predict this, but that Clinton fundraiser Monday that was reportedly going to be held by beleaguered Theranos founder Elizabeth Holmes at company headquarters ... is no longer going to be held by beleaguered Theranos founder Elizabeth Holmes at company headquarters. At least according to this \u003ca href=\"http://www.cnbc.com/2016/03/18/hillary-fundraiser-will-not-be-held-at-theranos-hq.html\" target=\"_blank\">CNBC report\u003c/a> . ...\u003c/p>\n\u003cblockquote>\u003cp>(A)n official invitation to the event, obtained by CNBC, shows that the Clinton fundraiser will not be held at the company's offices, but instead at the private home of Susie Hwang and Matt Glickman in Palo Alto. Holmes is listed first on a list of 11 female Silicon Valley figures hosting the event. According to the invitation, hosts contribute or raise $2,700 for Hillary for America presidential campaign, and attend a reception with the former first daughter.\u003c/p>\u003c/blockquote>\n\u003cp>A Clinton campaign official told the network that the event \"is not connected to a specific company or policy, but a chance to talk directly to women in tech. We frequently send initial invitations while host committees are still being formed and locations finalized. This was never a health care event and the location wasn't set. It will not be at Theranos.\"\u003c/p>\n\u003cp>\u003cem>Original post\u003c/em>\u003c/p>\n\u003cp>\"This is what happens when you work to change things,\" Theranos founder Elizabeth Holmes said last October, \"First they think you're crazy, then they fight you, then you change the world,\"\u003c/p>\n\u003cp>Whether Theranos has progressed from \"you're crazy\" to \"they fight you\" may be a moot point -- they definitely haven't changed the world. Holmes was misquoting -- or disrupting, if you prefer -- a stirring \u003ca href=\"http://www.brainyquote.com/quotes/quotes/m/mahatmagan103630.html\" target=\"_blank\">adage\u003c/a> attributed to Mahatma Gandhi (which apparently, \u003ca href=\"http://www.csmonitor.com/USA/Politics/2011/0603/Political-misquotes-The-10-most-famous-things-never-actually-said/First-they-ignore-you.-Then-they-laugh-at-you.-Then-they-attack-you.-Then-you-win.-Mohandas-Gandhi\" target=\"_blank\">he never said\u003c/a>), while she talked \u003ca href=\"http://www.cnbc.com/2015/10/15/theranos-ceo-fires-back-at-wsj-i-was-shocked.html\" target=\"_blank\">with CNBC's Jim Cramer.\u003c/a> The Wall Street Journal had just published the \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">first\u003c/a> in a string of negative articles questioning the accuracy of Theranos' proprietary blood-test technology. That investigation has transformed Theranos from the golden child of Silicon Valley innovation into the poster child for Silicon Valley hype.\u003c/p>\n\u003caside class=\"pullquote alignright\">'It's pretty bizarre that she has decided to have a (reportedly) corrupt corporation host her next big fund-raiser.'\u003ccite>New York magazine\u003c/cite>\u003c/aside>\n\u003cp>Holmes has kept a low profile in the past several months, and when her name does crop up, it's not exactly to award her a Nobel Prize. Last week, reports surfaced she had \u003ca href=\"http://medcitynews.com/2016/03/scripps-future-of-genomic-medicine-conference-nowhere-to-sit-nowhere-to-charge-and-no-elizabeth-holmes/\" target=\"_blank\">withdrawn from a conference on genomic medicine\u003c/a> without explanation. And this week, there's a big to-do over \u003ca href=\"http://recode.net/2016/03/14/theranos-ceo-elizabeth-holmes-is-holding-a-hillary-fundraiser-with-chelsea-clinton/\" target=\"_blank\">news\u003c/a> that Holmes will host a fundraiser at the company's Palo Alto headquarters for Hillary Clinton, with an appearance by Chelsea Clinton as the key attraction. The first takes on this tidbit are now in, and they're not good. Here's New York magazine's headline:\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"\u003ca href=\"http://nymag.com/daily/intelligencer/2016/03/clinton-lets-theranos-throw-her-a-fund-raiser.html\" target=\"_blank\">Hillary Clinton Lets Scandal-Plagued Corporation Throw Her a Fund-raiser, for Some Stupid Reason\u003c/a>.\"\u003c/p>\n\u003cp>\"One of Clinton’s primary liabilities in her race against Bernie Sanders is the perception that she is overly friendly with corrupt corporate interests. So it's pretty bizarre that she has decided to have a (reportedly) corrupt corporation host her next big fund-raiser,\" wrote Eric Levitz.\u003c/p>\n\u003cp>\u003ca href=\"http://www.statnews.com/2016/03/14/theranos-clinton-fundraiser/\" target=\"_blank\">STAT \u003c/a>recounted the history of ties between Theranos and the Clintons and asked Robert Wachter, chief of medicine at UCSF Medical Center, for a reaction.\u003c/p>\n\u003cp>\"Today’s narrative about Theranos is that the company has focused more on its political relationships than on its core business, and that doing so created a hype that far exceeds the true value of the company’s products,\" he said. \"Given that, I’m not sure how this fundraiser does anything other than promote that narrative — one that Theranos needs to be aggressively trying to undo.”\u003c/p>\n\u003cp>Twitter, of course, is doing what it does best to this kind of low-hanging fruit: rubbing it in. Vox wonk Ezra Klein simply \u003ca href=\"https://twitter.com/ezraklein/status/709503000558084097\" target=\"_blank\">tweeted\u003c/a>: \"This seems like a bad idea.\" Others showed less mercy:\u003c/p>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">Wonder if Chelsea Clinton will do a quick fundraiser over at Zenefits once she's done at Theranos.\u003c/p>\n\u003cp>— Dan Primack (@danprimack) \u003ca href=\"https://twitter.com/danprimack/status/709747837903491072\">March 15, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">Elizabeth Holmes—the only person who's dropped more in the polls than Hillary—to host fundraiser for her. \u003ca href=\"https://t.co/tP1iXi2q6K\">https://t.co/tP1iXi2q6K\u003c/a>\u003c/p>\n\u003cp>— Nicholas Thompson (@nxthompson) \u003ca href=\"https://twitter.com/nxthompson/status/709515755130191872\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\u003cp>oh ffs seriously? Let me google that for you, Clinton advance team \u003ca href=\"https://t.co/OKUVhhngcp\">https://t.co/OKUVhhngcp\u003c/a> \u003ca href=\"https://t.co/MB6g5QwBmK\">https://t.co/MB6g5QwBmK\u003c/a>\u003c/p>\n\u003cp>— Emil Caillaux (@emilcDC) \u003ca href=\"https://twitter.com/emilcDC/status/709481319647027200\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cblockquote class=\"twitter-tweet\">\n\u003cp dir=\"ltr\" lang=\"en\">there’s an argument to be made that this entire election hinges on a bar bet over who least wants to be president \u003ca href=\"https://t.co/vWno4pdkoy\">https://t.co/vWno4pdkoy\u003c/a>\u003c/p>\n\u003cp>— Holly Anderson (@HollyAnderson) \u003ca href=\"https://twitter.com/HollyAnderson/status/709472353034448896\">March 14, 2016\u003c/a>\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>The Clinton campaign has yet to comment, though Clinton surrogate Jennifer Granholm did give a non-response response on \u003ca href=\"https://www.youtube.com/watch?v=E1cNc_uZouw\" target=\"_blank\">CNBC\u003c/a> when the issue was pressed. Whether any of this will have even a tiny impact on the presidential campaign remains to be seen. But the only thing worse than having The Wall Street Journal all up in your business just might be a round of 140-character assaults on your declining fortunes by -- well, \u003ca href=\"https://twitter.com/realdonaldtrump?lang=en\" target=\"_blank\">you know who\u003c/a>.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/129430/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_1"
],
"tags": [
"futureofyou_816",
"futureofyou_814",
"futureofyou_815",
"futureofyou_617"
],
"featImg": "futureofyou_129625",
"label": "futureofyou_54"
},
"futureofyou_124849": {
"type": "posts",
"id": "futureofyou_124849",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "124849",
"score": null,
"sort": [
1457460056000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1457460056,
"format": "standard",
"disqusTitle": "WSJ: How Theranos Put Patients in 'Immediate Jeopardy'",
"title": "WSJ: How Theranos Put Patients in 'Immediate Jeopardy'",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>On Jan. 25, the Centers for Medicare & Medicaid \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/27/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients/\" target=\"_blank\">released a letter\u003c/a> it sent to the blood-test startup Theranos, informing the company an inspection of its Newark, California lab had found it to be deficient in five areas. CMS said deficiencies in one of those areas -- hematology -- put patients in \"immediate jeopardy,\" which is defined by the agency as a situation likely to cause \"serious injury or harm, or death\" to patients.\u003c/p>\n\u003caside class=\"“pullquote alignright\">Theranos ran a blood-clotting test on 81 patients \"despite erratic results from quality-control checks,\"\u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\"> The Wall Street Journal reports\u003c/a>.\u003c/aside>\n\u003cp>Sounded serious, to say the least. But what CMS did not release are the actual \u003cem>problems\u003c/em> it found in the lab that caused it to reach such a dire conclusion. Those were detailed on \u003ca href=\"https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/downloads/cms2567.pdf\" target=\"_blank\">Form CMS-2567\u003c/a>, called a Statement of Deficiencies. When we asked CMS for \u003cem>that\u003c/em>, a spokesperson would only say the form would become \"releasable\" after Theranos' plan of correction was approved.\u003c/p>\n\u003cp>Well, The Wall Street Journal, which has just about \u003ca href=\"https://www.google.com/search?q=wall+street+journal+theranos\" target=\"_blank\">single-handedly extinguished the hype\u003c/a> around Theranos as a \"disruptor\" of the blood-test industry, has \u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\">talked\u003c/a> to \"people familiar with the report.\"\u003c/p>\n\u003cp>Those sources said CMS found that Theranos \"ran an important blood test on 81 patients in a six-month period despite erratic results from quality-control checks meant to ensure the test’s accuracy,\" the Journal said.\u003c/p>\n\u003cp>The test, called the \u003ca href=\"http://www.healthline.com/health/prothrombin-time-pt#WhyIt'sDone2\" target=\"_blank\">prothrombin time test\u003c/a>, measures how long it takes blood to clot. Inaccurate results \"can be especially serious for patients taking blood thinners such as warfarin\" (better known as Coumadin), the paper said.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Any doctors who received results from tests conducted between April 23 and Sept. 15, 2015, when the quality control problems emerged, should have patients retested as soon as possible,\" one academic in laboratory medicine told the Journal. “Those results are not worth anything,” said Timothy Hamill, professor emeritus at the University of California, San Francisco.\u003c/p>\n\u003cp>In response to the Journal report, Theranos released a \u003ca href=\"https://www.theranos.com/news/posts/statement-regarding-newark-california-lab-survey\" target=\"_blank\">statement\u003c/a> in which it said it had contacted \"any potentially affected patients.\" Dr. Kingshuk Das, the new director of the lab, said: \"We have conducted assessments to identify any patients affected or having the potential to be affected by the issues identified by CMS, and we have no reason to believe that these issues have affected patients’ health.”\u003c/p>\n\u003cp>\u003cstrong>Report Held\u003c/strong>\u003c/p>\n\u003cp>News of these details raise the question of why CMS didn't release them in the first place?\u003c/p>\n\u003cp>\"The company has asked CMS not to publicly release the inspection report on the grounds that doing so would compromise Theranos trade secrets, according to people familiar with the company's position,\" wrote the Journal.\u003c/p>\n\u003cp>Meanwhile, Theranos watchers are waiting for the other shoe to drop regarding its partnership with Walgreen's. Last week, The Financial Times \u003ca href=\"http://www.ft.com/cms/s/0/09b69eb8-de5f-11e5-b072-006d8d362ba3.html#axzz42KmjmbLJ\" target=\"_blank\">reported\u003c/a> the drug store chain is looking for a legal way out of its contract with Theranos.\u003c/p>\n\u003cp>Also last week: 32-year-old Theranos founder Elizabeth Holmes \u003ca href=\"http://sdnews.com/view/full_story/27111919/article-Elizabeth-Holmes-backs-out-of-genomic-medicine-parley?instance=update1\" target=\"_blank\">backed out of speaking\u003c/a> at a conference on the future of genomic medicine. Why, we don't know.\u003c/p>\n\u003cp>You can read the entire Wall Street Journal report below. And if you want to see Wall Street Journal reporter John Carreyrou give the inside story of his Theranos reporting, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/02/04/wall-street-journal-reporter-discusses-theranos-investigation-video/\" target=\"_blank\">here he is in an extensive, wide-ranging interview\u003c/a> on Feb. 4.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\u003c/p>\n\n",
"disqusIdentifier": "124849 http://ww2.kqed.org/futureofyou/?p=124849",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/03/08/wsj-how-theranos-put-patients-in-immediate-jeopardy/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 586,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 15
},
"modified": 1457475574,
"excerpt": "The paper spoke to people familiar with an unreleased government report detailing problems at Theranos' lab.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The paper spoke to people familiar with an unreleased government report detailing problems at Theranos' lab.",
"title": "WSJ: How Theranos Put Patients in 'Immediate Jeopardy' | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "WSJ: How Theranos Put Patients in 'Immediate Jeopardy'",
"datePublished": "2016-03-08T10:00:56-08:00",
"dateModified": "2016-03-08T14:19:34-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "wsj-how-theranos-put-patients-in-immediate-jeopardy",
"status": "publish",
"path": "/futureofyou/124849/wsj-how-theranos-put-patients-in-immediate-jeopardy",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>On Jan. 25, the Centers for Medicare & Medicaid \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/01/27/government-says-theranos-lab-problems-pose-immediate-jeopardy-to-patients/\" target=\"_blank\">released a letter\u003c/a> it sent to the blood-test startup Theranos, informing the company an inspection of its Newark, California lab had found it to be deficient in five areas. CMS said deficiencies in one of those areas -- hematology -- put patients in \"immediate jeopardy,\" which is defined by the agency as a situation likely to cause \"serious injury or harm, or death\" to patients.\u003c/p>\n\u003caside class=\"“pullquote alignright\">Theranos ran a blood-clotting test on 81 patients \"despite erratic results from quality-control checks,\"\u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\"> The Wall Street Journal reports\u003c/a>.\u003c/aside>\n\u003cp>Sounded serious, to say the least. But what CMS did not release are the actual \u003cem>problems\u003c/em> it found in the lab that caused it to reach such a dire conclusion. Those were detailed on \u003ca href=\"https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/downloads/cms2567.pdf\" target=\"_blank\">Form CMS-2567\u003c/a>, called a Statement of Deficiencies. When we asked CMS for \u003cem>that\u003c/em>, a spokesperson would only say the form would become \"releasable\" after Theranos' plan of correction was approved.\u003c/p>\n\u003cp>Well, The Wall Street Journal, which has just about \u003ca href=\"https://www.google.com/search?q=wall+street+journal+theranos\" target=\"_blank\">single-handedly extinguished the hype\u003c/a> around Theranos as a \"disruptor\" of the blood-test industry, has \u003ca href=\"http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\" target=\"_blank\">talked\u003c/a> to \"people familiar with the report.\"\u003c/p>\n\u003cp>Those sources said CMS found that Theranos \"ran an important blood test on 81 patients in a six-month period despite erratic results from quality-control checks meant to ensure the test’s accuracy,\" the Journal said.\u003c/p>\n\u003cp>The test, called the \u003ca href=\"http://www.healthline.com/health/prothrombin-time-pt#WhyIt'sDone2\" target=\"_blank\">prothrombin time test\u003c/a>, measures how long it takes blood to clot. Inaccurate results \"can be especially serious for patients taking blood thinners such as warfarin\" (better known as Coumadin), the paper said.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Any doctors who received results from tests conducted between April 23 and Sept. 15, 2015, when the quality control problems emerged, should have patients retested as soon as possible,\" one academic in laboratory medicine told the Journal. “Those results are not worth anything,” said Timothy Hamill, professor emeritus at the University of California, San Francisco.\u003c/p>\n\u003cp>In response to the Journal report, Theranos released a \u003ca href=\"https://www.theranos.com/news/posts/statement-regarding-newark-california-lab-survey\" target=\"_blank\">statement\u003c/a> in which it said it had contacted \"any potentially affected patients.\" Dr. Kingshuk Das, the new director of the lab, said: \"We have conducted assessments to identify any patients affected or having the potential to be affected by the issues identified by CMS, and we have no reason to believe that these issues have affected patients’ health.”\u003c/p>\n\u003cp>\u003cstrong>Report Held\u003c/strong>\u003c/p>\n\u003cp>News of these details raise the question of why CMS didn't release them in the first place?\u003c/p>\n\u003cp>\"The company has asked CMS not to publicly release the inspection report on the grounds that doing so would compromise Theranos trade secrets, according to people familiar with the company's position,\" wrote the Journal.\u003c/p>\n\u003cp>Meanwhile, Theranos watchers are waiting for the other shoe to drop regarding its partnership with Walgreen's. Last week, The Financial Times \u003ca href=\"http://www.ft.com/cms/s/0/09b69eb8-de5f-11e5-b072-006d8d362ba3.html#axzz42KmjmbLJ\" target=\"_blank\">reported\u003c/a> the drug store chain is looking for a legal way out of its contract with Theranos.\u003c/p>\n\u003cp>Also last week: 32-year-old Theranos founder Elizabeth Holmes \u003ca href=\"http://sdnews.com/view/full_story/27111919/article-Elizabeth-Holmes-backs-out-of-genomic-medicine-parley?instance=update1\" target=\"_blank\">backed out of speaking\u003c/a> at a conference on the future of genomic medicine. Why, we don't know.\u003c/p>\n\u003cp>You can read the entire Wall Street Journal report below. And if you want to see Wall Street Journal reporter John Carreyrou give the inside story of his Theranos reporting, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/02/04/wall-street-journal-reporter-discusses-theranos-investigation-video/\" target=\"_blank\">here he is in an extensive, wide-ranging interview\u003c/a> on Feb. 4.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>http://www.wsj.com/articles/theranos-ran-tests-despite-quality-problems-1457399479\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/124849/wsj-how-theranos-put-patients-in-immediate-jeopardy",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_107",
"futureofyou_617"
],
"featImg": "futureofyou_103649",
"label": "futureofyou_54"
},
"futureofyou_108372": {
"type": "posts",
"id": "futureofyou_108372",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "108372",
"score": null,
"sort": [
1454698910000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1454698910,
"format": "aside",
"disqusTitle": "Theranos Given Extension to Correct Serious Lab Deficiencies",
"title": "Theranos Given Extension to Correct Serious Lab Deficiencies",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>The blood testing startup Theranos got a little more time, Friday.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services sent this statement today:\u003c/p>\n\u003cp>\"At the request of the laboratory’s director, Theranos was granted an extension until February 12 to submit their response to the CMS inspection report. This is a routine procedure in oversight of clinical labs.\"\u003c/p>\n\u003caside class=\"“pullquote alignright\">\"The idea that you should not let your customers rely on test results you have reason to think had a good chance of being inaccurate is not [complicated].\"\u003cbr>\n--\u003ccite>Hank Greely, director of Stanford's Center for Law and the Biosciences \u003c/cite>\u003c/aside>\n\u003cp>A CMS inspection of the lab, in Newark, California, had found deficiencies that “pose immediate jeopardy to patient health and safety,” according to a CMS letter sent to Theranos.\u003c/p>\n\u003cp>Immediate jeopardy, as defined by CMS, means “a situation in which immediate corrective action is necessary because the laboratory’s non-compliance … has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Originally, Theranos had been given 10 days from receipt of the letter to correct the deficiencies. That deadline was today.\u003c/p>\n\u003cp>CMS also directed the company to take \"corrective action\" for affected patients.\u003c/p>\n\u003cp>Theranos sent this statement about the extension:\u003c/p>\n\u003cp>“We are working to submit our plan of correction to CMS, addressing every issue raised in the audit report regarding the Newark, CA lab and will continue to actively work with them. CMS has granted an extension to February 12 for submission of our plan of correction, to allow our new Lab Director, Dr. Das, additional time to review our comprehensive response.”\u003c/p>\n\u003cp>So ... what should people whose blood has been tested by Theranos do in the meantime?\u003c/p>\n\u003cp>I asked a CMS spokesperson if the agency had any advice for those folks; she declined to respond.\u003c/p>\n\u003cp>Theranos did not respond to two queries asking the same question.\u003c/p>\n\u003cp>\u003cstrong>Medical Ethicist Weighs In\u003c/strong>\u003c/p>\n\u003cp>What does an expert in medical ethics think?\u003c/p>\n\u003cp>Hank Greely is the director of Stanford's Center for Law and the Biosciences. He said in an email that \"it wouldn't shock\" him if CMS' assertion of potential fatal consequences wasn't literal.\u003c/p>\n\u003cp>He said the language \"is enough to \u003cstrong>at least \u003c/strong>raise serious questions about getting customers/patients to get new tests.\"\u003c/p>\n\u003cp>Greely said the haste in which Theranos should be obligated to contact potentially affected patients would be determined by the substance and frequency of the errors CMS found.\u003c/p>\n\u003cp>\"If they got substantial error rates on a particular kind of test (I don’t know - total cholesterol), I would think they need to tell the customers who got that test. If instead they had a relatively low error rate (though still too high) scattered across all their testing, figuring out who to tell what is trickier. And some kinds of lab tests are going to be more critical than others.\"\u003c/p>\n\u003cp>Greely said he thought it would behoove Theranos to offer affected patients or even every patient a free retest, if it was able to do so.\u003c/p>\n\u003cp>\"Good PR, good for the patients (if the retests are accurate), and, if their tests are as cheap as they say they are, not expensive.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Greely said though the details of disclosure are complicated and depend on many factors, \"the idea that you should not let your customers rely on test results you have reason to think had a good chance of being inaccurate is not [complicated].\"\u003c/p>\n\n",
"disqusIdentifier": "108372 http://ww2.kqed.org/futureofyou/?p=108372",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/02/05/theranos-given-extension-to-submit-plan-for-deficient-lab/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 610,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 23
},
"modified": 1454956937,
"excerpt": "An inspection of its lab found deficiencies that “pose immediate jeopardy to patient health and safety.\"",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "An inspection of its lab found deficiencies that “pose immediate jeopardy to patient health and safety."",
"title": "Theranos Given Extension to Correct Serious Lab Deficiencies | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Given Extension to Correct Serious Lab Deficiencies",
"datePublished": "2016-02-05T11:01:50-08:00",
"dateModified": "2016-02-08T10:42:17-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-given-extension-to-submit-plan-for-deficient-lab",
"status": "publish",
"path": "/futureofyou/108372/theranos-given-extension-to-submit-plan-for-deficient-lab",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The blood testing startup Theranos got a little more time, Friday.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services sent this statement today:\u003c/p>\n\u003cp>\"At the request of the laboratory’s director, Theranos was granted an extension until February 12 to submit their response to the CMS inspection report. This is a routine procedure in oversight of clinical labs.\"\u003c/p>\n\u003caside class=\"“pullquote alignright\">\"The idea that you should not let your customers rely on test results you have reason to think had a good chance of being inaccurate is not [complicated].\"\u003cbr>\n--\u003ccite>Hank Greely, director of Stanford's Center for Law and the Biosciences \u003c/cite>\u003c/aside>\n\u003cp>A CMS inspection of the lab, in Newark, California, had found deficiencies that “pose immediate jeopardy to patient health and safety,” according to a CMS letter sent to Theranos.\u003c/p>\n\u003cp>Immediate jeopardy, as defined by CMS, means “a situation in which immediate corrective action is necessary because the laboratory’s non-compliance … has already caused, is causing, or is likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Originally, Theranos had been given 10 days from receipt of the letter to correct the deficiencies. That deadline was today.\u003c/p>\n\u003cp>CMS also directed the company to take \"corrective action\" for affected patients.\u003c/p>\n\u003cp>Theranos sent this statement about the extension:\u003c/p>\n\u003cp>“We are working to submit our plan of correction to CMS, addressing every issue raised in the audit report regarding the Newark, CA lab and will continue to actively work with them. CMS has granted an extension to February 12 for submission of our plan of correction, to allow our new Lab Director, Dr. Das, additional time to review our comprehensive response.”\u003c/p>\n\u003cp>So ... what should people whose blood has been tested by Theranos do in the meantime?\u003c/p>\n\u003cp>I asked a CMS spokesperson if the agency had any advice for those folks; she declined to respond.\u003c/p>\n\u003cp>Theranos did not respond to two queries asking the same question.\u003c/p>\n\u003cp>\u003cstrong>Medical Ethicist Weighs In\u003c/strong>\u003c/p>\n\u003cp>What does an expert in medical ethics think?\u003c/p>\n\u003cp>Hank Greely is the director of Stanford's Center for Law and the Biosciences. He said in an email that \"it wouldn't shock\" him if CMS' assertion of potential fatal consequences wasn't literal.\u003c/p>\n\u003cp>He said the language \"is enough to \u003cstrong>at least \u003c/strong>raise serious questions about getting customers/patients to get new tests.\"\u003c/p>\n\u003cp>Greely said the haste in which Theranos should be obligated to contact potentially affected patients would be determined by the substance and frequency of the errors CMS found.\u003c/p>\n\u003cp>\"If they got substantial error rates on a particular kind of test (I don’t know - total cholesterol), I would think they need to tell the customers who got that test. If instead they had a relatively low error rate (though still too high) scattered across all their testing, figuring out who to tell what is trickier. And some kinds of lab tests are going to be more critical than others.\"\u003c/p>\n\u003cp>Greely said he thought it would behoove Theranos to offer affected patients or even every patient a free retest, if it was able to do so.\u003c/p>\n\u003cp>\"Good PR, good for the patients (if the retests are accurate), and, if their tests are as cheap as they say they are, not expensive.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Greely said though the details of disclosure are complicated and depend on many factors, \"the idea that you should not let your customers rely on test results you have reason to think had a good chance of being inaccurate is not [complicated].\"\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/108372/theranos-given-extension-to-submit-plan-for-deficient-lab",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_617"
],
"featImg": "futureofyou_103649",
"label": "futureofyou_54"
},
"futureofyou_105202": {
"type": "posts",
"id": "futureofyou_105202",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "105202",
"score": null,
"sort": [
1454610980000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou",
"term": 54
},
"blocks": [],
"publishDate": 1454610980,
"format": "aside",
"disqusTitle": "Wall Street Journal Reporter Discusses Theranos Investigation (Video)",
"title": "Wall Street Journal Reporter Discusses Theranos Investigation (Video)",
"headTitle": "Future of You | KQED Future of You | KQED Science",
"content": "\u003cp>https://www.youtube.com/watch?v=zSgwJA-GOlg\u003c/p>\n\u003cp>The blood-testing firm Theranos has pushed back fiercely on The Wall Street Journal's reporting on a host of irregularities it found with the company's cheaper, less-intrusive blood-tests. In one \u003ca href=\"https://www.theranos.com/news/posts/statement-from-theranos-5\" target=\"_blank\">statement\u003c/a>, Theranos called a particular story \"inaccurate, misleading and defamatory.\"\u003c/p>\n\u003cp>So we thought this long interview with the Journal reporter who's written those stories was interesting. John Carreyrou appeared last week on the video podcast \"This Week in Startups,\" hosted by investor and entrepreneur Jason Calicanis. In the interview, Carreyrou defends his reporting and recaps some of his findings. He also says he repeatedly \u003ca href=\"https://www.youtube.com/watch?v=LqEmGEKFMxY&ab_channel=ThisWeekInStartups\" target=\"_blank\">tried to interview Theranos founder Elizabeth Holmes\u003c/a> but was rebuffed. You can see \u003ca href=\"https://www.youtube.com/user/ThisWeekIn/videos?&ab_channel=ThisWeekInStartups\" target=\"_blank\">selected clips from the interview here\u003c/a>, including one in which he talks about the \u003ca href=\"https://www.youtube.com/watch?v=RPwj4WJMbFg&ab_channel=ThisWeekInStartups\" target=\"_blank\">Journal's vetting process\u003c/a>.\u003c/p>\n\u003cp>Keep in mind Calicanis himself is a big critic of Theranos. He is not the most objective interviewer. (And you'll also have to sit through some ads.) Also keep in mind, again, that Theranos denies the claims made in the reports, which include allegations that the company hid test results and data that cast doubt on the accuracy of its technology.\u003c/p>\n\u003cp>\u003cstrong>To Recap...\u003c/strong>\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>For those unfamiliar with the story:\u003c/p>\n\u003cp>Last year, Theranos was valued at $9 billion, making then 31-year-old founder Elizabeth Holmes the world's youngest female billionaire, according to \u003ca href=\"http://www.forbes.com/sites/matthewherper/2015/07/15/giving-theranos-a-few-tests/#1448085d1721\" target=\"_blank\">Forbes\u003c/a>. Driving the investor rush: The company's claim that it could provide cheaper, less-intrusive blood tests.\u003c/p>\n\u003cp>But in a foreshadowing of what was to come, Forbes science and medicine reporter Matthew Herper wrote: \"How much is real and how much is hype? ... I still have no idea how Theranos’ technology works.\"\u003c/p>\n\u003cp>Nobody outside the company knew either. Now, the consensus leans more toward \"hype\" than \"real,\" thanks to Carryrou's \u003ca href=\"https://www.google.com/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=wall+street+journal+theranos\" target=\"_blank\">stories \u003c/a>and a federal government's inspection finding that the company's Newark, California lab posed \"immediate jeopardy\" to patients.\u003c/p>\n\u003cp>Theranos says the lab is under new management and that it's remediated problems there. It has until Friday to respond to the Centers for Medicare & Medicaid Services with a plan to correct deficiencies at the lab. CMS says a report will be released after that plan is reviewed and accepted, but it doesn't have a timeframe for when that will be.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Theranos has declined to say if it will make its plan public.\u003c/p>\n\n",
"disqusIdentifier": "105202 http://ww2.kqed.org/futureofyou/?p=105202",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/02/04/wall-street-journal-reporter-discusses-theranos-investigation-video/",
"stats": {
"hasVideo": true,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 422,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 12
},
"modified": 1454614041,
"excerpt": "John Carreyrou defended and recapped his reporting in a video podcast last week.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "John Carreyrou defended and recapped his reporting in a video podcast last week.",
"title": "Wall Street Journal Reporter Discusses Theranos Investigation (Video) | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Wall Street Journal Reporter Discusses Theranos Investigation (Video)",
"datePublished": "2016-02-04T10:36:20-08:00",
"dateModified": "2016-02-04T11:27:21-08:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "wall-street-journal-reporter-discusses-theranos-investigation-video",
"status": "publish",
"path": "/futureofyou/105202/wall-street-journal-reporter-discusses-theranos-investigation-video",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\u003cp>\u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutube'>\n \u003cspan class='utils-parseShortcode-shortcodes-__youtubeShortcode__embedYoutubeInside'>\n \u003ciframe\n loading='lazy'\n class='utils-parseShortcode-shortcodes-__youtubeShortcode__youtubePlayer'\n type='text/html'\n src='//www.youtube.com/embed/zSgwJA-GOlg'\n title='//www.youtube.com/embed/zSgwJA-GOlg'\n allowfullscreen='true'\n style='border:0;'>\u003c/iframe>\n \u003c/span>\n \u003c/span>\u003c/p>\u003cp>\u003cp>The blood-testing firm Theranos has pushed back fiercely on The Wall Street Journal's reporting on a host of irregularities it found with the company's cheaper, less-intrusive blood-tests. In one \u003ca href=\"https://www.theranos.com/news/posts/statement-from-theranos-5\" target=\"_blank\">statement\u003c/a>, Theranos called a particular story \"inaccurate, misleading and defamatory.\"\u003c/p>\n\u003cp>So we thought this long interview with the Journal reporter who's written those stories was interesting. John Carreyrou appeared last week on the video podcast \"This Week in Startups,\" hosted by investor and entrepreneur Jason Calicanis. In the interview, Carreyrou defends his reporting and recaps some of his findings. He also says he repeatedly \u003ca href=\"https://www.youtube.com/watch?v=LqEmGEKFMxY&ab_channel=ThisWeekInStartups\" target=\"_blank\">tried to interview Theranos founder Elizabeth Holmes\u003c/a> but was rebuffed. You can see \u003ca href=\"https://www.youtube.com/user/ThisWeekIn/videos?&ab_channel=ThisWeekInStartups\" target=\"_blank\">selected clips from the interview here\u003c/a>, including one in which he talks about the \u003ca href=\"https://www.youtube.com/watch?v=RPwj4WJMbFg&ab_channel=ThisWeekInStartups\" target=\"_blank\">Journal's vetting process\u003c/a>.\u003c/p>\n\u003cp>Keep in mind Calicanis himself is a big critic of Theranos. He is not the most objective interviewer. (And you'll also have to sit through some ads.) Also keep in mind, again, that Theranos denies the claims made in the reports, which include allegations that the company hid test results and data that cast doubt on the accuracy of its technology.\u003c/p>\n\u003cp>\u003cstrong>To Recap...\u003c/strong>\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>For those unfamiliar with the story:\u003c/p>\n\u003cp>Last year, Theranos was valued at $9 billion, making then 31-year-old founder Elizabeth Holmes the world's youngest female billionaire, according to \u003ca href=\"http://www.forbes.com/sites/matthewherper/2015/07/15/giving-theranos-a-few-tests/#1448085d1721\" target=\"_blank\">Forbes\u003c/a>. Driving the investor rush: The company's claim that it could provide cheaper, less-intrusive blood tests.\u003c/p>\n\u003cp>But in a foreshadowing of what was to come, Forbes science and medicine reporter Matthew Herper wrote: \"How much is real and how much is hype? ... I still have no idea how Theranos’ technology works.\"\u003c/p>\n\u003cp>Nobody outside the company knew either. Now, the consensus leans more toward \"hype\" than \"real,\" thanks to Carryrou's \u003ca href=\"https://www.google.com/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=wall+street+journal+theranos\" target=\"_blank\">stories \u003c/a>and a federal government's inspection finding that the company's Newark, California lab posed \"immediate jeopardy\" to patients.\u003c/p>\n\u003cp>Theranos says the lab is under new management and that it's remediated problems there. It has until Friday to respond to the Centers for Medicare & Medicaid Services with a plan to correct deficiencies at the lab. CMS says a report will be released after that plan is reviewed and accepted, but it doesn't have a timeframe for when that will be.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Theranos has declined to say if it will make its plan public.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/105202/wall-street-journal-reporter-discusses-theranos-investigation-video",
"authors": [
"80"
],
"programs": [
"futureofyou_54"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_751",
"futureofyou_617",
"futureofyou_750"
],
"featImg": "futureofyou_58611",
"label": "futureofyou_54"
}
},
"podcastsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"podcasts": {}
},
"radioProgramsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"radioPrograms": {}
},
"radioSearchSegmentsReducer": {},
"programsReducer": {
"all-things-considered": {
"id": "all-things-considered",
"title": "All Things Considered",
"info": "Every weekday, \u003cem>All Things Considered\u003c/em> hosts Robert Siegel, Audie Cornish, Ari Shapiro, and Kelly McEvers present the program's trademark mix of news, interviews, commentaries, reviews, and offbeat features. Michel Martin hosts on the weekends.",
"airtime": "MON-FRI 1pm-2pm, 4:30pm-6:30pm\u003cbr />SAT-SUN 5pm-6pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/All-Things-Considered-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/all-things-considered/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/all-things-considered"
},
"american-suburb-podcast": {
"id": "american-suburb-podcast",
"title": "American Suburb: The Podcast",
"tagline": "The flip side of gentrification, told through one town",
"info": "Gentrification is changing cities across America, forcing people from neighborhoods they have long called home. Call them the displaced. Now those priced out of the Bay Area are looking for a better life in an unlikely place. American Suburb follows this migration to one California town along the Delta, 45 miles from San Francisco. But is this once sleepy suburb ready for them?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/American-Suburb-Podcast-Tile-703x703-1.jpg",
"officialWebsiteLink": "/news/series/american-suburb-podcast",
"meta": {
"site": "news",
"source": "kqed",
"order": 19
},
"link": "/news/series/american-suburb-podcast/",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/RBrW",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=1287748328",
"tuneIn": "https://tunein.com/radio/American-Suburb-p1086805/",
"rss": "https://ww2.kqed.org/news/series/american-suburb-podcast/feed/podcast",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMzMDExODgxNjA5"
}
},
"baycurious": {
"id": "baycurious",
"title": "Bay Curious",
"tagline": "Exploring the Bay Area, one question at a time",
"info": "KQED’s new podcast, Bay Curious, gets to the bottom of the mysteries — both profound and peculiar — that give the Bay Area its unique identity. And we’ll do it with your help! You ask the questions. You decide what Bay Curious investigates. And you join us on the journey to find the answers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Bay-Curious-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Bay Curious",
"officialWebsiteLink": "/news/series/baycurious",
"meta": {
"site": "news",
"source": "kqed",
"order": 3
},
"link": "/podcasts/baycurious",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/bay-curious/id1172473406",
"npr": "https://www.npr.org/podcasts/500557090/bay-curious",
"rss": "https://ww2.kqed.org/news/category/bay-curious-podcast/feed/podcast",
"amazon": "https://music.amazon.com/podcasts/9a90d476-aa04-455d-9a4c-0871ed6216d4/bay-curious",
"stitcher": "https://www.stitcher.com/podcast/kqed/bay-curious",
"spotify": "https://open.spotify.com/show/6O76IdmhixfijmhTZLIJ8k"
}
},
"bbc-world-service": {
"id": "bbc-world-service",
"title": "BBC World Service",
"info": "The day's top stories from BBC News compiled twice daily in the week, once at weekends.",
"airtime": "MON-FRI 9pm-10pm, TUE-FRI 1am-2am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/BBC-World-Service-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.bbc.co.uk/sounds/play/live:bbc_world_service",
"meta": {
"site": "news",
"source": "BBC World Service"
},
"link": "/radio/program/bbc-world-service",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/global-news-podcast/id135067274?mt=2",
"tuneIn": "https://tunein.com/radio/BBC-World-Service-p455581/",
"rss": "https://podcasts.files.bbci.co.uk/p02nq0gn.rss"
}
},
"californiareport": {
"id": "californiareport",
"title": "The California Report",
"tagline": "California, day by day",
"info": "KQED’s statewide radio news program providing daily coverage of issues, trends and public policy decisions.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report",
"officialWebsiteLink": "/californiareport",
"meta": {
"site": "news",
"source": "kqed",
"order": 8
},
"link": "/californiareport",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-the-california-report/id79681292",
"amazon": "https://music.amazon.com/podcasts/26099305-72af-4542-9dde-ac1807fe36d5/kqed-s-the-california-report",
"npr": "https://www.npr.org/podcasts/432285393/the-california-report",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-the-california-report-podcast-8838",
"rss": "https://ww2.kqed.org/news/tag/tcram/feed/podcast"
}
},
"californiareportmagazine": {
"id": "californiareportmagazine",
"title": "The California Report Magazine",
"tagline": "Your state, your stories",
"info": "Every week, The California Report Magazine takes you on a road trip for the ears: to visit the places and meet the people who make California unique. The in-depth storytelling podcast from the California Report.",
"airtime": "FRI 4:30pm-5pm, 6:30pm-7pm, 11pm-11:30pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Magazine-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report Magazine",
"officialWebsiteLink": "/californiareportmagazine",
"meta": {
"site": "news",
"source": "kqed",
"order": 10
},
"link": "/californiareportmagazine",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-california-report-magazine/id1314750545",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM3NjkwNjk1OTAz",
"npr": "https://www.npr.org/podcasts/564733126/the-california-report-magazine",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-california-report-magazine",
"rss": "https://ww2.kqed.org/news/tag/tcrmag/feed/podcast"
}
},
"city-arts": {
"id": "city-arts",
"title": "City Arts & Lectures",
"info": "A one-hour radio program to hear celebrated writers, artists and thinkers address contemporary ideas and values, often discussing the creative process. Please note: tapes or transcripts are not available",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/cityartsandlecture-300x300.jpg",
"officialWebsiteLink": "https://www.cityarts.net/",
"airtime": "SUN 1pm-2pm, TUE 10pm, WED 1am",
"meta": {
"site": "news",
"source": "City Arts & Lectures"
},
"link": "https://www.cityarts.net",
"subscribe": {
"tuneIn": "https://tunein.com/radio/City-Arts-and-Lectures-p692/",
"rss": "https://www.cityarts.net/feed/"
}
},
"closealltabs": {
"id": "closealltabs",
"title": "Close All Tabs",
"tagline": "Your irreverent guide to the trends redefining our world",
"info": "Close All Tabs breaks down how digital culture shapes our world through thoughtful insights and irreverent humor.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/02/CAT_2_Tile-scaled.jpg",
"imageAlt": "KQED Close All Tabs",
"officialWebsiteLink": "/podcasts/closealltabs",
"meta": {
"site": "news",
"source": "kqed",
"order": 1
},
"link": "/podcasts/closealltabs",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/close-all-tabs/id214663465",
"rss": "https://feeds.megaphone.fm/KQINC6993880386",
"amazon": "https://music.amazon.com/podcasts/92d9d4ac-67a3-4eed-b10a-fb45d45b1ef2/close-all-tabs",
"spotify": "https://open.spotify.com/show/6LAJFHnGK1pYXYzv6SIol6?si=deb0cae19813417c"
}
},
"code-switch-life-kit": {
"id": "code-switch-life-kit",
"title": "Code Switch / Life Kit",
"info": "\u003cem>Code Switch\u003c/em>, which listeners will hear in the first part of the hour, has fearless and much-needed conversations about race. Hosted by journalists of color, the show tackles the subject of race head-on, exploring how it impacts every part of society — from politics and pop culture to history, sports and more.\u003cbr />\u003cbr />\u003cem>Life Kit\u003c/em>, which will be in the second part of the hour, guides you through spaces and feelings no one prepares you for — from finances to mental health, from workplace microaggressions to imposter syndrome, from relationships to parenting. The show features experts with real world experience and shares their knowledge. Because everyone needs a little help being human.\u003cbr />\u003cbr />\u003ca href=\"https://www.npr.org/podcasts/510312/codeswitch\">\u003cem>Code Switch\u003c/em> offical site and podcast\u003c/a>\u003cbr />\u003ca href=\"https://www.npr.org/lifekit\">\u003cem>Life Kit\u003c/em> offical site and podcast\u003c/a>\u003cbr />",
"airtime": "SUN 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Code-Switch-Life-Kit-Podcast-Tile-360x360-1.jpg",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/code-switch-life-kit",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/1112190608?mt=2&at=11l79Y&ct=nprdirectory",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93d3cubnByLm9yZy9yc3MvcG9kY2FzdC5waHA_aWQ9NTEwMzEy",
"spotify": "https://open.spotify.com/show/3bExJ9JQpkwNhoHvaIIuyV",
"rss": "https://feeds.npr.org/510312/podcast.xml"
}
},
"commonwealth-club": {
"id": "commonwealth-club",
"title": "Commonwealth Club of California Podcast",
"info": "The Commonwealth Club of California is the nation's oldest and largest public affairs forum. As a non-partisan forum, The Club brings to the public airwaves diverse viewpoints on important topics. The Club's weekly radio broadcast - the oldest in the U.S., dating back to 1924 - is carried across the nation on public radio stations and is now podcasting. Our website archive features audio of our recent programs, as well as selected speeches from our long and distinguished history. This podcast feed is usually updated twice a week and is always un-edited.",
"airtime": "THU 10pm, FRI 1am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Commonwealth-Club-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.commonwealthclub.org/podcasts",
"meta": {
"site": "news",
"source": "Commonwealth Club of California"
},
"link": "/radio/program/commonwealth-club",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/commonwealth-club-of-california-podcast/id976334034?mt=2",
"google": "https://podcasts.google.com/feed/aHR0cDovL3d3dy5jb21tb253ZWFsdGhjbHViLm9yZy9hdWRpby9wb2RjYXN0L3dlZWtseS54bWw",
"tuneIn": "https://tunein.com/radio/Commonwealth-Club-of-California-p1060/"
}
},
"forum": {
"id": "forum",
"title": "Forum",
"tagline": "The conversation starts here",
"info": "KQED’s live call-in program discussing local, state, national and international issues, as well as in-depth interviews.",
"airtime": "MON-FRI 9am-11am, 10pm-11pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Forum-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Forum with Mina Kim and Alexis Madrigal",
"officialWebsiteLink": "/forum",
"meta": {
"site": "news",
"source": "kqed",
"order": 9
},
"link": "/forum",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-forum/id73329719",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM5NTU3MzgxNjMz",
"npr": "https://www.npr.org/podcasts/432307980/forum",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-forum-podcast",
"rss": "https://feeds.megaphone.fm/KQINC9557381633"
}
},
"freakonomics-radio": {
"id": "freakonomics-radio",
"title": "Freakonomics Radio",
"info": "Freakonomics Radio is a one-hour award-winning podcast and public-radio project hosted by Stephen Dubner, with co-author Steve Levitt as a regular guest. It is produced in partnership with WNYC.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/freakonomicsRadio.png",
"officialWebsiteLink": "http://freakonomics.com/",
"airtime": "SUN 1am-2am, SAT 3pm-4pm",
"meta": {
"site": "radio",
"source": "WNYC"
},
"link": "/radio/program/freakonomics-radio",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/us/podcast/freakonomics-radio/id354668519",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/Freakonomics-Radio-p272293/",
"rss": "https://feeds.feedburner.com/freakonomicsradio"
}
},
"fresh-air": {
"id": "fresh-air",
"title": "Fresh Air",
"info": "Hosted by Terry Gross, \u003cem>Fresh Air from WHYY\u003c/em> is the Peabody Award-winning weekday magazine of contemporary arts and issues. One of public radio's most popular programs, Fresh Air features intimate conversations with today's biggest luminaries.",
"airtime": "MON-FRI 7pm-8pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Fresh-Air-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/fresh-air/",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/fresh-air",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=214089682&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Fresh-Air-p17/",
"rss": "https://feeds.npr.org/381444908/podcast.xml"
}
},
"here-and-now": {
"id": "here-and-now",
"title": "Here & Now",
"info": "A live production of NPR and WBUR Boston, in collaboration with stations across the country, Here & Now reflects the fluid world of news as it's happening in the middle of the day, with timely, in-depth news, interviews and conversation. Hosted by Robin Young, Jeremy Hobson and Tonya Mosley.",
"airtime": "MON-THU 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Here-And-Now-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://www.wbur.org/hereandnow",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/here-and-now",
"subsdcribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=426698661",
"tuneIn": "https://tunein.com/radio/Here--Now-p211/",
"rss": "https://feeds.npr.org/510051/podcast.xml"
}
},
"hidden-brain": {
"id": "hidden-brain",
"title": "Hidden Brain",
"info": "Shankar Vedantam uses science and storytelling to reveal the unconscious patterns that drive human behavior, shape our choices and direct our relationships.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/hiddenbrain.jpg",
"officialWebsiteLink": "https://www.npr.org/series/423302056/hidden-brain",
"airtime": "SUN 7pm-8pm",
"meta": {
"site": "news",
"source": "NPR"
},
"link": "/radio/program/hidden-brain",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/hidden-brain/id1028908750?mt=2",
"tuneIn": "https://tunein.com/podcasts/Science-Podcasts/Hidden-Brain-p787503/",
"rss": "https://feeds.npr.org/510308/podcast.xml"
}
},
"how-i-built-this": {
"id": "how-i-built-this",
"title": "How I Built This with Guy Raz",
"info": "Guy Raz dives into the stories behind some of the world's best known companies. How I Built This weaves a narrative journey about innovators, entrepreneurs and idealists—and the movements they built.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/howIBuiltThis.png",
"officialWebsiteLink": "https://www.npr.org/podcasts/510313/how-i-built-this",
"airtime": "SUN 7:30pm-8pm",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/how-i-built-this",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/3zxy",
"apple": "https://itunes.apple.com/us/podcast/how-i-built-this-with-guy-raz/id1150510297?mt=2",
"tuneIn": "https://tunein.com/podcasts/Arts--Culture-Podcasts/How-I-Built-This-p910896/",
"rss": "https://feeds.npr.org/510313/podcast.xml"
}
},
"hyphenacion": {
"id": "hyphenacion",
"title": "Hyphenación",
"tagline": "Where conversation and cultura meet",
"info": "What kind of no sabo word is Hyphenación? For us, it’s about living within a hyphenation. Like being a third-gen Mexican-American from the Texas border now living that Bay Area Chicano life. Like Xorje! Each week we bring together a couple of hyphenated Latinos to talk all about personal life choices: family, careers, relationships, belonging … everything is on the table. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/03/Hyphenacion_FinalAssets_PodcastTile.png",
"imageAlt": "KQED Hyphenación",
"officialWebsiteLink": "/podcasts/hyphenacion",
"meta": {
"site": "news",
"source": "kqed",
"order": 15
},
"link": "/podcasts/hyphenacion",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/hyphenaci%C3%B3n/id1191591838",
"spotify": "https://open.spotify.com/show/2p3Fifq96nw9BPcmFdIq0o?si=39209f7b25774f38",
"youtube": "https://www.youtube.com/c/kqedarts",
"amazon": "https://music.amazon.com/podcasts/6c3dd23c-93fb-4aab-97ba-1725fa6315f1/hyphenaci%C3%B3n",
"rss": "https://feeds.megaphone.fm/KQINC2275451163"
}
},
"jerrybrown": {
"id": "jerrybrown",
"title": "The Political Mind of Jerry Brown",
"tagline": "Lessons from a lifetime in politics",
"info": "The Political Mind of Jerry Brown brings listeners the wisdom of the former Governor, Mayor, and presidential candidate. Scott Shafer interviewed Brown for more than 40 hours, covering the former governor's life and half-century in the political game and Brown has some lessons he'd like to share. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Political-Mind-of-Jerry-Brown-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Political Mind of Jerry Brown",
"officialWebsiteLink": "/podcasts/jerrybrown",
"meta": {
"site": "news",
"source": "kqed",
"order": 18
},
"link": "/podcasts/jerrybrown",
"subscribe": {
"npr": "https://www.npr.org/podcasts/790253322/the-political-mind-of-jerry-brown",
"apple": "https://itunes.apple.com/us/podcast/id1492194549",
"rss": "https://ww2.kqed.org/news/series/jerrybrown/feed/podcast/",
"tuneIn": "http://tun.in/pjGcK",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-political-mind-of-jerry-brown",
"spotify": "https://open.spotify.com/show/54C1dmuyFyKMFttY6X2j6r?si=K8SgRCoISNK6ZbjpXrX5-w",
"amazon": "https://music.amazon.com/podcasts/44420f75-3b0e-4301-ab3b-16da6b09e543/the-political-mind-of-jerry-brown"
}
},
"latino-usa": {
"id": "latino-usa",
"title": "Latino USA",
"airtime": "MON 1am-2am, SUN 6pm-7pm",
"info": "Latino USA, the radio journal of news and culture, is the only national, English-language radio program produced from a Latino perspective.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/latinoUsa.jpg",
"officialWebsiteLink": "http://latinousa.org/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/latino-usa",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/xtTd",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=79681317&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Latino-USA-p621/",
"rss": "https://feeds.npr.org/510016/podcast.xml"
}
},
"marketplace": {
"id": "marketplace",
"title": "Marketplace",
"info": "Our flagship program, helmed by Kai Ryssdal, examines what the day in money delivered, through stories, conversations, newsworthy numbers and more. Updated Monday through Friday at about 3:30 p.m. PT.",
"airtime": "MON-FRI 4pm-4:30pm, MON-WED 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Marketplace-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.marketplace.org/",
"meta": {
"site": "news",
"source": "American Public Media"
},
"link": "/radio/program/marketplace",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201853034&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/APM-Marketplace-p88/",
"rss": "https://feeds.publicradio.org/public_feeds/marketplace-pm/rss/rss"
}
},
"masters-of-scale": {
"id": "masters-of-scale",
"title": "Masters of Scale",
"info": "Masters of Scale is an original podcast in which LinkedIn co-founder and Greylock Partner Reid Hoffman sets out to describe and prove theories that explain how great entrepreneurs take their companies from zero to a gazillion in ingenious fashion.",
"airtime": "Every other Wednesday June 12 through October 16 at 8pm (repeats Thursdays at 2am)",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Masters-of-Scale-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://mastersofscale.com/",
"meta": {
"site": "radio",
"source": "WaitWhat"
},
"link": "/radio/program/masters-of-scale",
"subscribe": {
"apple": "http://mastersofscale.app.link/",
"rss": "https://rss.art19.com/masters-of-scale"
}
},
"mindshift": {
"id": "mindshift",
"title": "MindShift",
"tagline": "A podcast about the future of learning and how we raise our kids",
"info": "The MindShift podcast explores the innovations in education that are shaping how kids learn. Hosts Ki Sung and Katrina Schwartz introduce listeners to educators, researchers, parents and students who are developing effective ways to improve how kids learn. We cover topics like how fed-up administrators are developing surprising tactics to deal with classroom disruptions; how listening to podcasts are helping kids develop reading skills; the consequences of overparenting; and why interdisciplinary learning can engage students on all ends of the traditional achievement spectrum. This podcast is part of the MindShift education site, a division of KQED News. KQED is an NPR/PBS member station based in San Francisco. You can also visit the MindShift website for episodes and supplemental blog posts or tweet us \u003ca href=\"https://twitter.com/MindShiftKQED\">@MindShiftKQED\u003c/a> or visit us at \u003ca href=\"/mindshift\">MindShift.KQED.org\u003c/a>",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Mindshift-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED MindShift: How We Will Learn",
"officialWebsiteLink": "/mindshift/",
"meta": {
"site": "news",
"source": "kqed",
"order": 12
},
"link": "/podcasts/mindshift",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/mindshift-podcast/id1078765985",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM1NzY0NjAwNDI5",
"npr": "https://www.npr.org/podcasts/464615685/mind-shift-podcast",
"stitcher": "https://www.stitcher.com/podcast/kqed/stories-teachers-share",
"spotify": "https://open.spotify.com/show/0MxSpNYZKNprFLCl7eEtyx"
}
},
"morning-edition": {
"id": "morning-edition",
"title": "Morning Edition",
"info": "\u003cem>Morning Edition\u003c/em> takes listeners around the country and the world with multi-faceted stories and commentaries every weekday. Hosts Steve Inskeep, David Greene and Rachel Martin bring you the latest breaking news and features to prepare you for the day.",
"airtime": "MON-FRI 3am-9am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Morning-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/morning-edition/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/morning-edition"
},
"onourwatch": {
"id": "onourwatch",
"title": "On Our Watch",
"tagline": "Deeply-reported investigative journalism",
"info": "For decades, the process for how police police themselves has been inconsistent – if not opaque. In some states, like California, these proceedings were completely hidden. After a new police transparency law unsealed scores of internal affairs files, our reporters set out to examine these cases and the shadow world of police discipline. On Our Watch brings listeners into the rooms where officers are questioned and witnesses are interrogated to find out who this system is really protecting. Is it the officers, or the public they've sworn to serve?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/On-Our-Watch-Podcast-Tile-703x703-1.jpg",
"imageAlt": "On Our Watch from NPR and KQED",
"officialWebsiteLink": "/podcasts/onourwatch",
"meta": {
"site": "news",
"source": "kqed",
"order": 11
},
"link": "/podcasts/onourwatch",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/id1567098962",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5ucHIub3JnLzUxMDM2MC9wb2RjYXN0LnhtbD9zYz1nb29nbGVwb2RjYXN0cw",
"npr": "https://rpb3r.app.goo.gl/onourwatch",
"spotify": "https://open.spotify.com/show/0OLWoyizopu6tY1XiuX70x",
"tuneIn": "https://tunein.com/radio/On-Our-Watch-p1436229/",
"stitcher": "https://www.stitcher.com/show/on-our-watch",
"rss": "https://feeds.npr.org/510360/podcast.xml"
}
},
"on-the-media": {
"id": "on-the-media",
"title": "On The Media",
"info": "Our weekly podcast explores how the media 'sausage' is made, casts an incisive eye on fluctuations in the marketplace of ideas, and examines threats to the freedom of information and expression in America and abroad. For one hour a week, the show tries to lift the veil from the process of \"making media,\" especially news media, because it's through that lens that we see the world and the world sees us",
"airtime": "SUN 2pm-3pm, MON 12am-1am",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/onTheMedia.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/otm",
"meta": {
"site": "news",
"source": "wnyc"
},
"link": "/radio/program/on-the-media",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/on-the-media/id73330715?mt=2",
"tuneIn": "https://tunein.com/radio/On-the-Media-p69/",
"rss": "http://feeds.wnyc.org/onthemedia"
}
},
"pbs-newshour": {
"id": "pbs-newshour",
"title": "PBS NewsHour",
"info": "Analysis, background reports and updates from the PBS NewsHour putting today's news in context.",
"airtime": "MON-FRI 3pm-4pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/PBS-News-Hour-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pbs.org/newshour/",
"meta": {
"site": "news",
"source": "pbs"
},
"link": "/radio/program/pbs-newshour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pbs-newshour-full-show/id394432287?mt=2",
"tuneIn": "https://tunein.com/radio/PBS-NewsHour---Full-Show-p425698/",
"rss": "https://www.pbs.org/newshour/feeds/rss/podcasts/show"
}
},
"perspectives": {
"id": "perspectives",
"title": "Perspectives",
"tagline": "KQED's series of daily listener commentaries since 1991",
"info": "KQED's series of daily listener commentaries since 1991.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/01/Perspectives_Tile_Final.jpg",
"imageAlt": "KQED Perspectives",
"officialWebsiteLink": "/perspectives/",
"meta": {
"site": "radio",
"source": "kqed",
"order": 14
},
"link": "/perspectives",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/id73801135",
"npr": "https://www.npr.org/podcasts/432309616/perspectives",
"rss": "https://ww2.kqed.org/perspectives/category/perspectives/feed/",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93dzIua3FlZC5vcmcvcGVyc3BlY3RpdmVzL2NhdGVnb3J5L3BlcnNwZWN0aXZlcy9mZWVkLw"
}
},
"planet-money": {
"id": "planet-money",
"title": "Planet Money",
"info": "The economy explained. Imagine you could call up a friend and say, Meet me at the bar and tell me what's going on with the economy. Now imagine that's actually a fun evening.",
"airtime": "SUN 3pm-4pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/planetmoney.jpg",
"officialWebsiteLink": "https://www.npr.org/sections/money/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/planet-money",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/M4f5",
"apple": "https://itunes.apple.com/us/podcast/planet-money/id290783428?mt=2",
"tuneIn": "https://tunein.com/podcasts/Business--Economics-Podcasts/Planet-Money-p164680/",
"rss": "https://feeds.npr.org/510289/podcast.xml"
}
},
"politicalbreakdown": {
"id": "politicalbreakdown",
"title": "Political Breakdown",
"tagline": "Politics from a personal perspective",
"info": "Political Breakdown is a new series that explores the political intersection of California and the nation. Each week hosts Scott Shafer and Marisa Lagos are joined with a new special guest to unpack politics -- with personality — and offer an insider’s glimpse at how politics happens.",
"airtime": "THU 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Political-Breakdown-2024-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Political Breakdown",
"officialWebsiteLink": "/podcasts/politicalbreakdown",
"meta": {
"site": "radio",
"source": "kqed",
"order": 5
},
"link": "/podcasts/politicalbreakdown",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/political-breakdown/id1327641087",
"amazon": "https://music.amazon.com/podcasts/e0c2d153-ad36-4c8d-901d-f1da6a724824/political-breakdown",
"npr": "https://www.npr.org/podcasts/572155894/political-breakdown",
"stitcher": "https://www.stitcher.com/podcast/kqed/political-breakdown",
"spotify": "https://open.spotify.com/show/07RVyIjIdk2WDuVehvBMoN",
"rss": "https://ww2.kqed.org/news/tag/political-breakdown/feed/podcast"
}
},
"possible": {
"id": "possible",
"title": "Possible",
"info": "Possible is hosted by entrepreneur Reid Hoffman and writer Aria Finger. Together in Possible, Hoffman and Finger lead enlightening discussions about building a brighter collective future. The show features interviews with visionary guests like Trevor Noah, Sam Altman and Janette Sadik-Khan. Possible paints an optimistic portrait of the world we can create through science, policy, business, art and our shared humanity. It asks: What if everything goes right for once? How can we get there? Each episode also includes a short fiction story generated by advanced AI GPT-4, serving as a thought-provoking springboard to speculate how humanity could leverage technology for good.",
"airtime": "SUN 2pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Possible-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.possible.fm/",
"meta": {
"site": "news",
"source": "Possible"
},
"link": "/radio/program/possible",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/possible/id1677184070",
"spotify": "https://open.spotify.com/show/730YpdUSNlMyPQwNnyjp4k"
}
},
"pri-the-world": {
"id": "pri-the-world",
"title": "PRI's The World: Latest Edition",
"info": "Each weekday, host Marco Werman and his team of producers bring you the world's most interesting stories in an hour of radio that reminds us just how small our planet really is.",
"airtime": "MON-FRI 2pm-3pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-World-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pri.org/programs/the-world",
"meta": {
"site": "news",
"source": "PRI"
},
"link": "/radio/program/pri-the-world",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pris-the-world-latest-edition/id278196007?mt=2",
"tuneIn": "https://tunein.com/podcasts/News--Politics-Podcasts/PRIs-The-World-p24/",
"rss": "http://feeds.feedburner.com/pri/theworld"
}
},
"radiolab": {
"id": "radiolab",
"title": "Radiolab",
"info": "A two-time Peabody Award-winner, Radiolab is an investigation told through sounds and stories, and centered around one big idea. In the Radiolab world, information sounds like music and science and culture collide. Hosted by Jad Abumrad and Robert Krulwich, the show is designed for listeners who demand skepticism, but appreciate wonder. WNYC Studios is the producer of other leading podcasts including Freakonomics Radio, Death, Sex & Money, On the Media and many more.",
"airtime": "SUN 12am-1am, SAT 2pm-3pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/radiolab1400.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/radiolab/",
"meta": {
"site": "science",
"source": "WNYC"
},
"link": "/radio/program/radiolab",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/radiolab/id152249110?mt=2",
"tuneIn": "https://tunein.com/radio/RadioLab-p68032/",
"rss": "https://feeds.wnyc.org/radiolab"
}
},
"reveal": {
"id": "reveal",
"title": "Reveal",
"info": "Created by The Center for Investigative Reporting and PRX, Reveal is public radios first one-hour weekly radio show and podcast dedicated to investigative reporting. Credible, fact based and without a partisan agenda, Reveal combines the power and artistry of driveway moment storytelling with data-rich reporting on critically important issues. The result is stories that inform and inspire, arming our listeners with information to right injustices, hold the powerful accountable and improve lives.Reveal is hosted by Al Letson and showcases the award-winning work of CIR and newsrooms large and small across the nation. In a radio and podcast market crowded with choices, Reveal focuses on important and often surprising stories that illuminate the world for our listeners.",
"airtime": "SAT 4pm-5pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/reveal300px.png",
"officialWebsiteLink": "https://www.revealnews.org/episodes/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/reveal",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/reveal/id886009669",
"tuneIn": "https://tunein.com/radio/Reveal-p679597/",
"rss": "http://feeds.revealradio.org/revealpodcast"
}
},
"rightnowish": {
"id": "rightnowish",
"title": "Rightnowish",
"tagline": "Art is where you find it",
"info": "Rightnowish digs into life in the Bay Area right now… ish. Journalist Pendarvis Harshaw takes us to galleries painted on the sides of liquor stores in West Oakland. We'll dance in warehouses in the Bayview, make smoothies with kids in South Berkeley, and listen to classical music in a 1984 Cutlass Supreme in Richmond. Every week, Pen talks to movers and shakers about how the Bay Area shapes what they create, and how they shape the place we call home.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Rightnowish-Podcast-Tile-500x500-1.jpg",
"imageAlt": "KQED Rightnowish with Pendarvis Harshaw",
"officialWebsiteLink": "/podcasts/rightnowish",
"meta": {
"site": "arts",
"source": "kqed",
"order": 16
},
"link": "/podcasts/rightnowish",
"subscribe": {
"npr": "https://www.npr.org/podcasts/721590300/rightnowish",
"rss": "https://ww2.kqed.org/arts/programs/rightnowish/feed/podcast",
"apple": "https://podcasts.apple.com/us/podcast/rightnowish/id1482187648",
"stitcher": "https://www.stitcher.com/podcast/kqed/rightnowish",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMxMjU5MTY3NDc4",
"spotify": "https://open.spotify.com/show/7kEJuafTzTVan7B78ttz1I"
}
},
"science-friday": {
"id": "science-friday",
"title": "Science Friday",
"info": "Science Friday is a weekly science talk show, broadcast live over public radio stations nationwide. Each week, the show focuses on science topics that are in the news and tries to bring an educated, balanced discussion to bear on the scientific issues at hand. Panels of expert guests join host Ira Flatow, a veteran science journalist, to discuss science and to take questions from listeners during the call-in portion of the program.",
"airtime": "FRI 11am-1pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Science-Friday-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/science-friday",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/science-friday",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=73329284&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Science-Friday-p394/",
"rss": "http://feeds.wnyc.org/science-friday"
}
},
"snap-judgment": {
"id": "snap-judgment",
"title": "Snap Judgment",
"tagline": "Real stories with killer beats",
"info": "The Snap Judgment radio show and podcast mixes real stories with killer beats to produce cinematic, dramatic radio. Snap's musical brand of storytelling dares listeners to see the world through the eyes of another. This is storytelling... with a BEAT!! Snap first aired on public radio stations nationwide in July 2010. Today, Snap Judgment airs on over 450 public radio stations and is brought to the airwaves by KQED & PRX.",
"airtime": "SAT 1pm-2pm, 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/05/Snap-Judgment-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Snap Judgment",
"officialWebsiteLink": "https://snapjudgment.org",
"meta": {
"site": "arts",
"source": "kqed",
"order": 4
},
"link": "https://snapjudgment.org",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/snap-judgment/id283657561",
"npr": "https://www.npr.org/podcasts/449018144/snap-judgment",
"stitcher": "https://www.pandora.com/podcast/snap-judgment/PC:241?source=stitcher-sunset",
"spotify": "https://open.spotify.com/show/3Cct7ZWmxHNAtLgBTqjC5v",
"rss": "https://snap.feed.snapjudgment.org/"
}
},
"soldout": {
"id": "soldout",
"title": "SOLD OUT: Rethinking Housing in America",
"tagline": "A new future for housing",
"info": "Sold Out: Rethinking Housing in America",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Sold-Out-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Sold Out: Rethinking Housing in America",
"officialWebsiteLink": "/podcasts/soldout",
"meta": {
"site": "news",
"source": "kqed",
"order": 13
},
"link": "/podcasts/soldout",
"subscribe": {
"npr": "https://www.npr.org/podcasts/911586047/s-o-l-d-o-u-t-a-new-future-for-housing",
"apple": "https://podcasts.apple.com/us/podcast/introducing-sold-out-rethinking-housing-in-america/id1531354937",
"rss": "https://feeds.megaphone.fm/soldout",
"spotify": "https://open.spotify.com/show/38dTBSk2ISFoPiyYNoKn1X",
"stitcher": "https://www.stitcher.com/podcast/kqed/sold-out-rethinking-housing-in-america",
"tunein": "https://tunein.com/radio/SOLD-OUT-Rethinking-Housing-in-America-p1365871/"
}
},
"spooked": {
"id": "spooked",
"title": "Spooked",
"tagline": "True-life supernatural stories",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/10/Spooked-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Spooked",
"officialWebsiteLink": "https://spookedpodcast.org/",
"meta": {
"site": "news",
"source": "kqed",
"order": 7
},
"link": "https://spookedpodcast.org/",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/spooked/id1279361017",
"npr": "https://www.npr.org/podcasts/549547848/snap-judgment-presents-spooked",
"spotify": "https://open.spotify.com/show/76571Rfl3m7PLJQZKQIGCT",
"rss": "https://feeds.simplecast.com/TBotaapn"
}
},
"tech-nation": {
"id": "tech-nation",
"title": "Tech Nation Radio Podcast",
"info": "Tech Nation is a weekly public radio program, hosted by Dr. Moira Gunn. Founded in 1993, it has grown from a simple interview show to a multi-faceted production, featuring conversations with noted technology and science leaders, and a weekly science and technology-related commentary.",
"airtime": "FRI 10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Tech-Nation-Radio-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://technation.podomatic.com/",
"meta": {
"site": "science",
"source": "Tech Nation Media"
},
"link": "/radio/program/tech-nation",
"subscribe": {
"rss": "https://technation.podomatic.com/rss2.xml"
}
},
"ted-radio-hour": {
"id": "ted-radio-hour",
"title": "TED Radio Hour",
"info": "The TED Radio Hour is a journey through fascinating ideas, astonishing inventions, fresh approaches to old problems, and new ways to think and create.",
"airtime": "SUN 3pm-4pm, SAT 10pm-11pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/tedRadioHour.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/ted-radio-hour/?showDate=2018-06-22",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/ted-radio-hour",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/8vsS",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=523121474&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/TED-Radio-Hour-p418021/",
"rss": "https://feeds.npr.org/510298/podcast.xml"
}
},
"thebay": {
"id": "thebay",
"title": "The Bay",
"tagline": "Local news to keep you rooted",
"info": "Host Devin Katayama walks you through the biggest story of the day with reporters and newsmakers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Bay-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Bay",
"officialWebsiteLink": "/podcasts/thebay",
"meta": {
"site": "radio",
"source": "kqed",
"order": 2
},
"link": "/podcasts/thebay",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-bay/id1350043452",
"amazon": "https://music.amazon.com/podcasts/d800ea4c-7a2c-42f2-b861-edaf78a5db0b/the-bay",
"npr": "https://www.npr.org/podcasts/586725995/the-bay",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-bay",
"spotify": "https://open.spotify.com/show/4BIKBKIujizLHlIlBNaAqQ",
"rss": "https://feeds.megaphone.fm/KQINC8259786327"
}
},
"thelatest": {
"id": "thelatest",
"title": "The Latest",
"tagline": "Trusted local news in real time",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/05/The-Latest-2025-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Latest",
"officialWebsiteLink": "/thelatest",
"meta": {
"site": "news",
"source": "kqed",
"order": 6
},
"link": "/thelatest",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-latest-from-kqed/id1197721799",
"npr": "https://www.npr.org/podcasts/1257949365/the-latest-from-k-q-e-d",
"spotify": "https://open.spotify.com/show/5KIIXMgM9GTi5AepwOYvIZ?si=bd3053fec7244dba",
"rss": "https://feeds.megaphone.fm/KQINC9137121918"
}
},
"theleap": {
"id": "theleap",
"title": "The Leap",
"tagline": "What if you closed your eyes, and jumped?",
"info": "Stories about people making dramatic, risky changes, told by award-winning public radio reporter Judy Campbell.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Leap-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Leap",
"officialWebsiteLink": "/podcasts/theleap",
"meta": {
"site": "news",
"source": "kqed",
"order": 17
},
"link": "/podcasts/theleap",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-leap/id1046668171",
"npr": "https://www.npr.org/podcasts/447248267/the-leap",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-leap",
"spotify": "https://open.spotify.com/show/3sSlVHHzU0ytLwuGs1SD1U",
"rss": "https://ww2.kqed.org/news/programs/the-leap/feed/podcast"
}
},
"the-moth-radio-hour": {
"id": "the-moth-radio-hour",
"title": "The Moth Radio Hour",
"info": "Since its launch in 1997, The Moth has presented thousands of true stories, told live and without notes, to standing-room-only crowds worldwide. Moth storytellers stand alone, under a spotlight, with only a microphone and a roomful of strangers. The storyteller and the audience embark on a high-wire act of shared experience which is both terrifying and exhilarating. Since 2008, The Moth podcast has featured many of our favorite stories told live on Moth stages around the country. For information on all of our programs and live events, visit themoth.org.",
"airtime": "SAT 8pm-9pm and SUN 11am-12pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/theMoth.jpg",
"officialWebsiteLink": "https://themoth.org/",
"meta": {
"site": "arts",
"source": "prx"
},
"link": "/radio/program/the-moth-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/the-moth-podcast/id275699983?mt=2",
"tuneIn": "https://tunein.com/radio/The-Moth-p273888/",
"rss": "http://feeds.themoth.org/themothpodcast"
}
},
"the-new-yorker-radio-hour": {
"id": "the-new-yorker-radio-hour",
"title": "The New Yorker Radio Hour",
"info": "The New Yorker Radio Hour is a weekly program presented by the magazine's editor, David Remnick, and produced by WNYC Studios and The New Yorker. Each episode features a diverse mix of interviews, profiles, storytelling, and an occasional burst of humor inspired by the magazine, and shaped by its writers, artists, and editors. This isn't a radio version of a magazine, but something all its own, reflecting the rich possibilities of audio storytelling and conversation. Theme music for the show was composed and performed by Merrill Garbus of tUnE-YArDs.",
"airtime": "SAT 10am-11am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-New-Yorker-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/tnyradiohour",
"meta": {
"site": "arts",
"source": "WNYC"
},
"link": "/radio/program/the-new-yorker-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/id1050430296",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/New-Yorker-Radio-Hour-p803804/",
"rss": "https://feeds.feedburner.com/newyorkerradiohour"
}
},
"the-sam-sanders-show": {
"id": "the-sam-sanders-show",
"title": "The Sam Sanders Show",
"info": "One of public radio's most dynamic voices, Sam Sanders helped launch The NPR Politics Podcast and hosted NPR's hit show It's Been A Minute. Now, the award-winning host returns with something brand new, The Sam Sanders Show. Every week, Sam Sanders and friends dig into the culture that shapes our lives: what's driving the biggest trends, how artists really think, and even the memes you can't stop scrolling past. Sam is beloved for his way of unpacking the world and bringing you up close to fresh currents and engaging conversations. The Sam Sanders Show is smart, funny and always a good time.",
"airtime": "FRI 12-1pm AND SAT 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/11/The-Sam-Sanders-Show-Podcast-Tile-400x400-1.jpg",
"officialWebsiteLink": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"meta": {
"site": "arts",
"source": "KCRW"
},
"link": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"subscribe": {
"rss": "https://feed.cdnstream1.com/zjb/feed/download/ac/28/59/ac28594c-e1d0-4231-8728-61865cdc80e8.xml"
}
},
"the-splendid-table": {
"id": "the-splendid-table",
"title": "The Splendid Table",
"info": "\u003cem>The Splendid Table\u003c/em> hosts our nation's conversations about cooking, sustainability and food culture.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Splendid-Table-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.splendidtable.org/",
"airtime": "SUN 10-11 pm",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/the-splendid-table"
},
"this-american-life": {
"id": "this-american-life",
"title": "This American Life",
"info": "This American Life is a weekly public radio show, heard by 2.2 million people on more than 500 stations. Another 2.5 million people download the weekly podcast. It is hosted by Ira Glass, produced in collaboration with Chicago Public Media, delivered to stations by PRX The Public Radio Exchange, and has won all of the major broadcasting awards.",
"airtime": "SAT 12pm-1pm, 7pm-8pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/thisAmericanLife.png",
"officialWebsiteLink": "https://www.thisamericanlife.org/",
"meta": {
"site": "news",
"source": "wbez"
},
"link": "/radio/program/this-american-life",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201671138&at=11l79Y&ct=nprdirectory",
"rss": "https://www.thisamericanlife.org/podcast/rss.xml"
}
},
"tinydeskradio": {
"id": "tinydeskradio",
"title": "Tiny Desk Radio",
"info": "We're bringing the best of Tiny Desk to the airwaves, only on public radio.",
"airtime": "SUN 8pm and SAT 9pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/04/300x300-For-Member-Station-Logo-Tiny-Desk-Radio-@2x.png",
"officialWebsiteLink": "https://www.npr.org/series/g-s1-52030/tiny-desk-radio",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/tinydeskradio",
"subscribe": {
"rss": "https://feeds.npr.org/g-s1-52030/rss.xml"
}
},
"wait-wait-dont-tell-me": {
"id": "wait-wait-dont-tell-me",
"title": "Wait Wait... Don't Tell Me!",
"info": "Peter Sagal and Bill Kurtis host the weekly NPR News quiz show alongside some of the best and brightest news and entertainment personalities.",
"airtime": "SUN 10am-11am, SAT 11am-12pm, SAT 6pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Wait-Wait-Podcast-Tile-300x300-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/wait-wait-dont-tell-me/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/wait-wait-dont-tell-me",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/Xogv",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=121493804&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Wait-Wait-Dont-Tell-Me-p46/",
"rss": "https://feeds.npr.org/344098539/podcast.xml"
}
},
"weekend-edition-saturday": {
"id": "weekend-edition-saturday",
"title": "Weekend Edition Saturday",
"info": "Weekend Edition Saturday wraps up the week's news and offers a mix of analysis and features on a wide range of topics, including arts, sports, entertainment, and human interest stories. The two-hour program is hosted by NPR's Peabody Award-winning Scott Simon.",
"airtime": "SAT 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-saturday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-saturday"
},
"weekend-edition-sunday": {
"id": "weekend-edition-sunday",
"title": "Weekend Edition Sunday",
"info": "Weekend Edition Sunday features interviews with newsmakers, artists, scientists, politicians, musicians, writers, theologians and historians. The program has covered news events from Nelson Mandela's 1990 release from a South African prison to the capture of Saddam Hussein.",
"airtime": "SUN 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-sunday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-sunday"
}
},
"racesReducer": {},
"racesGenElectionReducer": {},
"racesGenElection2026Reducer": {},
"racesGeneralEl2026Reducer": {},
"radioSchedulesReducer": {},
"listsReducer": {
"posts/futureofyou?tag=theranos": {
"isFetching": false,
"latestQuery": {
"from": 24,
"size": 12
},
"vitalsOnly": false,
"totalRequested": 12,
"isLoading": false,
"isLoadingMore": true,
"total": {
"value": 41,
"relation": "eq"
},
"items": [
"futureofyou_157867",
"futureofyou_156558",
"futureofyou_152359",
"futureofyou_148241",
"futureofyou_148427",
"futureofyou_145291",
"futureofyou_141585",
"futureofyou_138294",
"futureofyou_129430",
"futureofyou_124849",
"futureofyou_108372",
"futureofyou_105202"
],
"complete": true
}
},
"recallGuideReducer": {
"intros": {},
"policy": {},
"candidates": {}
},
"savedArticleReducer": {
"articles": [],
"status": {}
},
"newslettersReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"newsletters": {},
"isSubscribing": false,
"isUnsubscribing": false,
"subscribedNewsletters": {}
},
"termsReducer": {
"about": {
"name": "About",
"type": "terms",
"id": "about",
"slug": "about",
"link": "/about",
"taxonomy": "site"
},
"arts": {
"name": "Arts & Culture",
"grouping": [
"arts",
"pop",
"trulyca"
],
"description": "KQED Arts provides daily in-depth coverage of the Bay Area's music, art, film, performing arts, literature and arts news, as well as cultural commentary and criticism.",
"type": "terms",
"id": "arts",
"slug": "arts",
"link": "/arts",
"taxonomy": "site"
},
"artschool": {
"name": "Art School",
"parent": "arts",
"type": "terms",
"id": "artschool",
"slug": "artschool",
"link": "/artschool",
"taxonomy": "site"
},
"bayareabites": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "bayareabites",
"slug": "bayareabites",
"link": "/food",
"taxonomy": "site"
},
"bayareahiphop": {
"name": "Bay Area Hiphop",
"type": "terms",
"id": "bayareahiphop",
"slug": "bayareahiphop",
"link": "/bayareahiphop",
"taxonomy": "site"
},
"campaign21": {
"name": "Campaign 21",
"type": "terms",
"id": "campaign21",
"slug": "campaign21",
"link": "/campaign21",
"taxonomy": "site"
},
"careers": {
"name": "Careers",
"type": "terms",
"id": "careers",
"slug": "careers",
"link": "/careers",
"taxonomy": "site"
},
"checkplease": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "checkplease",
"slug": "checkplease",
"link": "/food",
"taxonomy": "site"
},
"education": {
"name": "Education",
"grouping": [
"education"
],
"type": "terms",
"id": "education",
"slug": "education",
"link": "/education",
"taxonomy": "site"
},
"elections": {
"name": "Elections",
"type": "terms",
"id": "elections",
"slug": "elections",
"link": "/elections",
"taxonomy": "site"
},
"events": {
"name": "Events",
"type": "terms",
"id": "events",
"slug": "events",
"link": "/events",
"taxonomy": "site"
},
"event": {
"name": "Event",
"alias": "events",
"type": "terms",
"id": "event",
"slug": "event",
"link": "/event",
"taxonomy": "site"
},
"filmschoolshorts": {
"name": "Film School Shorts",
"type": "terms",
"id": "filmschoolshorts",
"slug": "filmschoolshorts",
"link": "/filmschoolshorts",
"taxonomy": "site"
},
"food": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"type": "terms",
"id": "food",
"slug": "food",
"link": "/food",
"taxonomy": "site"
},
"forum": {
"name": "Forum",
"relatedContentQuery": "posts/forum?",
"parent": "news",
"type": "terms",
"id": "forum",
"slug": "forum",
"link": "/forum",
"taxonomy": "site"
},
"futureofyou": {
"name": "Future of You",
"grouping": [
"science",
"futureofyou"
],
"parent": "science",
"type": "terms",
"id": "futureofyou",
"slug": "futureofyou",
"link": "/futureofyou",
"taxonomy": "site"
},
"jpepinheart": {
"name": "KQED food",
"relatedContentQuery": "posts/food,bayareabites,checkplease",
"parent": "food",
"type": "terms",
"id": "jpepinheart",
"slug": "jpepinheart",
"link": "/food",
"taxonomy": "site"
},
"liveblog": {
"name": "Live Blog",
"type": "terms",
"id": "liveblog",
"slug": "liveblog",
"link": "/liveblog",
"taxonomy": "site"
},
"livetv": {
"name": "Live TV",
"parent": "tv",
"type": "terms",
"id": "livetv",
"slug": "livetv",
"link": "/livetv",
"taxonomy": "site"
},
"lowdown": {
"name": "The Lowdown",
"relatedContentQuery": "posts/lowdown?",
"parent": "news",
"type": "terms",
"id": "lowdown",
"slug": "lowdown",
"link": "/lowdown",
"taxonomy": "site"
},
"mindshift": {
"name": "Mindshift",
"parent": "news",
"description": "MindShift explores the future of education by highlighting the innovative – and sometimes counterintuitive – ways educators and parents are helping all children succeed.",
"type": "terms",
"id": "mindshift",
"slug": "mindshift",
"link": "/mindshift",
"taxonomy": "site"
},
"news": {
"name": "News",
"grouping": [
"news",
"forum"
],
"type": "terms",
"id": "news",
"slug": "news",
"link": "/news",
"taxonomy": "site"
},
"newsletters": {
"name": "newsletters",
"type": "terms",
"id": "newsletters",
"slug": "newsletters",
"link": "/newsletters",
"taxonomy": "site"
},
"perspectives": {
"name": "Perspectives",
"parent": "radio",
"type": "terms",
"id": "perspectives",
"slug": "perspectives",
"link": "/perspectives",
"taxonomy": "site"
},
"podcasts": {
"name": "Podcasts",
"type": "terms",
"id": "podcasts",
"slug": "podcasts",
"link": "/podcasts",
"taxonomy": "site"
},
"pop": {
"name": "Pop",
"parent": "arts",
"type": "terms",
"id": "pop",
"slug": "pop",
"link": "/pop",
"taxonomy": "site"
},
"pressroom": {
"name": "Pressroom",
"type": "terms",
"id": "pressroom",
"slug": "pressroom",
"link": "/pressroom",
"taxonomy": "site"
},
"quest": {
"name": "Quest",
"parent": "science",
"type": "terms",
"id": "quest",
"slug": "quest",
"link": "/quest",
"taxonomy": "site"
},
"radio": {
"name": "Radio",
"grouping": [
"forum",
"perspectives"
],
"description": "Listen to KQED Public Radio – home of Forum and The California Report – on 88.5 FM in San Francisco, 89.3 FM in Sacramento, 88.3 FM in Santa Rosa and 88.1 FM in Martinez.",
"type": "terms",
"id": "radio",
"slug": "radio",
"link": "/radio",
"taxonomy": "site"
},
"root": {
"name": "KQED",
"image": "https://ww2.kqed.org/app/uploads/2020/02/KQED-OG-Image@1x.png",
"imageWidth": 1200,
"imageHeight": 630,
"headData": {
"title": "KQED | News, Radio, Podcasts, TV | Public Media for Northern California",
"description": "KQED provides public radio, television, and independent reporting on issues that matter to the Bay Area. We’re the NPR and PBS member station for Northern California."
},
"type": "terms",
"id": "root",
"slug": "root",
"link": "/root",
"taxonomy": "site"
},
"science": {
"name": "Science",
"grouping": [
"science",
"futureofyou"
],
"description": "KQED Science brings you award-winning science and environment coverage from the Bay Area and beyond.",
"type": "terms",
"id": "science",
"slug": "science",
"link": "/science",
"taxonomy": "site"
},
"stateofhealth": {
"name": "State of Health",
"parent": "science",
"type": "terms",
"id": "stateofhealth",
"slug": "stateofhealth",
"link": "/stateofhealth",
"taxonomy": "site"
},
"support": {
"name": "Support",
"type": "terms",
"id": "support",
"slug": "support",
"link": "/support",
"taxonomy": "site"
},
"thedolist": {
"name": "The Do List",
"parent": "arts",
"type": "terms",
"id": "thedolist",
"slug": "thedolist",
"link": "/thedolist",
"taxonomy": "site"
},
"trulyca": {
"name": "Truly CA",
"grouping": [
"arts",
"pop",
"trulyca"
],
"parent": "arts",
"type": "terms",
"id": "trulyca",
"slug": "trulyca",
"link": "/trulyca",
"taxonomy": "site"
},
"tv": {
"name": "TV",
"type": "terms",
"id": "tv",
"slug": "tv",
"link": "/tv",
"taxonomy": "site"
},
"voterguide": {
"name": "Voter Guide",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "voterguide",
"slug": "voterguide",
"link": "/voterguide",
"taxonomy": "site"
},
"guiaelectoral": {
"name": "Guia Electoral",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "guiaelectoral",
"slug": "guiaelectoral",
"link": "/guiaelectoral",
"taxonomy": "site"
},
"futureofyou_tag_theranos": {
"isLoading": true
},
"futureofyou_617": {
"type": "terms",
"id": "futureofyou_617",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "617",
"found": true
},
"relationships": {},
"featImg": null,
"name": "theranos",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "theranos Archives | KQED Arts",
"ogDescription": null
},
"ttid": 617,
"slug": "theranos",
"isLoading": false,
"link": "/futureofyou/tag/theranos"
},
"futureofyou_1060": {
"type": "terms",
"id": "futureofyou_1060",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1060",
"found": true
},
"relationships": {},
"featImg": null,
"name": "DIY Health",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "DIY Health Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1060,
"slug": "diy-health",
"isLoading": false,
"link": "/futureofyou/category/diy-health"
},
"futureofyou_164": {
"type": "terms",
"id": "futureofyou_164",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "164",
"found": true
},
"relationships": {},
"featImg": null,
"name": "blood tests",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "blood tests Archives | KQED Arts",
"ogDescription": null
},
"ttid": 164,
"slug": "blood-tests",
"isLoading": false,
"link": "/futureofyou/tag/blood-tests"
},
"futureofyou_814": {
"type": "terms",
"id": "futureofyou_814",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "814",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Elizabeth Holmes",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Elizabeth Holmes Archives | KQED Arts",
"ogDescription": null
},
"ttid": 814,
"slug": "elizabeth-holmes",
"isLoading": false,
"link": "/futureofyou/tag/elizabeth-holmes"
},
"futureofyou_909": {
"type": "terms",
"id": "futureofyou_909",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "909",
"found": true
},
"relationships": {},
"featImg": null,
"name": "LabCorp",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "LabCorp Archives | KQED Arts",
"ogDescription": null
},
"ttid": 909,
"slug": "labcorp",
"isLoading": false,
"link": "/futureofyou/tag/labcorp"
},
"futureofyou_908": {
"type": "terms",
"id": "futureofyou_908",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "908",
"found": true
},
"relationships": {},
"featImg": null,
"name": "WellnessFX",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "WellnessFX Archives | KQED Arts",
"ogDescription": null
},
"ttid": 908,
"slug": "wellnessfx",
"isLoading": false,
"link": "/futureofyou/tag/wellnessfx"
},
"futureofyou_452": {
"type": "terms",
"id": "futureofyou_452",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "452",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Health Policy",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Health Policy Archives | KQED Arts",
"ogDescription": null
},
"ttid": 452,
"slug": "health-policy",
"isLoading": false,
"link": "/futureofyou/category/health-policy"
},
"futureofyou_1": {
"type": "terms",
"id": "futureofyou_1",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED Future Of You",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED Future Of You Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1,
"slug": "future-of-you",
"isLoading": false,
"link": "/futureofyou/category/future-of-you"
},
"futureofyou_73": {
"type": "terms",
"id": "futureofyou_73",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "73",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED News",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED News Archives | KQED Arts",
"ogDescription": null
},
"ttid": 73,
"slug": "kqed-news",
"isLoading": false,
"link": "/futureofyou/category/kqed-news"
},
"futureofyou_87": {
"type": "terms",
"id": "futureofyou_87",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "87",
"found": true
},
"relationships": {},
"featImg": null,
"name": "silicon valley",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "silicon valley Archives | KQED Arts",
"ogDescription": null
},
"ttid": 87,
"slug": "silicon-valley",
"isLoading": false,
"link": "/futureofyou/tag/silicon-valley"
},
"futureofyou_865": {
"type": "terms",
"id": "futureofyou_865",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "865",
"found": true
},
"relationships": {},
"featImg": null,
"name": "AACC",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "AACC Archives | KQED Arts",
"ogDescription": null
},
"ttid": 865,
"slug": "aacc",
"isLoading": false,
"link": "/futureofyou/tag/aacc"
},
"futureofyou_54": {
"type": "terms",
"id": "futureofyou_54",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "54",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Future of You",
"description": null,
"taxonomy": "program",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Future of You Archives | KQED Arts",
"ogDescription": null
},
"ttid": 54,
"slug": "future-of-you",
"isLoading": false,
"link": "/futureofyou/program/future-of-you"
},
"futureofyou_816": {
"type": "terms",
"id": "futureofyou_816",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "816",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Chelsea Clinton",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Chelsea Clinton Archives | KQED Arts",
"ogDescription": null
},
"ttid": 816,
"slug": "chelsea-clinton",
"isLoading": false,
"link": "/futureofyou/tag/chelsea-clinton"
},
"futureofyou_815": {
"type": "terms",
"id": "futureofyou_815",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "815",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Hillary Clinton",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Hillary Clinton Archives | KQED Arts",
"ogDescription": null
},
"ttid": 815,
"slug": "hillary-clinton",
"isLoading": false,
"link": "/futureofyou/tag/hillary-clinton"
},
"futureofyou_107": {
"type": "terms",
"id": "futureofyou_107",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "107",
"found": true
},
"relationships": {},
"featImg": null,
"name": "kqedescience",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "kqedescience Archives | KQED Arts",
"ogDescription": null
},
"ttid": 107,
"slug": "kqedescience",
"isLoading": false,
"link": "/futureofyou/tag/kqedescience"
},
"futureofyou_751": {
"type": "terms",
"id": "futureofyou_751",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "751",
"found": true
},
"relationships": {},
"featImg": null,
"name": "John Carreyrou",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "John Carreyrou Archives | KQED Arts",
"ogDescription": null
},
"ttid": 751,
"slug": "john-carreyrou",
"isLoading": false,
"link": "/futureofyou/tag/john-carreyrou"
},
"futureofyou_750": {
"type": "terms",
"id": "futureofyou_750",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "750",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Wall Street Journal",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Wall Street Journal Archives | KQED Arts",
"ogDescription": null
},
"ttid": 750,
"slug": "wall-street-journal",
"isLoading": false,
"link": "/futureofyou/tag/wall-street-journal"
}
},
"userPermissionsReducer": {
"wpLoggedIn": false
},
"eventsReducer": {},
"fssReducer": {},
"tvDailyScheduleReducer": {},
"tvWeeklyScheduleReducer": {},
"tvPrimetimeScheduleReducer": {},
"tvMonthlyScheduleReducer": {},
"userAccountReducer": {
"user": {
"email": null,
"emailStatus": "EMAIL_UNVALIDATED",
"loggedStatus": "LOGGED_OUT",
"loggingChecked": false,
"articles": [],
"firstName": null,
"lastName": null,
"phoneNumber": null,
"fetchingMembership": false,
"membershipError": false,
"memberships": [
{
"id": null,
"startDate": null,
"firstName": null,
"lastName": null,
"familyNumber": null,
"memberNumber": null,
"memberSince": null,
"expirationDate": null,
"pfsEligible": false,
"isSustaining": false,
"membershipLevel": "Prospect",
"membershipStatus": "Non Member",
"lastGiftDate": null,
"renewalDate": null,
"lastDonationAmount": null
}
]
},
"authModal": {
"isOpen": false,
"view": "LANDING_VIEW"
},
"error": null
},
"youthMediaReducer": {},
"checkPleaseReducer": {
"filterData": {
"region": {
"key": "Restaurant Region",
"filters": [
"Any Region"
]
},
"cuisine": {
"key": "Restaurant Cuisine",
"filters": [
"Any Cuisine"
]
}
},
"restaurantDataById": {},
"restaurantIdsSorted": [],
"error": null
},
"userAgentReducer": {
"userAgent": "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)",
"isBot": true
},
"requestOutcomesReducer": {
"notFound": []
},
"navPromosReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": true,
"promos": {
"news": {},
"podcasts-radio": {},
"video-tv": {},
"events": {},
"support": {
"name": "Shop exclusive Bay Area offers",
"link": "https://shop.kqed.org/",
"imageURL": "https://cdn.kqed.org/wp-content/uploads/2026/11/Nav-Support-KQED-Marketplace@2x-e29b8111.png",
"description": "100% of net proceeds go to support KQED’s mission."
}
}
}
}